Search this site

This Week in European HealthTech and MedTech: 23rd January 2026 European HealthTech this week is being shaped by fresh EU-level funding calls for digital health and AI, tightening but slightly simplified device and AI regulation, and continued emphasis on compliance‑driven M&A and scaling of AI decision‑support. Capital is available but flowing selectively into data‑rich platforms, cross‑border care models, and AI‑enabled diagnostics that can navigate the emerging AI Act / MDR / HTA stack. Policy and regulatory moves The EU’s 2026 Health Technology Assessment work programme is ramping up, with around 50 joint clinical assessments planned for medicines and high‑risk devices, raising the bar for evidence and pan‑EU launch planning. Draft MDR/IVDR simplification removes the five‑year certificate validity cap and shifts toward continuous, risk‑based surveillance, aiming to ease bottlenecks while tightening expectations on cybersecurity, documentation and post‑market data. New EU‑wide cybersecurity obligations via the Cyber Resilience Act and device‑specific rules will push connected devices, SaMD and apps to treat security and incident reporting as core compliance work streams, not optional add‑ons.​ EU and national funding windows The Innovative Health Initiative’s “Call 12” opened this week, offering large‑ticket funding for AI‑driven decision support, mobile health, remote monitoring and interoperability projects, with submissions due in April 2026.​ The 2026 Future of Health Grant cycle is opening for early‑stage digital health startups in Switzerland, targeting telemedicine, preventive care, patient analytics and digital therapeutics as priority themes. Horizon Europe’s 2026–2027 work programme earmarks a meaningful slice of a €14bn envelope for health and digital technologies, reinforcing EU‑level co‑funding for data, AI and platform‑centric HealthTech. Market, adoption and M&A signals Expert commentary this week frames European MedTech and HealthTech as entering a “compliance‑driven M&A” phase, where acquisitive strategics buy smaller players as much for regulatory approvals and MDR‑ready infrastructure as for the underlying tech. Nelson Advisors highlights this as a core 2026 pattern.​ Adoption of AI‑powered clinical administration (ambient voice, AI scribes, workflow tools) is expected to become widespread in European clinical settings, with usage governed tightly by the EU AI Act and national health‑system guidelines.​ Broader European thought‑pieces position 2026 as the year digital health moves from pilots to scaled deployment, but with investor selectivity increasing around real‑world data, interoperability and reimbursement readiness. Country‑level highlights (UK and DACH focus) In the UK, planned “Innovator Passports” should allow HealthTech validated in one NHS organisation to scale across others without repeating assessments, directly benefiting proven digital tools and AI platforms.​ The UK is also backing an AI research‑screening platform and expansion of surgical robotics aligned with NICE guidance, signalling sustained appetite for AI‑enabled diagnostics, workflow tools and high‑acuity MedTech.​ Swiss‑backed programmes such as the Future of Health Grant continue to position Switzerland as a hub for early‑stage digital health, offering non‑dilutive capital that can be leveraged alongside VC for telemedicine and analytics plays. Signals for dealmakers and operators Regulatory simplification plus tougher HTA and cybersecurity rules make evidence generation, interoperability and cyber‑hardening central value drivers in valuations and due diligence. Portfolio reviews at strategics are likely to favour targets that combine MDR/IVDR‑ready status with AI or data moats, enabling acquirers to “buy compliance” and accelerate EU‑wide scale under the new regime. For founders, the live IHI and Horizon calls provide a window to de‑risk capital plans for data‑heavy or infrastructure‑like platforms, especially if structured around cross‑border consortia and HTA‑aligned clinical programmes >>> European MedTech this week is defined by tightening but clearer MDR/IVDR and EUDAMED timelines, a visible “compliance‑driven M&A” narrative, and at least one notable cross‑border platform acquisition alongside continued interest in cardiology and AMR‑linked devices. Regulatory simplification is easing some bottlenecks while making cyber, data and AI readiness central to value, due diligence and portfolio strategy. Regulation and guidance The Commission’s late‑2025 MDR/IVDR “simplification” package is setting the 2026 agenda, targeting notified‑body bottlenecks and shifting toward more risk‑based, continuous surveillance while keeping high evidence expectations. EUDAMED has four functional modules live, with a six‑month transition to full mandatory use by 28 May 2026, making registration and vigilance data a non‑negotiable gateway for EU market access. New draft rules and guidance sharpen expectations around software, AI‑enabled devices and cybersecurity, aligning MDR/IVDR with the AI Act and broader “Digital Omnibus” data framework from 2026 onwards. Funding rounds and capital flows French MedTech FineHeart has raised around €83m (mix of private and European public capital) to advance its implantable device for advanced heart failure, underlining persistent appetite for complex cardiovascular hardware plus data.​ Eindhoven‑based ShanX Medtech has secured roughly €24m to scale ultra‑rapid AMR diagnostics, reinforcing antimicrobial resistance as a strategic EU theme and the Netherlands as a diagnostics hub.​ Weekly deal wraps continue to place these cardiology and AMR diagnostics financings among the top European MedTech startup transactions in early January, setting a strong tone for Q1 2026 fundraising.​ M&A and strategic moves Sector commentary highlights a growing pattern of “compliance‑driven M&A”, as larger strategics acquire smaller players partly to secure MDR/IVDR‑ready product lines and regulatory approvals as financial assets. G Square has acquired a majority stake in Finnish MedTech company Serres from Paree Group, with the partners aiming to develop Serres into a leading international platform via new product investment and global expansion.​ US investors are reported to be increasingly active in European robotics and AI‑enabled MedTech, seeking exposure before valuations converge with US peers, which supports cross‑border growth and exit options.​ Market and adoption themes Analysts frame 2026 European MedTech growth around AI‑supported workflows in cardiovascular, neurovascular, advanced diagnostics and surgical robotics, designed to plug into emerging European health data infrastructures. EUDAMED‑driven transparency on actors, certificates and vigilance is expected to raise payer scrutiny and to hard‑wire regulatory quality into commercial and M&A evaluations.Trade bodies continue to push for pragmatic implementation of MDR/IVDR timelines and notified‑body rules to avoid device shortages, while broadly supporting reforms that are innovation‑friendly but well governed. Implications for dealmakers and operators Evidence generation, real‑world performance data, and cyber/AI governance are becoming central value drivers in MedTech transactions, not hygiene factors. For acquirers, MDR/IVDR‑ready portfolios and EUDAMED clean data create opportunities to “buy compliance” and accelerate pan‑EU scale; for founders, this favours device‑plus‑data platforms with clear regulatory narratives. Funding and M&A activity indicate particular strength in high‑acuity cardiology hardware and AMR diagnostics, suggesting these niches will remain heavily competed for capital and strategic interest. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Digital Bridge: Integrations of Clinical Musculoskeletal Pathways and Workforce Economic Activity via the getUBetter Platform Executive Summary The nexus between individual health and economic productivity has become a focal point of public policy in the United Kingdom, particularly in the wake of post-pandemic shifts in workforce participation. A significant driver of economic inactivity is the prevalence of long-term sickness, with musculoskeletal (MSK) conditions representing a dominant category of morbidity. The traditional bifurcation of health services, delivered by the National Health Service (NHS) and employment support, overseen by the Department for Work and Pensions (DWP) and private employers, has created systemic inefficiencies. Patients suffering from conditions such as low back pain or sciatica often find themselves navigating two disconnected systems: a clinical pathway focused on symptomatic relief and an employment landscape demanding functional capacity. The resulting "silo effect" contributes to prolonged recovery times, increased medicalisation of social problems, and unnecessary exits from the labour market. This report presents an analysis of getUBetter, a digital health platform designed to bridge this chasm. Operating as a Class 1 Medical Device, getUBetter provides evidence-based, self-management support across the entire clinical pathway for common MSK injuries and women's pelvic health conditions. However, its strategic significance extends beyond clinical therapeutics; by integrating specific "work support" modules and connecting directly with local employment services, the platform functions as a digital infrastructure for the "Work as a Health Outcome" agenda. Our analysis draws upon a wide array of evaluations, policy documents, and clinical case studies to demonstrate how getUBetter aligns with national initiatives such as the WorkWell vanguard programme. The evidence suggests that the platform’s "whole pathway" approach, combining immediate digital triage, safety netting, and vocational guidance, delivers measurable economic benefits. These include a return on investment (ROI) of £4.20 for every £1 spent, an 11% reduction in sickness absence notes in pilot areas, and significant decreases in primary and secondary care utilisation. Furthermore, the platform's robust governance framework, utilising Digital Technology Assessment Criteria (DTAC) certification and co-design principles, provides a scalable model for addressing health inequalities and digital exclusion. As the NHS faces unprecedented demand and the government seeks to reverse trends in economic inactivity, getUBetter illustrates the potential of digital therapeutics to serve as a "force multiplier," enhancing clinical capacity while simultaneously supporting the vocational rehabilitation of the workforce. 1. The Macro-Strategic Context: The Crisis of MSK Health and Economic Inactivity 1.1 The Burden of Musculoskeletal Conditions on the UK Economy To understand the strategic necessity of platforms like getUBetter, one must first appreciate the scale of the MSK crisis. Musculoskeletal conditions, encompassing back pain, osteoarthritis, and soft tissue injuries—are the leading cause of years lived with disability in the UK. They account for approximately 30% of all General Practitioner (GP) consultations and cost the NHS an estimated £5 Billion annually in direct treatment costs.However, the indirect costs to the wider economy, driven by lost productivity and sickness absence, are exponentially higher. Data from the Office for National Statistics (ONS), referenced within the getUBetter impact framework, highlights that in June 2022 alone, 262,272 people reported having back and neck pain significant enough to force them to leave the workforce entirely. This statistic represents a profound failure of early intervention. For many of these individuals, the journey from acute pain to permanent economic inactivity is gradual. It often begins with a minor injury, followed by a wait for physiotherapy, leading to physical de-conditioning, loss of confidence, and eventual detachment from the labour market. The economic implications are stark. The "Get Britain Working" White Paper and subsequent Green Papers have identified health-related economic inactivity as a critical barrier to national growth. The government’s ambition to raise the employment rate to 80% is fundamentally largely dependent on stemming the flow of workers onto long-term sickness benefits. In this context, MSK health is not merely a clinical issue; it is a macroeconomic variable. 1.2 The Systemic "Silo" Failure The core structural deficiency addressing this crisis is the historical separation of clinical care and vocational support. The Clinical Silo: When a patient presents to a GP with back pain, the clinical focus is on pain reduction and pathology exclusion. The GP has limited time (typically 10 minutes) and often lacks the specific occupational health training to advise on workplace adjustments. Consequently, the default administrative action is often the issuance of a "fit note" signing the patient off work entirely, rather than a nuanced plan for modified duties. The Employment Silo: Employers and Jobcentres operate with limited visibility into the clinical reality of their employees or clients. Occupational Health (OH) services are often restricted to large corporate entities, leaving Small and Medium Enterprises (SMEs) and the self-employed, who make up a vast proportion of the workforce, without professional guidance. This disconnection creates a vacuum where the patient receives neither adequate medical treatment (due to waiting lists) nor adequate vocational support. getUBetter was conceptualised specifically to dismantle these silos. By embedding work-specific guidance within the clinical recovery app, it ensures that "return to work" is treated as a clinical outcome, intrinsic to the recovery process rather than an afterthought. 1.3 The Psychological Impact of Waiting The "waiting list" is a passive state in traditional healthcare, but biologically and psychologically, it is an active period of deterioration. Patients waiting for MSK appointments often engage in "fear-avoidance" behaviours—avoiding movement or work for fear of causing damage. This inactivity leads to muscle atrophy (de-conditioning) and reinforces a "sick role" identity. getUBetter intervenes in this specific temporal gap. By providing immediate access to safety-netted advice and exercises, it transforms the "wait" into a period of "pre-habilitation." The platform’s data indicates that 50% of patients on a physiotherapy waiting list who used the app felt sufficiently recovered to remove themselves from the list. This finding suggests that for a significant cohort, the provision of confidence and knowledge is as effective as clinical contact, preventing the psychological entrenchment of disability. 2. Platform Architecture and Clinical Philosophy 2.1 The "Whole Pathway" Approach A distinguishing feature of getUBetter is its rejection of the "point solution" model often seen in digital health, where an app might address only "back pain exercises" or "mindfulness for pain." Instead, getUBetter employs a "whole pathway" architecture. This means the digital infrastructure mirrors the patient's entire journey through the health system, from the initial onset of symptoms (acute phase) through to recovery, return to work, and long-term prevention. The platform covers a comprehensive suite of MSK pathways: Spinal: Non-specific low back pain, back and leg pain (sciatica), neck pain. Peripheral Joints: Shoulder, elbow, wrist, hand, hip, knee, ankle, and foot pain. Soft Tissue: Sprains, strains, and tendinopathies (Achilles, gluteal, tennis elbow, etc.). Complex/Chronic: Osteoarthritis management and "Living with Pain" modules. Women’s Pelvic Health: Pre- and post-natal care, incontinence, and menopause support. Crucially, the "whole pathway" concept extends to the setting of care. The app is designed to be accessible wherever the patient interacts with the system. A patient might be signposted to the app by a community pharmacist, self-refer via a GP website, or be directed by NHS 111. Regardless of the entry point, the patient enters a standardized, evidence-based care funnel that is consistent with local clinical protocols. 2.2 Mechanism of Action: The COM-B Behaviour Change Model The efficacy of getUBetter is rooted in behavioural science, specifically the COM-B model (Capability, Opportunity, Motivation - Behaviour). The platform operates on the premise that information alone is insufficient to drive recovery; patients require behavioural scaffolding to change how they manage their condition. COM-B Component Implementation in getUBetter Strategic Implication Capability Provides educational videos, symptom checkers, and clear explanations of conditions to increase health literacy and physical skills for exercises. Patients understand why they hurt, reducing fear and increasing compliance with rehab. Opportunity Offers 24/7 access on mobile devices, removing barriers related to appointment availability, travel, or waiting lists. Connects users to local physical assets (e.g., leisure centres). Democratizes access to high-quality physio advice, regardless of geography or shift patterns. Motivation Uses progress tracking, reassurance ("safety netting"), and personalized goals to build confidence (self-efficacy) and reduce anxiety about pain or work. shifts the patient from a passive recipient of care to an active manager of their health. This behavioural framework is particularly relevant to the "return to work" objective. A patient who possesses the capability to manage a flare-up at work (e.g., knowing specific stretches) and the motivation derived from understanding that hurt does not equal harm, is significantly more likely to remain in employment. 2.3 Safety Netting and Risk Stratification As a Class 1 Medical Device, getUBetter incorporates a robust safety architecture designed to manage clinical risk remotely. This is achieved through a multi-layered system of "safety netting". Initial Triage: Upon registration, patients must answer a series of "red flag" screening questions. These screen for signs of serious pathology such as Cauda Equina Syndrome (bladder/bowel dysfunction), severe trauma (fractures), or infection. If a red flag is detected, the app prevents registration and directs the patient to the appropriate urgent care service (A&E or GP), thereby preventing inappropriate self-management of dangerous conditions. Longitudinal Symptom Checking: The app does not assume a linear recovery. It includes regular symptom checks. If a patient reports worsening symptoms or new neurological signs (e.g., numbness), the app triggers a safety alert, advising the user to seek professional help. This automates the clinical safety netting that a doctor would verbally provide, ensuring it is reinforced throughout the recovery journey. Clinical Governance: All content is signed off by local clinical teams within the Integrated Care System (ICS). This ensures that the advice aligns with local protocols and formularies, and that the "signposting" directs patients to valid local services. 3. Connecting Health and Work: The Digital Intervention 3.1 The "I'm Struggling to Work" Module Recognising that employment concerns are a primary driver of patient anxiety and system cost, getUBetter has developed specific "targeted support modules" that sit within the condition pathways. These include "I'm struggling to work," "I'm on a waiting list," "I have pain," and "I have arthritis". The "I'm struggling to work" module represents a significant innovation in digital MSK care. It moves beyond generic medical advice to provide specific vocational guidance: Sickness Absence Administration: The module provides clear information on self-certification, the role of the "fit note" (formerly sick note), and statutory sick pay rights. This demystifies the administrative burden for patients who may be navigating the benefits system for the first time. Return to Work Planning: It offers practical frameworks for phased returns, discussing "reasonable adjustments" with employers, and managing fatigue. This empowers the employee to approach their line manager with a constructive plan rather than a binary "sick/not sick" status. Vocational Confidence: The content addresses the psychological barriers to returning to work, such as the fear of re-injury. It includes techniques for managing pain in the workplace, tailored to different job archetypes (e.g., sedentary desk work vs. active manual labour). Local Signposting: Crucially, the module connects the digital user to physical employment support. It can signpost directly to local Access to Work schemes, occupational health providers, or initiatives like the WorkWell coaching service. This module effectively decentralizes occupational health advice. By making high-quality vocational guidance available to the general population, it supports the millions of workers in the "gig economy," small businesses, or self-employment who lack access to corporate occupational health departments. 3.2 The Birmingham and Solihull Employer Portal The practical application of this "Health and Work" strategy is exemplified by the Birmingham and Solihull (BSol) ICS deployment. Here, getUBetter has been integrated not just into GP practices, but directly into the regional employment infrastructure. The ICS established a dedicated registration portal for local employers. This initiative allows any employer in the region, from a small café to a large manufacturing plant—to register and provide getUBetter to their staff as a free wellbeing benefit. Process: Employers complete a simple form with their company details. They receive a unique access code or QR code to distribute to staff. Accessibility: Employees register using the app, entering their work postcode if they live outside the area but work within it. This ensures the transient workforce is covered. Confidentiality: A critical design feature is the strict firewall between the user's health data and the employer. The app is completely independent; the employer knows they have provided the tool, but receives no data on who is using it or for what condition. This overcomes the "trust barrier" where employees fear disclosing health issues to management. Integration with "Easychange": The BSol deployment also integrates with Easychange, a broader wellbeing app covering stress, smoking cessation, and alcohol reduction. This creates a comprehensive "digital occupational health" suite for the region's employers, funded entirely by the ICS. 3.3 The Role of Occupational Health Providers getUBetter also partners with private Occupational Health (OH) providers. In this context, the platform serves as an adjunct to professional OH services. An OH advisor might assess an employee and then "prescribe" the app to provide daily recovery support between appointments. This hybrid model enhances the capacity of OH services, allowing high-cost human professionals to focus on complex case management while the digital platform handles routine education and rehab adherence. 4. National Policy Integration: WorkWell and NHS 111 4.1 The WorkWell Vanguard Programme The WorkWell programme is a flagship UK government initiative, jointly funded by the DWP and DHSC with a £64 Million investment. It aims to integrate health and employment support at a local level, piloting in 15 "Vanguard" areas. getUBetter has been positioned as a key digital enabler within these pilots. In Birmingham and Solihull, designated as a WorkWell Vanguard, getUBetter functions as a digital triage point for the service. The workflow is designed to identify "at-risk" workers early: Identification: A worker struggling with back pain is identified via their GP, employer, or self-referral. Digital Intervention: They access getUBetter for immediate clinical support. Risk Stratification: If the user engages with the "I'm struggling to work" module or reports high vocational distress, the app can signpost them to the WorkWell service. Human Intervention: A Work and Health Coach then picks up the case. The coach focuses on the psychosocial and structural barriers to employment (e.g., negotiating hours, CV support), knowing that the clinical management is being handled by the app. This symbiosis allows for "low-level health interventions" (like the app) to run in parallel with intensive employment coaching, preventing the duplication of effort and ensuring the patient receives holistic support. 4.2 Sussex WorkWell Discovery In Sussex, another WorkWell area, the discovery phase highlighted the need for services that act as "connectors" across fragmented systems. Stakeholders emphasized that a digital front door like getUBetter could help "clear pathways" for specific cohorts, avoiding the confusion of multiple entry points. The report underscored the necessity of embedding such tools within trusted community settings (e.g., VCSEs) and aligning them with existing MSK pathways to ensure sustainability. 4.3 Integration with NHS 111 in South East London A critical advancement in systemic integration is the embedding of getUBetter into the NHS 111 pathway. NHS 111 is often the first point of contact for acute MSK pain. In South East London (Lambeth, Southwark, Bexley), the system has been configured so that patients contacting 111 with low back pain can be directed to getUBetter. Current State: Call handlers or clinicians can refer suitable patients to the app via SMS after telephone triage. Future State (NLP): The project is advancing towards using AI-powered Natural Language Processing (NLP). This technology will analyse the caller's spoken symptoms to identify "low back pain" cases automatically, offering the app earlier in the journey. This "left shift" prevents patients from needing to wait for a clinician callback or attend an Urgent Treatment Centre (UTC), reducing pressure on the 111 service and empowering patients with immediate relief. 4.4 DWP and "Better Working Futures" In South London, getUBetter has formed a partnership with Better Working Futures, an employment support programme. Jobcentre Plus advisors and employment coaches can recommend the app to participants whose health is a barrier to finding work. This cross-sector referral acknowledges that a job seeker with untreated knee pain is unlikely to be successful in securing employment. By treating the health condition, the employment service improves its own outcomes. 5. Clinical Validity, Governance and Safety 5.1 Regulatory Status and Certification For a digital health technology to be adopted at scale within the NHS, it must meet rigorous regulatory standards. getUBetter has achieved a high level of compliance, which is essential for building trust among the clinicians who prescribe it. Medical Device Class 1: The platform is registered with the Medicines and Healthcare products Regulatory Agency (MHRA) as a Class 1 Medical Device. This certifies that it meets essential safety and performance requirements. DTAC Certified: It has passed the Digital Technology Assessment Criteria (DTAC), the NHS's baseline standard for digital health. This assessment covers clinical safety, data protection, technical security, and usability/accessibility. DCB0129 Compliance: The company adheres to the DCB0129 clinical risk management standard, employing Clinical Safety Officers to oversee the design and deployment of the algorithms. ORCHA Rating: getUBetter is the highest-scoring MSK app on the ORCHA app library (scoring 91%). ORCHA is the leading independent review body for health apps, providing assurance on data privacy, clinical assurance, and user experience. 5.2 NICE Recommendations The National Institute for Health and Care Excellence (NICE) has specifically recommended getUBetter in its Early Value Assessment (EVA) guidance for the management of non-specific low back pain. NICE highlighted the platform's potential to reduce GP appointments and its suitability for safe self-management, provided screening questionnaires are used (which are built into the app). This endorsement is a critical driver of adoption, signalling to ICS commissioners that the technology is evidence-based. 5.3 Data Privacy and Security Given the sensitivity of health data, particularly in the context of employment, getUBetter employs enterprise-grade security. Encryption: Data is encrypted in transit and at rest. Hosting: The service is hosted on AWS Cloud, benefiting from 24/7 monitoring by a Network Operations Centre (NOC). Data Sanitisation: Explicit overwriting of storage is used before reallocation to ensure deleted data cannot be accessed. Penetration Testing: Annual "IT Health Checks" are performed by CREST-approved providers to identify vulnerabilities. No Commercial Data Sharing: The platform explicitly states that patient data is never sold to third parties. This is crucial for maintaining user trust. 6. Women's Pelvic Health: A Workforce Catalyst 6.1 The Hidden Barrier to Employment getUBetter places a strong strategic emphasis on Women’s Pelvic Health, identifying it as a neglected area that significantly impacts female workforce participation. Conditions such as stress urinary incontinence, prolapse, and menopause symptoms affect a vast proportion of the female workforce. Over 80% of women report that these symptoms affect their ability to work, yet stigma often prevents them from seeking help or discussing adjustments with employers. 6.2 Targeted Modules and SBRI Funding The platform offers dedicated pathways designed to support women through key life stages that interact with their careers: Perinatal Support: Pathways for pregnancy and post-natal recovery help women manage pelvic floor issues, diastasis recti, and return to physical activity. This support is vital for facilitating a smooth return to work after maternity leave. Menopause: A specific module addresses the MSK and pelvic symptoms associated with menopause. As the workforce ages, retaining experienced women going through menopause is a key economic priority. The app provides symptom management strategies that can help women remain productive and reduce exit from the labour market. Wales SBRI Project: The strategic importance of this work was validated by a funding award from SBRI Healthcare to scale the pelvic health platform across Cwm Taf Morgannwg University Health Board in NHS Wales. This project aims to reduce inequalities in a region with high deprivation, using the digital platform to provide equitable access to pelvic health support. 6.3 Digital Inclusion in Pelvic Health The pelvic health modules are designed with inclusivity at the core. They include features like "touch to speak" and video subtitles in 10 languages, ensuring that women from minority ethnic backgrounds or those with lower literacy can access the support. This is critical in areas like East Birmingham or the Welsh Valleys, where health inequalities often correlate with language barriers. 7. Real-World Evidence and Economic Impact 7.1 Return on Investment (ROI) The economic argument for getUBetter is robust, supported by evaluations across multiple ICSs involving thousands of patients. The platform consistently demonstrates a Return on Investment (ROI) of approximately 1:4.2, meaning that for every £1 an ICS spends on the license, it recoups £4.20 in system savings. 7.2 Utilisation Metrics and "Left Shift" The platform drives a significant "left shift" of activity, moving care from high-cost clinical settings to low-cost self-management. GP Appointments: Evaluations show a 13% reduction in first-time GP appointments and a 15% reduction in repeat appointments for MSK conditions. This releases valuable GP time for complex patients. Physiotherapy: Referrals to physiotherapy are reduced by 20%. Furthermore, patients who use the app while on a waiting list require 40% fewer appointments when they are eventually seen, suggesting the app acts as effective "pre-habilitation". Urgent Care: A striking 66% reduction in Urgent Care/Emergency Department attendances for MSK issues has been reported. This is a critical metric for reducing pressure on the overstretched emergency pathway. Prescriptions: A 50% reduction in MSK medication prescriptions indicates that users are effectively managing pain using the non-pharmacological techniques (exercise, heat/ice, behavioural change) provided by the app. 7.3 Return to Work and Sickness Absence The impact on workforce metrics is equally compelling. Sick Note Reduction: In the Frimley ICS area, the deployment of getUBetter was associated with an 11% reduction in sick notes issued for MSK conditions. This directly translates to improved workforce productivity and reduced costs for employers and the state. Waiting List Validation: In a study involving 14,500 patients on a community MSK waiting list, 69.6% of getUBetter users removed themselves from the list—a rate nearly 30% higher than non-users. Additionally, 21% of users explicitly reported that the app helped them get back to work, citing improved confidence as a key factor. Patient Feedback: Qualitative data reinforces the quantitative findings. Patients report feeling "reassured" and "confident," with one user noting, "It helped me get better faster, and with more confidence... extremely helpful to see the exercises being done". 7.4 Table of Key Impact Metrics Metric Reduction / Improvement Strategic Consequence Source ROI 1 : 4.2 High value for money; sustainable for ICS budgets. NHS GP Appts (First) - 13% Releases primary care capacity. NHS GP Appts (Repeat) - 15% Reduces "frequent flyer" demand. NHS Physio Referrals - 20% Shortens waiting lists for complex cases. NHS Urgent Care Visits - 66% Relieves A&E pressure. NHS Prescriptions - 50% Reduces opioid dependency risk; cost saving. NHS Sick Notes - 11% Improves workforce retention (Frimley). NHS Waiting List Removal 69.6% Validates "wait well" / pre-hab strategy. NHS 8. Deployment Strategy and Future Outlook 8.1 The Rapid Clinical Transformation Model getUBetter has developed a methodology for deployment that allows it to launch across an entire ICS (serving millions of people) in as little as four weeks.This "Rapid Clinical Transformation Model" involves: Local Configuration: Adapting the app to local pathways (e.g., ensuring the "self-referral" button links to the correct local physio provider). Stakeholder Engagement: Workshops with GPs, physios, and patient groups to ensure buy-in. Technical Integration: Seamless integration with GP systems (like EMIS and SystmOne) to allow "one-click" prescribing via SMS. Campaign Assets: Providing physical and digital marketing materials (posters, social media assets) to drive patient uptake. 8.2 Environmental Impact (The Green Plan) The platform aligns with the NHS "Green Plan" (Net Zero). By enabling remote management, it significantly reduces the carbon footprint associated with patient travel to appointments. The reduction in unnecessary physical appointments contributes to a greener, more sustainable health service. 8.3 Future Roadmap: AI and The NHS App Looking ahead, getUBetter is positioning itself for deeper integration into the national digital infrastructure. NHS App Integration: The platform is working towards full interoperability with the NHS App. Once achieved, this will allow the 30+ million NHS App users to access getUBetter content directly, potentially making it the default standard of care for MSK across England. Predictive Analytics: The collection of anonymized population health data (e.g., heatmaps of back pain prevalence) offers the potential for predictive analytics. This could help ICSs and local authorities proactively target public health interventions (e.g., subsidised gym memberships) in areas with emerging MSK hotspots. Conclusion The convergence of high MSK disease burden, growing economic inactivity, and strained healthcare capacity creates a "perfect storm" that traditional models of care cannot weather. getUBetter has emerged not merely as a therapeutic app, but as a systemic solution to this multifaceted crisis. By successfully bridging the gap between the clinical silo (NHS) and the vocational silo (DWP/Employers), getUBetter operationalizes the concept that work is a health outcome. Its integration into flagship government programmes like WorkWell, its deep embedding into NHS 111, and its partnerships with employment services demonstrate a maturity that transcends the typical "digital health startup" narrative. The evidence is clear: when patients are empowered with the capability to understand their condition, the opportunity to access immediate care, and the motivation derived from safety-netted support, they recover faster and return to work sooner. For an Integrated Care System, getUBetter offers a rare "triple win": improved patient outcomes, reduced system costs, and a healthier, more productive regional workforce. As the UK seeks to "Get Britain Working," the scalable, evidence-based digital infrastructure provided by getUBetter offers a blueprint for the future of integrated health and employment support. https://www.getubetter.com getUbetter

10 Key Factors affecting the Enterprise Value to Equity Value bridge in European HealthTech and MedTech 2026 Executive Summary The enterprise value (EV) to equity value bridge represents the critical calculation that determines what shareholders actually receive in a transaction, the difference between a buyer's headline offer and the cash distributed to founders and investors. In the European HealthTech and MedTech sectors entering 2026, this bridge calculation has become increasingly complex, driven by structural market shifts including the end of the zero interest rate policy (ZIRP) era, heightened regulatory compliance burdens under MDR/IVDR, refinancing pressures from 2019-2021 vintage debt, and the maturation of the sector from "growth at all costs" to "industrial efficiency." This report examines the ten most significant factors affecting the EV to equity value bridge, ranked by their typical financial impact and prevalence in 2026 European HealthTech and MedTech transactions. Each factor is analysed through the lens of current market conditions, including the €2.5 Trillion private equity dry powder deployment cycle, distressed M&A driven by regulatory Darwinism, and the flight to quality favouring profitable, compliant platforms over high-burn ventures. Understanding these bridge factors is essential for founders, investors and acquirers navigating an environment where enterprise values for AI-enabled, MDR-compliant assets command 6x-8x revenue multiples and 12x-15x EBITDA multiples, while non-compliant or sub-scale assets face distressed exits at 3x-4x revenue. 1. Net Debt Adjustment Impact Magnitude: Dollar-for-dollar reduction to equity value Prevalence: Universal across all transactions 2026 Amplification: Refinancing pressure from maturing 2019-2021 debt tranches Mechanism and Calculation Net debt represents the most fundamental and mechanically straightforward adjustment in the EV to equity value bridge. The calculation subtracts a company's gross debt from its cash and cash equivalents, with the net figure then deducted from enterprise value to arrive at equity value. Net Debt = Total Debt – Cash and Cash Equivalents Total debt encompasses all interest-bearing liabilities including short-term borrowings, long-term debt, capital leases, vendor financing, and convertible instruments. Cash and cash equivalents include physical cash, demand deposits, marketable securities with maturities under 90 days, and money market instruments. European HealthTech Debt Landscape in 2026 The debt composition in European HealthTech and MedTech has evolved significantly, with three primary debt categories dominating balance sheets: Venture Debt: Growth-stage companies increasingly rely on venture debt to extend runway between equity rounds without excessive dilution. These structures typically include 10-12% annual interest rates, warrant coverage of 5-15%, and covenants tied to revenue milestones or regulatory approvals. Venture debt is particularly prevalent among companies that raised Series B or Series C rounds in 2021-2023 and now face the Series B+ Gap—the widening chasm for growth capital rounds exceeding €50 million. Equipment Financing and Capital Leases: MedTech companies with hardware components (surgical robotics, imaging equipment, diagnostic devices) commonly utilize equipment financing and capital leases. These arrangements allow manufacturers to place capital-intensive equipment in hospitals and clinics while preserving cash flow. Under IFRS 16, most leases are capitalised on the balance sheet and treated as debt-like obligations in M&A transactions. Convertible Notes and Loan Notes: European life sciences and digital health companies have embraced convertible loan notes (CLNs) as bridge financing. CLNs typically carry 10-30% discounts to the next equity round valuation and 1-3 year maturity periods. These instruments convert to equity upon triggering events (usually a qualified financing round), but if unconverted at acquisition, they are treated as debt and subtracted from enterprise value. 2026-Specific Debt Servicing Pressure A critical dynamic intensifying net debt's impact in 2026 is the maturity of debt tranches originated during the 2019-2021 fundraising boom. As these debt facilities reach their refinancing windows, HealthTech platforms, particularly those in "buy-and-build" strategies in dental, veterinary, and ophthalmology services, face refinancing risk. Companies that aggressively leveraged during the low-cost capital era now confront higher interest rates and stricter lending standards, forcing some into distressed M&A scenarios where net debt significantly erodes equity value. The net debt to EBITDA ratio has emerged as a key valuation screen, with lenders and acquirers viewing ratios above 3.0x as elevated risk in the current environment. For companies carrying excessive net debt relative to cash generation, the EV to equity bridge can produce minimal or even negative equity value for common shareholders after senior creditors and preferred equity holders are satisfied. Treatment of Restricted Cash and Off-Balance Sheet Obligations A nuanced consideration in calculating net debt is the treatment of restricted cash. While general cash balances offset debt dollar-for-dollar, cash pledged as collateral, held in escrow for regulatory compliance, or restricted under debt covenants may be excluded from the offset calculation, thereby increasing net debt. This is particularly relevant for MedTech companies maintaining cash reserves to satisfy notified body requirements under MDR/IVDR. Additionally, the definition of "debt-like items" extends beyond traditional borrowings to include accrued bonuses tied to transaction completion, deferred consideration from prior acquisitions, unfunded pension liabilities (more common in legacy European MedTech manufacturers), and contingent liabilities from litigation. The negotiation of what constitutes debt versus working capital can shift millions in equity value, making this a heavily contested area during due diligence. 2. Preferred Stock Liquidation Preferences Impact Magnitude: Can eliminate 40-100% of common equity value in moderate exits Prevalence: Universal in venture-backed companies 2026 Amplification: Down rounds and flat rounds increasing preference overhang Structure and Mechanics Liquidation preferences represent contractual rights granted to preferred shareholders, typically venture capital and growth equity investors, that entitle them to receive a defined return of capital before common shareholders (founders, employees, angel investors) receive any proceeds in a liquidity event. The standard structure includes two key parameters: Preference Multiple: The most common structure is a 1x liquidation preference, meaning investors receive their original investment amount before any distribution to common shareholders. In more challenging financing environments or down rounds, investors may negotiate 2x or 3x multiples, effectively doubling or tripling their priority claim on exit proceeds. Participation Rights: Preferences can be non-participating (investors choose between their preference amount OR their pro-rata share of proceeds) or participating (investors receive their preference amount AND participate pro-rata in remaining proceeds with common shareholders). Participating preferences create "double dipping" that dramatically reduces common shareholder returns, particularly in moderate-value exits. Impact on Equity Value Distribution To illustrate the material impact, consider a European digital health company that raised €15 Million across seed, Series A, and Series B rounds, with Series B investors holding a 1x participating preferred preference: Enterprise Value at Exit: €40 million Net Debt: €5 million Equity Value: €35 million Series B Preference: €10 million (1x of €10M investment) Series B Post-Preference Participation: 25% of remaining €25M = €6.25M Total to Series B: €16.25 million Remaining for Series A, Seed, Common: €18.75 million Before any additional preferences from earlier rounds, the Series B investors have captured 46% of equity value despite holding 25% ownership on a fully diluted basis. This scenario is increasingly common in 2026 as companies that raised at peak 2021 valuations face flat or down exits. 2026 Market Conditions Amplifying Preference Impact The shift from "growth at all costs" to "profitable efficiency" has compressed valuation multiples for unprofitable HealthTech companies from 8x-10x revenue in 2021 to 3x-4x revenue in 2026. For companies that raised multiple rounds at escalating valuations during 2020-2021, the cumulative liquidation preference stack can exceed current enterprise values, resulting in zero equity value for common shareholders. A specific risk in the European market is the prevalence of participating preferences in growth-stage financings. While U.S. venture markets have largely standardised on non-participating preferences for Series A and beyond, European investors more frequently negotiate participating structures, particularly in competitive rounds or when providing rescue financing. The Series B+ Gap—where companies struggle to raise €50M+ growth rounds, has forced many HealthTech platforms to accept "inside rounds" (led by existing investors at flat or reduced valuations) with enhanced liquidation preferences, creating compounding preference overhang that severely impacts founder and employee equity value at exit. Calculating Waterfall Distributions The practical calculation of preference distributions follows a "waterfall" methodology where proceeds flow sequentially through priority tiers: Senior Debt and Transaction Costs are satisfied first (covered in Factors 1, 4) Most Recent Preferred Round receives its preference (typically "last in, first out") Earlier Preferred Rounds receive preferences in reverse chronological order Participating Preferred Shareholders participate pro-rata in remaining proceeds Common Shareholders receive residual proceeds This waterfall structure means that in transactions below the total capitalisation table preference stack, common shareholders—the primary recipients of equity compensation and founders' holdings—may receive nothing despite a nominally successful acquisition. 3. Working Capital Adjustments Impact Magnitude: Typically ±5-15% of purchase price, dollar-for-dollar adjustment Prevalence: Standard in 85%+ of transactions 2026 Amplification: Deferred revenue complexity in SaaS models, A/R quality deterioration Purpose and Calculation Methodology Working capital adjustments ensure the buyer receives a business with sufficient operating liquidity to maintain normal operations without immediate capital injection. The mechanism compares actual working capital at closing against a negotiated "target" or "peg" level, with any surplus or shortfall resulting in a dollar-for-dollar purchase price adjustment. Working Capital Adjustment = Actual Working Capital at Closing – Target Working Capital Target working capital is typically calculated as the normalized average of the trailing 12 months, adjusted for seasonality, one-off transactions, and growth trends. Most European HealthTech transactions utilize a "cash-free, debt-free" structure where working capital is defined as current assets (excluding cash) minus current liabilities (excluding debt) Components and HealthTech-Specific Considerations Accounts Receivable: For healthcare services businesses (telehealth platforms, home health, specialty pharmacy), accounts receivable quality is paramount. The 2026 environment has seen deteriorating collection cycles, with 60% of healthcare providers facing cash flow issues due to delayed reimbursements from payers. Buyers increasingly demand aging analysis showing receivables over 90 days, with adjustments for uncollectable balances. Reimbursement delays from governmental payers (NHS in the UK, statutory health insurers in Germany) and private insurers have extended from historical 30-45 day cycles to 60-90+ days in 2026, straining working capital positions. Companies with reimbursement-dependent revenue streams must demonstrate sustainable collection patterns to avoid punitive working capital adjustments. Inventory and Work-in-Progress: MedTech manufacturers holding physical inventory face scrutiny regarding obsolescence, particularly for products approaching the end of MDR/IVDR certificate validity periods. Slow-moving inventory over 180 days is typically written down or excluded from working capital calculations. Accounts Payable and Accrued Expenses: Buyers examine payment cycles to identify aggressive payable management—a tactic where sellers delay payments to suppliers to inflate cash balances pre-closing. Such manipulation is detected through payables aging analysis and results in working capital shortfalls post-closing. Accrued expenses, particularly accrued bonuses, vacation liabilities, and regulatory compliance costs, are negotiated items. In HealthTech, year-end accruals for clinical trial costs, regulatory filing fees, and quality management system audits can significantly impact working capital levels. Deferred Revenue: The SaaS Trap The treatment of deferred revenue has emerged as the most contentious working capital negotiation point in European HealthTech, particularly for SaaS-based digital health platforms. Deferred revenue represents customer prepayments for future service obligations—a liability on the balance sheet that creates a structural disconnect between sellers (who have received cash) and buyers (who must fulfil the service obligation). Three primary treatment approaches exist: Option 1 – Treat as Debt (Most Buyer-Favorable): Deferred revenue is excluded from working capital and treated as a debt-like item, resulting in a dollar-for-dollar reduction to equity value. This approach compensates the buyer for assuming service obligations without receiving the associated cash. While theoretically sound, it is rarely accepted by sellers and represents only 15-20% of European HealthTech transactions. Option 2 – Include in Working Capital (Most Seller-Favorable): Deferred revenue is included in both the target working capital peg and the closing working capital calculation. This "no special treatment" approach is simple but fails to compensate buyers for the cost of fulfilling prepaid obligations. It appears in approximately 25-30% of transactions, typically where deferred revenue is immaterial or where sellers have significant negotiating leverage. Option 3 – Exclude but Leave "Cost to Serve" Cash (Balanced, Most Common in 2026): Deferred revenue is excluded from working capital entirely, but sellers leave sufficient cash to fund the cost of fulfilling prepaid obligations. The "cost to serve" is calculated as the inverse of gross margin, for a SaaS platform with 80% gross margins, 20% of deferred revenue remains as cash. This third approach has become the market standard in 2026, representing 50-60% of European HealthTech transactions. It balances the economic reality that sellers received customer cash while buyers inherit service obligations. Purchase Accounting Haircut An additional complexity in deferred revenue treatment is the ASC 805 (U.S. GAAP) and IFRS 3 purchase accounting requirement to remeasure deferred revenue at fair value post-acquisition. Fair value reflects the cost plus reasonable margin to fulfil remaining obligations, typically resulting in a 30-60% "haircut" to the deferred revenue liability on the buyer's opening balance sheet. This haircut reduces post-acquisition revenue recognition, creating a temporary revenue dip in the first 12-24 months post-deal, a dynamic that sophisticated buyers price into their valuation models but can surprise sellers expecting trailing revenue run rates to continue uninterrupted. Working Capital True-Up Process The working capital adjustment follows a two-step process: Estimated Adjustment at Closing: Based on the most recent pre-closing balance sheet (typically month-end within 30 days of closing), an estimated working capital figure is calculated and applied at closing. Final True-Up (60-90 Days Post-Closing): After closing, the buyer prepares audited closing balance sheet figures, and both parties reconcile to determine the final working capital position. Any delta between estimated and actual results in a cash payment (if actual exceeds target) to the seller or a clawback (if actual falls short) from escrow or directly from the seller. Disputes over working capital true-ups are common, appearing in 35-40% of transactions according to escrow claim data, with financial statement definitions (GAAP vs. management accounts), one-off item treatment, and allocation of transaction-related expenses as primary friction points. 4. Transaction Costs and Advisory Fees Impact Magnitude: 1-4% of transaction value, typically 2-3% in middle-market deals Prevalence: Universal across all transactions 2026 Amplification: Regulatory complexity increasing legal/advisory costs Composition of Transaction Costs Transaction costs represent the cumulative fees and expenses incurred to complete an M&A transaction, typically paid from transaction proceeds and thus reducing equity value distributed to shareholders. The major cost categories include: M&A Advisory and Investment Banking Fees: The largest component, representing 1-5% of transaction value on a sliding scale: Deals under €10M: 5-8% success fees plus €10-20k monthly retainers Deals €10-50M: 3-6% success fees plus €15-30k monthly retainers Deals €50-100M: 2-4% success fees plus €25-40k monthly retainers Deals €100M+: 1-3% success fees plus €40-50k+ monthly retainers In the European HealthTech market, boutique advisors specializing in the sector (such as sector-focused M&A firms) typically command premium fees due to deep buyer networks and regulatory expertise. The Lehman Formula (5% on first €1M, 4% on second €1M, 3% on third €1M, 2% on fourth €1M, 1% thereafter) remains a common baseline negotiating framework. Legal Fees: Legal counsel for both buyer and seller represents €100,000-€500,000+ depending on deal complexity: Transaction lawyers (buy-side and sell-side): €100-500k each Regulatory specialists (MDR/IVDR, GDPR, AI Act compliance): €50-150k Employment law (TUPE transfers, works council consultations): €20-75k Intellectual property counsel: €15-50k Cross-border transactions involving U.S. buyers acquiring European targets, or pan-European consolidations, incur dual legal fees in multiple jurisdictions, easily pushing total legal costs to €750,000-€1.5M for transactions in the €50-150M range. Accounting and Financial Due Diligence: Quality of Earnings (QoE) reports, financial due diligence, tax structuring, and transaction accounting represent €30,000-€200,000: Financial due diligence and QoE: €50-150k Tax advisors: €20-100k Transaction auditors: €30-75k Valuation specialists: €10-50k Regulatory and Compliance Consultants: In HealthTech and MedTech, regulatory diligence is critical and costly: MDR/IVDR compliance assessment: €25-75k GDPR and data protection audits: €15-40k Clinical evidence review: €30-100k Notified body liaison: €10-30k Other Costs: Escrow agent fees (€5-25k), financing arrangement fees (0.5-2% of debt), employee retention consultants (€10-50k), and miscellaneous costs (travel, data room, communication) add €50-150k. Total Transaction Cost Impact For a typical €75 million European HealthTech transaction in 2026, representative transaction costs might include: M&A advisory: €2.25M (3% success fee) Legal fees: €350k Accounting/tax: €125k Regulatory consultants: €75k Other costs: €100k Total: €2.9M (3.9% of transaction value) This €2.9 million is deducted from equity value before distribution to shareholders, a material reduction that founders must account for when evaluating headline offers. 2026 Cost Escalation Factors Several dynamics are increasing transaction costs in 2026 European HealthTech deals: Regulatory Complexity: MDR/IVDR compliance verification, AI Act high-risk classification assessments (for AI-driven diagnostics and treatment planning software), and GDPR data transfer mechanism reviews (particularly for cross-border deals) are adding €100-250k in incremental regulatory diligence costs. Distressed M&A Dynamics: The wave of distressed transactions driven by regulatory non-compliance and cash scarcity requires extensive restructuring advice, insolvency specialists, and work-out negotiations, increasing professional fees by 30-50% compared to friendly transactions. Cross-Border Structuring: U.S. corporate venture arms and strategic buyers entering Europe to acquire AI and robotics platforms require dual-jurisdiction structuring (U.S. and European legal counsel, tax optimization across jurisdictions, transfer pricing analysis), meaningfully increasing costs. 5. Earn outs and Deferred Consideration Impact Magnitude: 10-30% of headline purchase price, risk-adjusted value 50-70% of face value Prevalence: 35-45% of European HealthTech transactions in 2026 2026 Amplification: Valuation uncertainty driving increased earn out usage Structure and Economic Purpose Earnouts represent contingent, deferred payments to sellers based on the achievement of post-closing performance milestones—effectively bridging valuation gaps between buyer and seller expectations. They enable transactions to proceed when parties disagree on future performance trajectory, risk profile, or achievable synergies. In European HealthTech and MedTech, earn outs typically represent 15-35% of total consideration, with milestone payments triggered by: Financial Metrics: Revenue targets, EBITDA thresholds, gross margin maintenance, customer retention rates (particularly in SaaS models with annual recurring revenue) Regulatory Milestones: CE Mark approval under MDR, FDA clearance, ISO 13485 certification, reimbursement code assignment (DiGA approval in Germany, PECAN listing in France) Commercial Milestones: Product launch dates, key account wins (NHS framework agreements, hospital system contracts), integration completion (for platform consolidations) Clinical and Scientific Milestones: Clinical trial endpoints, peer-reviewed publication, real-world evidence generation Earn out Duration and Payment Structures Typical earnout periods in European HealthTech range from 12 months (short-term revenue earnouts) to 36+ months (regulatory approval-based earnouts for early-stage medical devices). Payment structures vary: Binary Milestones: All-or-nothing payments upon regulatory approval, product launch, or other discrete events Graduated Financial Earn outs: Sliding scale payments based on achieved revenue/EBITDA levels (e.g., 100% payout if €15M revenue achieved, 50% if €12.5M, 0% if under €10M) Tiered Structures: Multiple tranches with different triggers (Year 1 revenue earn out + Year 2 regulatory milestone) Valuation and Risk Adjustment From a seller's perspective, earnouts represent contingent value that must be risk-adjusted. A €10 million earnout conditional on achieving regulatory approval carries far less certain value than €10 million in cash at closing. Industry practice applies probability-weighted valuations: Low-Risk Financial Earn outs (revenue/EBITDA targets, 12-24 month periods): 70-85% probability-weighted value Moderate-Risk Milestones (reimbursement approval, product launch): 50-70% probability-weighted value High-Risk Milestones (regulatory approvals for novel devices, clinical trial outcomes): 30-50% probability-weighted value Common Friction Points and Seller Protections Earnouts are fertile ground for post-closing disputes, with key areas of friction including: Buyer's Post-Acquisition Conduct: If the buyer deprioritizes the acquired product line, reallocates resources, or makes decisions that undermine earnout achievement, sellers may claim breach of implied good faith obligations. Sale and purchase agreements increasingly include affirmative covenants requiring buyers to maintain specified investment levels, personnel, and sales support. Accounting and Measurement Disputes: Financial earn outs require precise definitions of revenue (gross vs. net, treatment of discounts/returns), EBITDA calculation methodologies (alignment with historical accounting policies vs. buyer's group policies), and treatment of inter company transactions. Change of Control Scenarios: If the buyer sells the acquired business during the earn out period, sellers negotiate provisions requiring immediate payout of earn outs (sometimes at assumed 100% achievement) or rights to receive a proportional share of the subsequent sale proceeds. 2026 Market Dynamics Increasing Earnout Prevalence The valuation uncertainty characterizing the 2026 European HealthTech market has driven increased earnout adoption. With buyers skeptical of revenue projections made during the ZIRP era and sellers resistant to accepting 2024-2025 compressed multiples, earn outs bridge the gap. Specific scenarios driving earn out structures in 2026: MDR/IVDR Transition Uncertainty: Medical device companies in the MDR transition process (particularly those with certificates expiring in Q2-Q3 2026) face binary outcomes, successful recertification maintaining full market access versus compliance failure forcing product withdrawal. Earnouts tied to successful recertification by specified deadlines have become standard. Reimbursement Pathway Risk: Digital health platforms pursuing DiGA approval in Germany or PECAN assessment in France face 9-18 month timelines with uncertain outcomes. Buyers structure earnouts paying 60-70% of consideration upfront, with the balance contingent on reimbursement approval within 18-24 months. AI Act Compliance Unknown: AI-driven diagnostic platforms and clinical decision support tools facing high-risk classification under the EU AI Act carry regulatory uncertainty. Earnouts defer 20-30% of consideration until AI Act compliance is demonstrated and product can maintain unrestricted EU market access. 10 Key Factors affecting the Enterprise Value to Equity Value bridge in European HealthTech and MedTech 2026 6. Escrow and Holdback Provisions Impact Magnitude: 7-15% of purchase price, held for 12-18 months Prevalence: 60-70% of European middle-market transactions 2026 Amplification: Increased usage due to warranty/compliance concerns Purpose and Mechanics Escrow and holdback mechanisms provide buyers with security for post-closing indemnification claims arising from breaches of representations and warranties, undisclosed liabilities, or other seller obligations. Rather than requiring sellers to pay out-of-pocket for indemnification claims, buyers withhold a portion of purchase price in a segregated account (escrow) or on their own balance sheet (holdback) for a defined period. Escrow: A third-party financial institution holds funds in a segregated account, releasing them to the seller if no valid claims arise by the expiration date, or to the buyer to satisfy verified claims. Escrow provides neutral administration and is the preferred structure for institutional investors and cross-border deals. Escrow agent fees typically range from €5,000-€25,000. Holdback: The buyer retains funds on its own balance sheet, creating a payable to the seller. Holdbacks are administratively simpler and eliminate escrow fees, but provide less security for sellers (funds are commingled with buyer's general assets and at risk if buyer becomes insolvent). Holdbacks have gained market share in 2026, representing 20% of security arrangements versus 33% for escrows. Bank Guarantee: The seller's bank provides a guarantee securing the buyer's potential claims. Bank guarantees preserve seller liquidity (funds are not tied up) but incur guarantee fees (typically 1-3% annually of guaranteed amount) and require seller creditworthiness. Usage has declined from 31% in 2023 to 19% in 2024. Typical Terms Amount: Escrow amounts in European HealthTech transactions typically range from 7-15% of purchase price, with several determinants: Deal Size: Smaller transactions (<€25M) average 10-12% escrow; mid-market deals (€25-100M) average 7-9%; larger deals (€100M+) average 5-7% Business Complexity: Multi-subsidiary structures, international operations, and regulated products drive higher escrows (10-15%) Due Diligence Quality: Limited diligence or seller resistance to providing access increases escrow requirement Cap on Indemnification: Escrows often represent the maximum liability exposure (the "cap") for general indemnification claims Duration: Standard escrow periods align with statute of limitations for contractual claims and survival periods for representations and warranties: 12 months: 52% of European transactions, covering fundamental warranties and general representations 18 months: 17% of transactions, extending protection through a full fiscal year-end and audit cycle 24+ months: Used for tax indemnity escrows (aligned with tax assessment windows) and specific regulatory/reimbursement risks Release Mechanisms: Escrows typically release in tranches—50% at 12 months if no claims are pending, remainder at 18 months—providing partial liquidity to sellers while maintaining claim security. Claim Dynamics and Recovery Rates Market data from European escrow transactions reveals: 22% of transactions result in at least one claim against the escrow Average claim amount: 34% of total escrow value Claim timing: 35% of claims are presented in the first 6 months (often financial statement or tax-related), 39% in the final 30 days before escrow expiration (strategic timing to preserve claim rights) Dispute rate: 78% of first-half claims are disputed by sellers versus buyer assertions Payment timing: 52% of valid claims are paid within 30 days of claim presentation Common claim categories in HealthTech/MedTech transactions include tax liabilities (32% of claims), financial statement inaccuracies (28%), undisclosed litigation (22%), intellectual property issues (7%), regulatory compliance gaps (5%), un collectable accounts receivable (3%), and undisclosed accounts payable (2%). 2026-Specific Escrow Considerations MDR/IVDR Compliance Escrows: Buyers acquiring medical device companies in MDR/IVDR transition are negotiating specific "regulatory escrows" of 10-20% of purchase price, held for 18-36 months and released upon confirmation of continued compliance and no regulatory enforcement actions. Reimbursement Escrows: For digital health platforms claiming (but not yet having secured) reimbursement eligibility, buyers are escrowing 15-25% of purchase price, released contingently on reimbursement approval and sustained payer coverage for 12+ months. Cybersecurity and Data Breach Escrows: Following NIS2 implementation, buyers are establishing specific escrows (5-10% of purchase price) to cover potential cybersecurity incident costs, GDPR fines, and remediation expenses for 12-18 months post-closing. 7. Minority Interest and Non-Controlling Interest Adjustments Impact Magnitude: Varies by subsidiary ownership structure, typically 5-25% of subsidiary value Prevalence: 15-20% of European HealthTech platform transactions 2026 Amplification: PE buy-and-build strategies creating complex minority structures Conceptual Framework Minority interest (also termed non-controlling interest or NCI) represents the portion of a subsidiary's equity not owned by the parent company, typically less than 50% ownership held by other investors, founders, or financial partners. When calculating enterprise value and equity value, minority interest adjustments ensure that consolidated financial metrics (which include 100% of subsidiary results) are reconciled with actual ownership economics. Inclusion in EV Calculation Minority interest is added to enterprise value (not subtracted) when bridging from equity value to enterprise value, or equivalently, subtracted when moving from enterprise value to equity value available to controlling shareholders. The logic: Consolidated financial statements include 100% of a partly-owned subsidiary's revenue, EBITDA, and assets, even though the parent owns only 51-80%. When valuation multiples are applied to these consolidated figures (e.g., EV/EBITDA), the resulting enterprise value represents the entire consolidated entity. To isolate the value attributable to the parent's shareholders, the minority shareholders' claim must be deducted. Equity Value (Parent Shareholders) = Enterprise Value – Net Debt – Minority Interest Valuation Methodology Minority interest is valued at market value, not book value (the figure appearing on the consolidated balance sheet). In private company contexts where market values are not observable, minority interest is typically valued using the same multiple applied to the overall business, proportional to the minority ownership stake. For example, if a European HealthTech platform holds 70% of a German telehealth subsidiary valued at €20 million (using comparable company multiples), the minority interest represents €6 million (30% x €20M) and is deducted from the parent's equity value. European HealthTech Applications in 2026 Minority interest structures are increasingly prevalent in European HealthTech due to several 2026 market dynamics: PE Buy-and-Build Platforms: Private equity sponsors executing buy-and-build strategies in fragmented services (dental, veterinary, ophthalmology, fertility) often acquire 51-80% controlling stakes in individual clinics or service providers, leaving founder-operators with 20-49% minority stakes. These minority stakes incentivize continued operational engagement while limiting PE capital deployment. When the platform itself is sold, each subsidiary's minority interest must be valued and deducted. JV Structures with Strategic Partners: MedTech companies entering new markets (particularly CEE and Southern Europe) via joint ventures with local distributors or hospital systems create minority interest positions. A U.K.-based surgical robotics company owning 60% of an Italian distribution JV must account for the 40% minority interest when calculating equity value. Founder Rollover and Earnout Equity: In management buyout (MBO) structures, founders may retain 10-30% equity stakes post-transaction, creating minority interests. While these are typically structured as common equity participations (not minorities in subsidiaries), they function similarly in reducing equity value available to the financial sponsor and other investors. Complications in Multi-Subsidiary Structures Complex platform businesses with 5-15 subsidiary entities, each with different minority ownership percentages, require detailed subsidiary-by-subsidiary valuation. This introduces negotiation friction over: Valuation Methodology Consistency: Should all subsidiaries use the same EBITDA multiple, or should adjustments reflect subsidiary-specific risk, growth, and scale? Liquidity and Control Discounts: Do minority positions warrant discounts for lack of control and illiquidity (typically 20-35% discounts in private company valuations)? Put/Call Rights: Do minority shareholders have put rights requiring the parent to purchase their stakes at defined prices, effectively converting minorities to debt-like obligations? 8. Pension Liabilities and Unfunded Obligations Impact Magnitude: 10-40% of enterprise value for legacy MedTech manufacturers with DB schemes Prevalence: 10-15% of European MedTech transactions (concentrated in Germany, UK, legacy manufacturers) 2026 Amplification: Declining discount rates increasing liability valuations Defined Benefit vs. Defined Contribution Schemes European pension schemes bifurcate into two categories with radically different M&A implications: Defined Contribution (DC) Schemes: Employers contribute fixed amounts to employee pension accounts, with no residual liability for investment performance or benefit adequacy. DC schemes create minimal balance sheet impact and no post-transaction obligations for buyers. Defined Benefit (DB) Schemes: Employers guarantee specific pension benefits based on salary and tenure, bearing investment risk and longevity risk. DB schemes create significant balance sheet liabilities—the present value of future benefit obligations minus pension fund assets—and impose mandatory funding requirements. Unfunded Pension Liabilities as Debt-Like Obligations In M&A transactions, unfunded pension liabilities (where benefit obligations exceed pension assets) are treated as debt-like items and deducted from enterprise value dollar-for-dollar. The economic rationale parallels debt: future mandatory cash outflows to discharge obligations. For a German MedTech manufacturer with €150 million enterprise value and €30 million underfunded DB pension obligations, the equity value calculation includes: Enterprise Value: €150M Net Debt: €25M Unfunded Pension Liability: €30M Equity Value: €95M The €30 million pension deficit erodes 20% of enterprise value before common shareholders receive any proceeds. Mandatory Contribution Requirements Beyond the static liability, DB schemes impose ongoing mandatory contribution obligations that constrain post-acquisition cash flows and investment capacity. Under the U.K. Pensions Regulator framework and equivalent European regimes, sponsors must amortise funding deficits over 3-7 year recovery periods via annual cash contributions. These mandatory contributions compete with capital allocation for growth investments, R&D, and debt service, effectively increasing the buyer's cost of capital and reducing financial flexibility. For highly levered PE-backed platforms, pension contribution requirements can violate debt covenants or trigger technical defaults. 2026-Specific Pension Risks Declining Discount Rates: Pension liability valuations use discount rates typically benchmarked to high-quality corporate bond yields. The 2024-2025 interest rate environment has seen yields decline from 2023 peaks, increasing the present value of pension liabilities by 10-20% for many European DB schemes. Longevity Risk: Improving life expectancy extends the duration of benefit payments, increasing liability valuations. European DB schemes are particularly exposed to longevity risk given aging participant demographics. Regulatory Intervention: U.K. and German pension regulators have increased scrutiny of M&A transactions involving DB schemes, requiring comfort letters, contribution acceleration, or security enhancements (charge over assets, parent company guarantees) before approving ownership changes. This regulatory friction adds 3-6 months to transaction timelines and introduces contingency risk. European Geography Matters Pension liability prevalence varies dramatically across European geographies: United Kingdom: DB schemes common in legacy MedTech and pharmaceutical companies; rigorous regulatory oversight by The Pensions Regulator Germany: Book reserve "Pensionszusage" structures create unfunded, on-balance-sheet liabilities; manufacturing sector exposure high Nordics: Shift to DC largely complete; minimal DB exposure in growth-stage HealthTech Southern Europe: Mixed prevalence; state pension systems reduce private DB exposure Acquirers targeting German or U.K. legacy MedTech assets must budget for comprehensive actuarial diligence, regulatory navigation, and potentially £10-50 Million+ liability assumptions. 9. Options, Warrants and Dilution Impact Magnitude: 5-15% dilution of equity value in venture-backed companies Prevalence: 70-80% of venture-backed HealthTech companies 2026 Amplification: Increased warrant coverage in venture debt deals Mechanism and Valuation Stock options and warrants represent rights to purchase equity at predetermined strike prices, creating dilution when exercised by increasing the total shares outstanding and reducing existing shareholders' ownership percentages. Stock Options (Employee Equity): Companies grant employees call options on company stock, typically vesting over 3-4 years. Upon exercise, employees purchase shares at the strike price (often the fair market value at grant date), and the company issues new shares. In M&A transactions, unvested options typically accelerate (vest immediately) upon change of control, and vested options are either cashed out (paid the difference between strike price and per-share deal price) or exchanged for acquirer equity. Warrants: Common in European venture debt and growth financing, warrants grant lenders or investors the right to purchase equity at specified prices. Warrant coverage typically ranges from 5-15% of the loan amount, with 10-year exercise periods. Unlike employee options, warrant exercise results in cash proceeds to the company (from strike price payment), which increases total equity value, partially offsetting dilution. Treasury Stock Method The standard approach to calculating dilutive impact uses the treasury stock method: Calculate Gross Shares from Exercise: If 1 million options/warrants with €5 strike prices are exercised, 1 million new shares are issued. Calculate Proceeds: 1 million shares x €5 = €5 million cash to company. Calculate Shares Repurchased: If the company's share price is €15, the €5 million proceeds could repurchase 333,333 shares at market price. Net Dilution: 1,000,000 new shares – 333,333 repurchased shares = 666,667 net dilutive shares This method assumes the company uses exercise proceeds to buy back shares, reducing net dilution. Fully Diluted Equity Value When calculating equity value in M&A, buyers determine "fully diluted" equity value, the value inclusive of all exercisable options and warrants. The per-share purchase price is calculated as: Price per Share = Total Equity Value ÷ Fully Diluted Shares Outstanding For a company with: 10 million common shares outstanding 2 million employee stock options (weighted average strike €3) 500,000 warrants (strike €5) Total equity value €100 million Implied share price €8 (before dilution) Using treasury stock method with €8 share price: Options: 2M new shares – (2M x €3 ÷ €8 = 750k repurchased) = 1.25M net dilution Warrants: 500k new shares – (500k x €5 ÷ €8 = 312.5k repurchased) = 187.5k net dilution Fully Diluted Shares: 10M + 1.25M + 187.5k = 11.4375M Price per Fully Diluted Share: €100M ÷ 11.4375M = €8.74 While the headline equity value remains €100 million, the per-share value is diluted from a nominal €10 (if no options/warrants existed) to €8.74, reducing founder and early investor returns by 12.6%. 2026 Venture Debt Warrant Coverage The proliferation of venture debt in European HealthTech has increased warrant overhang. Venture debt tranches of €5-20 million carry warrant coverage of 8-12%, translating to €400k-€2.4M in warrant value. For companies raising multiple venture debt facilities (initial tranche in 2023, additional funding in 2025), cumulative warrant dilution can reach 15-20% of equity value. In-the-Money vs. Out-of-the-Money Critical to dilution analysis is determining which options/warrants are "in the money" (strike price below acquisition price per share) versus "out of the money" (strike price above acquisition price). Only in-the-money instruments are dilutive, out-of-the-money options are worthless and excluded from fully diluted calculations. In the current compressed valuation environment, companies that granted options at peak 2021 valuations now face scenarios where many employee options are underwater (out of the money), creating employee retention challenges but reducing dilutive impact on exit proceeds. 10. Normalised EBITDA Adjustments and Other Balance Sheet Items Impact Magnitude: ±10-30% of EBITDA (affects valuation multiple application) Prevalence: Universal in middle-market transactions 2026 Amplification: One-time regulatory compliance costs creating large adjustments Purpose of EBITDA Normalisation While not a direct component of the EV-to-equity bridge calculation (which adjusts from EV to equity value), EBITDA normalization fundamentally affects the enterprise value itself by adjusting the earnings metric upon which valuation multiples are applied. Buyers and sellers negotiate "normalised" or "adjusted" EBITDA, stripping out one-time, non-recurring, and non-operational items to reveal sustainable, go-forward profitability. The delta between reported EBITDA and normalised EBITDA can shift valuations by 15-40%. Common HealthTech EBITDA Adjustments Owner/Director Compensation Normalisation: Private HealthTech companies often pay founders/directors below-market salaries (supplemented with dividends for tax optimisation) or above-market compensation. Normalized EBITDA adjusts to market-rate compensation for equivalent roles. For a €5M revenue digital health platform paying its CEO/founder €150k (when market is €250k), EBITDA increases by €100k upon normalisation. Non-Recurring Professional Fees: Legal fees for one-off litigation, restructuring costs, previous M&A transaction expenses, and regulatory compliance costs (initial MDR/IVDR certification vs. ongoing surveillance) are added back to EBITDA. In 2026, MDR/IVDR transition costs are a significant source of adjustment contention. Legacy MedTech companies incurring €500k-€2M in one-time technical file upgrades, clinical evaluation report development, and notified body submission fees argue for full add-backs, while buyers counter that ongoing compliance costs (annual surveillance audits, post-market clinical follow-up) are recurring operational expenses. Stock-Based Compensation: While a non-cash expense, treatment of stock-based compensation varies. Sellers argue it should be added back (non-cash), while sophisticated buyers argue it represents real economic dilution and recurring talent retention costs, particularly in high-growth SaaS platforms with broad-based equity programs. Discontinued Operations and Product Line Exits: Costs associated with product lines being sunset, markets exited, or facilities closed are adjusted out of EBITDA to reflect continuing operations. One-Time Customer/Supplier Events: Loss of a major customer or supplier, one-time revenue from a contract not expected to repeat, or unusual warranty/product liability events are normalised. Accrued Expenses and Other Balance Sheet Adjustments Beyond EBITDA normalisation, several other balance sheet items create adjustments in the EV-to-equity bridge: Accrued Expenses: Year-end bonus accruals, unused vacation liabilities, accrued regulatory fees, and other short-term obligations are negotiated. Sellers argue these are normal course liabilities included in working capital, while buyers may seek to exclude unusual or inflated accruals. Intercompany Balances: In group structures with multiple subsidiaries, intercompany receivables/payables must be eliminated during consolidation to avoid double-counting. Failure to properly reconcile and eliminate intercompany balances creates phantom assets/liabilities distorting equity value calculations. Deferred Tax Assets/Liabilities: Created during purchase accounting when assets are stepped up to fair value, deferred tax liabilities reduce equity value while deferred tax assets increase it (though buyers often discount DTA value given uncertainty of utilisation). Capitalized Software Development Costs: SaaS platforms capitalizing internal software development costs must amortize these over 3-10 year periods. The accounting treatment affects both reported EBITDA (amortisation expense) and balance sheet assets, creating negotiation points around normalisation. Conclusion and 2026 Outlook The EV to equity value bridge in European HealthTech and MedTech has grown materially more complex in 2026, driven by the confluence of macroeconomic headwinds (elevated cost of capital, debt refinancing pressure), regulatory Darwinism (MDR/IVDR creating compliance moats and non-compliance crises) and market bifurcation (flight to quality favouring profitable, compliant platforms over high-burn ventures). The ten factors examined, net debt, liquidation preferences, working capital adjustments, transaction costs, earn outs, escrows, minority interests, pension liabilities, dilution, and EBITDA normalisation, collectively determine the translation of headline enterprise values into actual cash distributed to founders and investors. In an environment where AI-enabled, MDR-compliant assets command 12x-15x EBITDA multiples while non-compliant or sub-scale assets face distressed exits at 3x-4x revenue, understanding these bridge mechanics is essential for maximising shareholder value. For European HealthTech founders navigating this landscape, several imperatives emerge: Proactively manage balance sheet health: Minimise net debt, optimise working capital, and address pension/unfunded obligations before entering sale processes Negotiate protective liquidation preference terms: Resist participating preferences and 2x+ multiples that eliminate common equity value in moderate exits Structure deferred consideration thoughtfully: Ensure earn outs have objective, measurable triggers and include protective covenants against buyer conduct that undermines milestone achievement Budget for transaction costs: Reserve 2-4% of expected proceeds for professional fees and regulatory compliance verification Understand fully diluted capitalisation: Model dilution from employee options and warrant coverage to set realistic per-share exit expectations Secure regulatory compliance: MDR/IVDR certificates and reimbursement approvals are no longer administrative hurdles, they are primary determinants of asset value and bridge dynamics. As the European HealthTech sector matures from venture-subsidised experimentation to industrial-scale commercialisation, the EV to equity bridge will remain the critical translation mechanism determining whether founders capture the value created through years of product development, regulatory navigation, and market building. Mastering its components is not optional, it is the difference between financial success and value leakage. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The 10 Best MOATs in HealthTech and MedTech In the rapidly consolidating European HealthTech and MedTech landscape of 2026, competitive moats have evolved from technological novelty to institutional grade defensibility. The €180-400 billion patent cliff facing medical device incumbents and the regulatory Darwinism imposed by the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have fundamentally restructured what constitutes a sustainable competitive advantage. This report examines the ten most defensible moats in the sector, ranked by durability and replicability barriers, with particular emphasis on their role in M&A valuation and strategic positioning. Executive Summary: The Industrialisation of Healthcare Innovation The HealthTech ecosystem has bifurcated into "industrial winners" and capital-constrained aspirants. The former category, exemplified by Flo Health, Sword Health, Oura and Owkin, demonstrates that sustainable moats are constructed at the intersection of regulatory compliance, proprietary data assets and operational infrastructure. The 2026 market is witnessing "compliance-driven M&A," where strategics acquire not merely for technology but to secure regulatory approvals that now function as tradable financial assets. Understanding which moats compound over time versus which erode under competitive pressure is essential for allocating capital in an environment where 62% of healthcare organisations have switched EHR systems at least once, clinical trial infrastructure remains fragmented, and reimbursement pathways require 2+ years to secure. I. Regulatory and Compliance Moats: The New Infrastructure Advantage The MDR/IVDR Fortress The full implementation of the EU MDR and IVDR has created a capital-intensive barrier to entry that functions as a guillotine for undercapitalised Small and Medium-sized Enterprises (SMEs). The costs associated with Notified Body certification and clinical data generation are untenable for standalone firms, driving them into the arms of larger strategics who possess the necessary regulatory infrastructure. This dynamic has produced a wave of "compliance driven M&A," where acquirers such as Roche, Siemens Healthineers, and Abbott purchase not just intellectual property and customer bases, but the regulatory approvals themselves, which now serve as significant financial assets. Strategic Implications: Companies with established ISO 13485 quality management systems, existing Notified Body relationships, and multi-jurisdictional regulatory portfolios command premium valuations. The regulatory moat is particularly durable because it compounds over time: each additional approval reduces the marginal cost and timeline of subsequent submissions while creating optionality for geographic expansion. FDA Regulatory Clearances and Pathway Mastery In the United States, FDA regulatory strategy has transitioned from a compliance hurdle to a competitive weapon. Medical technology companies that embrace early engagement through Pre-Submission (Q-Sub) meetings, design for predicate devices from inception, and leverage expedited pathways (Breakthrough Designation, De Novo, Fast Track) achieve time-to-market advantages measured in years rather than months. Regulatory approval serves as "marketing gold" with providers, payers and hospital procurement teams, functioning as a third-party validation of safety and efficacy that competitors must replicate through the same rigorous process. Quantitative Evidence: The median clinical trial setup time in the UK is 273 days, while FDA approval pathways for novel devices can extend 2-5 years depending on classification. Companies that have already navigated this process possess a first-mover advantage that is exceptionally difficult to overcome, particularly in capital-intensive categories such as surgical robotics (e.g., CMR Surgical's Versius system). The AI Act and High-Risk Categorisation The EU AI Act has categorized many medical AI tools as "high-risk," necessitating robust data governance, transparency, and clinical validation that early-stage startups often lack. This creates a bifurcated market where established players with existing compliance infrastructure can rapidly integrate AI capabilities, while new entrants face multi-year validation timelines. The Act effectively raises the technical baseline for startups, particularly around data models, interoperability layers, and enterprise-grade deployment expectations. Investment Thesis: The regulatory moat is strongest when it creates both temporal advantage (first-mover benefit) and structural advantage (compliance infrastructure that scales across products). Companies that treat regulation as a strategic function, embedding compliance into product architecture from day one, build moats that competitors cannot circumvent through superior technology alone. II. Proprietary Data Moats: The Fuel for AI Flywheels The Data Scarcity Problem in Healthcare Unlike consumer internet companies that can scrape public web data, healthcare AI companies face a structurally fragmented data landscape governed by HIPAA, GDPR, and institutional data silos. The ability to aggregate, clean and standardise vast amounts of proprietary data, whether electronic health records (EHRs), medical images, genomic sequences, or claims data, creates an advantage that is nearly impossible for competitors to replicate. This data acts as the "fuel" for AI models, making them more accurate and effective over time through continuous learning loops. The Medtronic Flywheel: Device-Generated Data at Scale Medtronic's AI strategy exemplifies the power of the data flywheel. The company's massive installed base of millions of market-leading devices generates a continuous stream of unique, high-fidelity clinical data. This proprietary dataset is used to train superior AI algorithms—such as the AccuRhythm™ platform for cardiac monitoring—which enhance device performance, deliver measurable clinical benefits (97.4% reduction in false pause alerts), and drive further market adoption. The flywheel effect creates self-reinforcing momentum: better data → superior algorithms → improved clinical outcomes → expanded installed base → even more data. Competitive Moat Analysis: While competitors, including large technology companies, may have access to "big data," they do not have access to this specific, longitudinal, device-generated clinical data. The data Medtronic collects is not generic; it is directly relevant to the physiological parameters its devices monitor and treat. This relevance is the key differentiator, creating a formidable data moat that compounds annually. Tempus AI: Multi-Modal Data Aggregation Tempus AI has constructed one of the most defensible moats in healthcare AI through the combination of proprietary genomic sequencing data, clinical patient records, outcome-linked datasets, and diagnostic data tied to real-world decision-making. This multi-modal data aggregation creates an advantage that new entrants cannot replicate without years of clinic partnerships, patient enrollment, and regulatory approvals. The company's ability to link genomic data to clinical outcomes enables both therapeutic development partnerships with pharmaceutical companies and diagnostic applications for oncologists, a cross-side network effect that deepens the moat with each additional data source. Network Effects: Epic's Cosmos and Doximity's Physician Platform Epic Systems demonstrates how network effects operate in healthcare software. The company's Cosmos data platform enables health systems to leverage the collective power of clinical data from across Epic's participating customer base to "inform clinical interventions, make new discoveries, and advance medicine". This creates both same-sided network effects (hospitals benefit from other hospitals joining and sharing best practices) and cross-sided network effects (the Epic Payer Platform connects health systems and payers, creating efficiency gains that attract more users to both sides). Doximity, the physician networking platform, generates revenue primarily through pharmaceutical and health system clients who pay for access to engaged clinicians. The company achieves 90%+ gross margins through same-sided network effects: engaged physicians attract more physicians, which increases the platform's value to pharmaceutical advertisers and healthcare recruiters, creating a self-reinforcing flywheel. Investment Framework: The data moat is strongest when it exhibits three characteristics: (1) Exclusivity – the data cannot be obtained elsewhere, (2) Longitudinality – tracking patients or devices over years creates temporal depth, and (3) Outcome linkage – tying data to clinical or financial outcomes enables monetisation across multiple stakeholders (providers, payers, pharma). III. Clinical Workflow Integration and Switching Costs The EHR Lock-In Problem Electronic Health Record (EHR) systems represent one of the highest switching cost moats in enterprise software. The true cost of moving from one EHR to another extends far beyond licensing fees to encompass data migration (tens of thousands of dollars per-record transfer in some cases), hardware and infrastructure upgrades, productivity losses during transition (which can last months), interface fees for integrating ancillary systems, and consultant costs for implementation and training. The UK's median clinical trial setup time of 273 days illustrates the operational drag of healthcare IT transitions. Quantitative Benchmarks: A typical physician practice faces comprehensive costs that often exceed initial budgets by 40-60%, with hidden expenses such as maintaining the previous EHR system online to meet record retention requirements (an ongoing OPEX burden) and lost revenue during the transition period. For large hospital systems, EHR switching costs can reach $50+ million, creating a powerful economic disincentive to change vendors even when superior alternatives exist. Workflow Embedding as Competitive Strategy Healthcare software companies that embed their platforms into customers' core workflows, becoming an anchor to care delivery and/or life sciences technology stacks, build defensibility for years to come. This workflow lock-in operates through multiple mechanisms: (1) Training and adoption costs, retraining clinical staff on new systems disrupts patient care, (2) Data dependencies, clinical decision support tools that rely on historical patient data lose effectiveness when data is fragmented across systems, and (3) Process integration, automating admission criteria, medical necessity documentation, or prior authorisation workflows creates dependencies that are painful to unwind. Case Study – Insiteflow: Insiteflow's EHR integration platform connects third-party solutions directly into the EHR workflow, enabling clinicians to access external data and recommendations within their existing systems through seamless display, single sign-on, and write-back capabilities. This creates a "platform within a platform" moat where value accrues to the integration layer that reduces friction rather than to individual point solutions. FHIR Interoperability: Threat or Opportunity? The Fast Healthcare Interoperability Resources (FHIR) standard is democratizing data access and lowering integration barriers. While this reduces one source of switching costs, it simultaneously creates an early adopter advantage for companies that build FHIR-native architectures. Organisations that proactively invest in FHIR implementation gain cost savings (dramatic reductions in administrative burden within months), competitive advantage (interoperable systems attract enterprise customers), and regulatory compliance (alignment with mandates such as the 21st Century Cures Act). Strategic Takeaway: Workflow integration moats are most durable when they combine deep process embedding (becoming mission-critical to daily operations) with technical interoperability (FHIR compliance reduces migration friction but maintains stickiness through data depth and user adoption). IV. Reimbursement and Payor Pathway Moats The CPT Code Fortress Current Procedural Terminology (CPT) codes, maintained by the American Medical Association, are the gateway to reimbursement for medical procedures and devices in the United States. Securing a Category I CPT code—which describes procedures performed by physicians and commands Medicare payment rates established by CMS, requires a minimum 2-year timeline and endorsement from the Coding and Reimbursement Committee of a relevant specialty society. This creates a temporal and relational moat: companies must cultivate relationships with Key Opinion Leaders (KOLs) and specialty societies, gather clinical data demonstrating medical necessity, and navigate annual CPT Editorial Panel meetings. Reimbursement Pathway Economics: Even after FDA approval, medical device companies face a sequential gauntlet: (1) Coding – obtaining CPT/HCPCS codes (6 months to 2+ years), (2) Coverage – securing payer policies affirming medical necessity (variable by payer, often 1-3 years post-code), and (3) Payment – negotiating adequate reimbursement rates. Companies that complete this pathway first establish de facto market standards, as subsequent entrants must demonstrate not just clinical equivalence but clinical superiority to justify payer attention. Payor Contracts and Negotiated Rate Advantages Favorable payor contracts create a revenue moat that is difficult for competitors to overcome. Healthcare organisations with strong payer contract management systems can identify underpayments (46% of denials stem from missing or inaccurate data), optimise fee schedules, and negotiate better terms during renewal cycles. The complexity of managing contracts across Medicare, Medicaid, PPOs, and self-funded ERISA plans creates an operational advantage for organisations with dedicated contract management infrastructure and analytics capabilities. Value-Based Contracting: The shift toward value-based care models, where payments are tied to quality metrics, population health outcomes, or shared savings, creates additional stickiness. Once a provider or technology company establishes a value-based contract with a payer, the data requirements, risk-sharing arrangements, and outcome measurement frameworks create switching costs that extend beyond technology to organisational capabilities and financial architecture. Real-World Evidence (RWE) as a Strategic Asset Real-world data (RWD) from electronic health records, claims databases, registries, and patient-generated sources, when analysed to produce real-world evidence (RWE), can accelerate both regulatory approvals and reimbursement decisions. Medical device companies that systematically collect RWD during post-market surveillance build evidence bases that support: (1) Reimbursement expansion, demonstrating impact on outcomes valued by payers (hospitalisations, total cost of care), (2) Label expansion, identifying subpopulations where the device delivers greatest benefit, and (3) Competitive positioning, quantifying real-world effectiveness versus competitors. Investment Implication: The reimbursement moat is strongest when it combines regulatory approval, established CPT codes, favourable payer contracts, and ongoing RWE generation that continuously reinforces clinical and economic value propositions. V. Brand, Trust and Clinical Evidence Moats Regulatory Credibility as a Trust Signal In healthcare, where purchasing decisions directly impact patient outcomes and organisational reputation, trust is not just a marketing asset, it is a competitive moat. Companies that achieve regulatory milestones such as FDA clearance, CE marking under MDR, or ISO 13485 certification signal institutional quality that reduces perceived risk for hospital procurement committees. This is particularly critical in medical AI, where explainability, bias mitigation, and clinical validation are essential for physician adoption. Case Study – SkinVision: SkinVision's achievement of Class IIa certification under the EU MDR required demonstrating medical purpose, accuracy, safety, and consistency across devices through 11 peer-reviewed clinical studies. This regulatory approval became a commercialization asset, enabling 30+ global partnerships with insurers and health providers by proving operational discipline and long-term reliability. Decision Defensibility in B2B Procurement The most decisive factor in B2B healthcare buying is not price or performance, but fear, specifically, the fear of not being able to defend a purchasing decision if it fails. What buyers truly seek is a "career-proof rationale": clinical evidence, peer recommendations, thought leadership, risk mitigation frameworks, and social proof from similar organizations. This creates a brand moat for companies that invest in generating defensible decision frameworks: peer-reviewed publications, comparative effectiveness studies, health economics and outcomes research (HEOR), and testimonials from respected institutions. Quantitative Evidence: 64% of consumers read provider reviews, and star ratings below 3.7 are often seen as red flags. In enterprise healthcare, the importance of reputation is magnified: hospital procurement committees evaluate not just clinical efficacy but also vendor financial stability, regulatory compliance history and references from peer institutions. Key Opinion Leader (KOL) Relationships Relationships with Key Opinion Leaders, physicians and researchers who are recognised experts in their specialties—provide both credibility and market access. KOLs influence clinical study design, provide feedback on product development, educate other healthcare professionals, and lend reputational endorsement that shapes physician prescribing behavior. The moat created by KOL relationships operates through trust networks: a recommendation from a renowned specialist significantly impacts other physicians' willingness to adopt a new treatment or technology. Strategic Approach: Effective KOL engagement requires understanding the "why" for each stakeholders, some seek research collaboration, others continuing medical education opportunities, and still others desire to influence therapeutic development. Companies that provide transparent scientific support, sponsor clinical trials, and create collaborative environments build multi-year relationships that competitors cannot easily replicate. VI. Scale, Network Effects and Platform Economics The Installed Base Consumables Model Medical device companies with large installed bases of capital equipment create recurring revenue moats through consumables, spare parts, and service contracts. This "razor-and-blades" model is particularly powerful in diagnostics (instruments driving reagent pull-through) and surgical robotics (platforms requiring proprietary tools and maintenance). The moat is strongest when the original equipment manufacturer's consumables and service genuinely reduce risk and downtime, not merely through closed compatibility, but through superior performance and rapid support response. Lifecycle Benchmarks: High-risk medical devices exhibit replacement cycles of 13-18 years (anesthesia machines: 13 years, defibrillators: 14 years, heart-lung machines: 16 years, ventilators: 13 years). During this period, the installed base generates annuity-like revenue streams from consumables and service contracts. However, the moat requires continuous investment: a shrinking placement engine eventually slows the annuity, and competitors can erode margins if service quality deteriorates. Cross-Side Network Effects in Healthcare Platforms Multi-sided platforms that connect distinct stakeholder groups create network effects that compound as the platform scales. Epic's Payer Platform exemplifies this: by connecting health systems and payers for prior authorization, event notifications, and care coordination, Epic creates value for both sides while making itself the default solution for complex workflows. The cross-side network effect operates through increasing returns: more payers join because more health systems use it, and vice versa, raising barriers for competitors who must achieve similar scale to be relevant. Verse Medical Case Study: Verse Medical provides nurses with a free, AI-powered platform for ordering medical supplies, capturing the entire procurement transaction workflow. The company monetises by positioning itself as the intermediary between medical suppliers and insurance payers. As Verse scales, it gains negotiating leverage with suppliers (volume discounts) and demonstrates improved patient outcomes to payers (value-based pricing), deepening the moat and making the platform increasingly indispensable. Patient and Clinical Data Accumulation Companies that accumulate longitudinal patient data create flywheels where better AI-driven insights lead to improved outcomes, which attract more patients and clinicians, generating more data, which enables even better AI insights. Talkspace, for example, leverages millions of therapy sessions to identify which therapeutic approaches work best for specific conditions and predict patient outcomes. The proprietary nature of this dataset, built through direct patient-therapist interactions over years, creates a barrier that competitors cannot overcome without similar time investment.[ The platform moat is most defensible when it combines network effects (value increases with user count), data accumulation (proprietary datasets improve over time), and transaction capture (monetisation embedded in workflow rather than charged separately). VII. Intellectual Property and Patent Portfolios The AI Patent Race in Healthcare Leading biotech and medtech innovators are engaged in an aggressive AI patent race, with companies such as Gritstone Bio, Guardant Health, and Recursion filing dozens of AI-related patents since 2020. Guardant Health, a leader in liquid-biopsy cancer diagnostics, filed 26 AI patents and had 17 granted in that period, securing intellectual property around algorithms and data pipelines critical to analysing genomic data from blood. This patent activity signals R&D commitment, deters competitors through defensive IP, and attracts investors who view strong patent portfolios as validation of technical differentiation. Strategic Value: Patents provide competitive intelligence and first-mover advantage in nascent AI-medical fields. However, the moat is sustainable only when patents cover system-level functionality (how data is ingested, normalised, validated, and operationalised in clinical settings) rather than narrow implementation details that can be designed around. Well-designed digital health patents protect functional capabilities, not just source code, establishing enforceable boundaries that persist even as competitors build similar systems using different approaches. Patents vs. Trade Secrets: A Hybrid Strategy For AI healthcare inventions, a combination of patents and trade secrets typically provides stronger legal and commercial advantages than relying solely on copyright protection. Patents offer broader scope of protection and exclusive rights that prevent others from making, using, or selling the patented technology. Trade secrets protect proprietary algorithms, training datasets, and operational processes that are not publicly disclosed. The hybrid approach leverages patents for core innovations that require public disclosure (attracting investment and partnership opportunities) and trade secrets for continuously evolving methodologies (maintaining competitive advantage without expiration) As AI models become commoditised and foundation models are trained on public data, the value of proprietary data is shifting from model training to domain-specific fine-tuning and feedback loops. Companies must demonstrate that their data moat is not dependent on a single fragile data source and that it can port forward as new model generations (GPT-6, Gemini 3, Claude 4) are released. VIII. Clinical Trial Infrastructure and Real-World Evidence Capabilities The Infrastructure Deficit Clinical evidence generation from and for representative populations requires modern trial infrastructure that broadens research into routine practice. However, inefficient infrastructure and limited supporting resources impede the ability of healthcare organizations to incorporate research into clinical workflows. Administrative requirements, complex budgeting, contracts, and varied Institutional Review Board expectations, create operational challenges that discourage trial activation, especially at locations unaccustomed to participating in research. Quantitative Barriers: The UK's limited clinical trial infrastructure (39 clinical trial sites per million population, ranked 12th globally) and median setup time of 273 days reduce competitiveness and undermine the UK's ability to enroll patients in time-sensitive studies. This infrastructure deficit represents a barrier to entry for companies seeking to generate clinical evidence required for regulatory approval and reimbursement. Biobanks and Tissue Sample Repositories Large-scale biobanking initiatives create unique research assets that are difficult to replicate. The UK Biobank's sequencing of approximately 500,000 participants, combined with phenotypic data, creates one of the largest resources for understanding the relationship between genetic variation and human traits. Companies such as Regeneron Genetics Center and GSK that have access to this data through collaborative agreements gain insights into drug target identification, validation, and pharmacogenomics that competitors without similar datasets cannot match. Competitive Moat: Tissue banks that enroll thousands of patients and collect specimens for genomic, epigenomic, transcriptomic, metabolomic, and proteomic analysis create longitudinal datasets that compound in value over time. These repositories enable real-world evidence generation, biomarker discovery, and patient stratification strategies that inform both clinical development and commercialization. Pragmatic Trial and RWE Capabilities The ability to conduct pragmatic clinical trials, which evaluate interventions in real-world settings rather than highly controlled conditions—creates a strategic advantage. Pragmatic trials are cheaper than traditional randomized controlled trials (RCTs), can obtain data on a larger number of clinical outcomes, and generate evidence that is more generalizable to routine practice. Companies that build decentralised trial infrastructure, point-of-care randomisation capabilities, and virtual data warehouses can accelerate evidence generation while reducing costs. Investment Implication: The clinical trial infrastructure moat is strongest when it combines patient recruitment networks (established relationships with healthcare sites), regulatory expertise (efficient protocol design and IRB navigation), and data infrastructure (real-world data capture and analysis capabilities). IX. Customer Lifetime Value and Retention Economics The Economics of Healthcare Customer Retention In healthcare, customer lifetime value (CLV) is substantially higher than in most B2B sectors due to long contract cycles, high switching costs, and regulatory lock-in. Customer retention is 5-10x cheaper than acquisition, and loyal customers not only contribute recurring revenue but also generate referrals and participate in co-development initiatives that improve product-market fit. CLV Drivers in Healthcare: The most important factors influencing CLV include product alignment with clinical workflows (reduces abandonment), long-term contractual relationships (3-5 year terms are common in hospital software), loyalty programs and VIP support tiers (particularly relevant for physician networks and digital health apps), and customer-oriented services that continuously deliver value. Companies that monitor CLV and link it to operational marketing systems can make data-driven decisions about which customer segments justify higher acquisition costs and which require retention-focused interventions. Value Based Care and Risk-Sharing Models Value-based care (VBC) contracts create exceptional customer stickiness because they require deep integration between payers, providers, and technology platforms. Once a technology company establishes a VBC arrangement—such as shared savings agreements, bundled payments, or capitation models, the data exchange requirements, performance measurement frameworks, and financial risk alignment create multi-dimensional switching costs. Exiting such relationships would require not just replacing technology but also renegotiating financial models and compliance frameworks. Gross Margin Trajectories: Tech-enabled services businesses in healthcare exhibit stepwise gross margin improvement as they scale: 25% gross margins at early stage, 35% at $10-25M ARR, 45% at $25-50M ARR, and 60%+ beyond $50M ARR. This trajectory reflects increasing leverage from technology deployment, more efficient provider panels, and the ability to command higher service prices as clinical outcomes data accumulates. Healthcare SaaS Benchmarks: Healthcare SaaS companies average 70-85% gross margins at scale (similar to cloud software), with best-in-class companies exceeding 80%. These margins are supported by high customer retention rates (often 90%+ net revenue retention for mission-critical software) and the ability to expand within accounts as customers add modules, users, or clinical use cases. X. Vertical Integration and End-to-End Solutions The Vertical SaaS Opportunity Vertical SaaS solutions tailored to specific healthcare workflows exhibit higher adoption rates, better regulatory compliance, and stronger customer retention than horizontal software platforms. By embedding industry-specific best practices, compliance requirements (HIPAA, GDPR, FSSAI), and integrations with existing healthcare IT infrastructure, vertical SaaS companies reduce implementation friction and create stickiness through deep process dependencies. Double-Edged Sword: While vertical specialisation drives product-market fit, it also creates vendor lock-in risks. As businesses become heavily reliant on a specific vertical SaaS solution, transitioning to a different provider becomes costly and disruptive, particularly when the software is deeply integrated into clinical processes and workflows. This lock-in works to the advantage of incumbents but requires continuous innovation to prevent customer dissatisfaction and competitive displacement. Orchestration Over Point Solutions The healthcare technology landscape is littered with point solutions, tools designed to tackle specific tasks (denial prediction, transcription, prior authorisation, coding improvement) that do not integrate with each other. The future competitive advantage lies in orchestration: AI systems that seamlessly integrate disparate tools, interpret inputs across multiple systems, adjust based on context and feedback, and deliver tangible outcomes rather than isolated insights. Strategic Shift: Companies that design for end-to-end orchestration, even if they initially deliver a point solution, position themselves to capture value as the ecosystem matures. This requires building composable architectures with plug-and-play APIs, edge + cloud hybrid models for environments with unreliable connectivity, and FHIR-native interoperability from day one.[ Strategic Recommendations for M&A and Investment For Strategic Acquirers Prioritise Compliance Infrastructure Over Technology Novelty: In the current regulatory environment, companies with established MDR/IVDR certification, FDA clearances, and ISO 13485 QMS are strategic assets that enable faster product rollouts across acquired portfolios. Value Data Flywheels, Not Data Lakes: Acquisition targets should be evaluated on whether their data assets create self-reinforcing loops (device data → algorithm improvement → clinical outcomes → market share → more data) rather than static repositories. Assess Workflow Lock-In Depth: The stickiness of a software platform is a function of process embedding (how mission-critical it is to daily operations), data dependencies (how much historical patient data drives value), and switching costs (financial and operational burden of migration). Reimbursement Readiness is a Valuation Multiplier: Companies with established CPT codes, favorable payer contracts, and ongoing RWE generation command premium multiples because they de-risk commercialisation for acquirers. For Private Equity Investors Gross Margin Trajectories Signal Operational Maturity: Healthcare SaaS companies should exhibit 70-85% gross margins at scale, while tech-enabled services businesses should show stepwise progression from 25% to 60%+ as they deploy technology and improve provider efficiency. Network Effects and Platform Economics Drive Disproportionate Returns: Multi-sided platforms that capture transaction workflows (not just facilitate them) can negotiate better rates, demonstrate outcomes to payers, and deepen moats with scale. Value-Based Care Alignment Creates Contractual Moats: Portfolio companies with VBC contracts benefit from multi-year revenue visibility, lower churn, and alignment with healthcare's long-term shift toward outcomes-based payment. For Venture Capital and Growth Investors Regulatory Strategy as Day-One Priority: Companies that integrate regulatory compliance into product development from inception (not as a post-market afterthought) achieve faster market entry, attract strategic partners, and build defensible moats. Clinical Evidence Generation is Non-Negotiable: Peer-reviewed publications, RCTs, and real-world evidence studies are not marketing expenses—they are moat-building investments that drive physician adoption, payer coverage, and acquisition valuations. KOL Relationships Require Long-Term Cultivation: Trust networks among Key Opinion Leaders cannot be built overnight. Early-stage companies should invest in scientific advisory boards, collaborative research, and transparent data sharing to establish credibility. Conclusion: The Era of Industrial HealthTech The winners in the 2026 HealthTech and MedTech ecosystem are those with the strongest "Compliance Moats," the most "Interoperable Data," and the clearest "Industrial Logic", profitability, unit economics, and infrastructure status. The industry is graduating from the "laboratory" phase to the "factory" phase, and consolidation is the primary mechanism of this maturation. Sustainable competitive advantage is no longer about first-to-market technology or venture capital firepower; it is about constructing institutional-grade moats at the intersection of regulatory approval, proprietary data assets, workflow integration, reimbursement pathways, clinical evidence, and operational scale. For investors and M&A professionals, understanding which moats compound versus which erode under competitive pressure is the difference between acquiring strategic assets and overpaying for features that commoditise within 18 months. The companies that will command premium valuations in this environment are those that demonstrate not just innovation, but defensible innovation, moats that deepen with every regulatory approval, every patient enrolled, every data point captured, and every year of clinical evidence accumulated. These are the businesses that executives, investors, and decision-makers would pay premium consulting fees to access, and they represent the future of healthcare technology M&A. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 16th January 2026 European HealthTech this week is being shaped by early implementation steps around the EU AI Act / MDR–IVDR stack, fresh EU‑level funding windows, and several notable AI‑driven digital health rounds in Switzerland and Spain. Deal flow is clustering around preventive AI, automation of clinical workflows and AMR diagnostics, with MedTech regulatory tightening continuing to drive portfolio and due‑diligence behaviour into 2026. Policy and regulation The EU’s “Digital Omnibus” proposal is moving through Parliament and Council, aiming to push back and smooth some high‑risk AI timelines under the AI Act and to ease reporting for smaller AI developers, directly impacting AI SaMD roadmaps beyond 2026. Regulators and commentators are now treating the AI Act, MDR/IVDR and the Digital Omnibus as a core stack for health AI, intended to harmonise rules, reduce compliance friction, and clarify expectations for software and AI‑enabled devices from 2026 onward. EU‑level programmes and HTA Horizon Europe’s 2026–2027 work programme channels part of a €14Bn R&I envelope into health and digital technologies, with Global Health EDCTP3 allocating up to €147M to infectious‑disease‑linked digital and clinical innovation, which is supportive for data‑rich platforms and diagnostics. The Commission has opened the first submission window for Joint Scientific Consultations under the new EU Health Technology Assessment framework, providing an earlier, centralised read‑across on clinical evidence and cost‑effectiveness for upcoming therapies and possibly complex devices. MDR/IVDR, MedTech and EUDAMED New MDR/IVDR guidance and implementing measures, including MDCG‑endorsed documents on software and AI, are feeding into 2026 planning, with a narrative of tighter but more predictable oversight as Notified Body capacity and expectations become clearer. EUDAMED’s staged roll‑out now has four functional modules, with a six‑month transition into a fully mandatory state by 28 May 2026, increasing transparency on actors, certificates and vigilance and raising the data available for payer scrutiny and M&A due diligence. Funding rounds and startup moves Zurich‑based Ahead Health has raised about $6m led by RTP Global to build an AI‑powered “health OS” focused on preventive care, positioning itself as a pan‑European infrastructure layer for risk prediction and engagement. Spain’s Tucuvi has secured roughly €17m to scale its LOLA voice‑AI platform, which reports up to 80% automation of nursing follow‑up, reinforcing the thesis around telephonic/voice automation for chronic‑care operations in European providers. MedTech and diagnostics themes French MedTech FineHeart has raised around €83m (mix of private and European public capital) to progress its implantable device for advanced heart failure, signalling continued investor appetite for complex cardiovascular hardware plus data plays. Dutch, female‑led ShanX Medtech has closed a ~€24m round to accelerate ultra‑rapid AMR diagnostics from Eindhoven, underlining antimicrobial resistance as a strategically backed European theme and reinforcing the region as an innovation hub for high‑throughput diagnostics. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk >>> European MedTech this week is defined by tightening but clearer MDR/IVDR and EUDAMED timelines, strong early‑year funding for cardiology and AMR diagnostics, and growing focus on robotics, neuro and data‑rich devices. Portfolio rationalisation under MDR pressure and a shift toward platforms that pair hardware with defensible data and AI‑enhanced workflows are central dealmaking themes.​ Regulation and guidance The Commission’s late‑2025 MDR/IVDR simplification proposal is now shaping 2026 work plans, with emphasis on digitalised procedures, harmonised Notified Body practice and crisper rules for software, AI and cybersecurity in MedTech.​ EUDAMED has been confirmed as fully mandatory from 28 May 2026, with four live modules (actors, UDI/devices, notified bodies & certificates, market surveillance) making transparency and post‑market surveillance central to EU MedTech strategy.​ Market structure and MDR pressure 2026 is framed as a defining MDR year, with looming 2027–2028 transition deadlines and Notified Body bottlenecks accelerating portfolio pruning, launch cancellations and selective product withdrawals across European MedTech.​ Analysts describe a “Great Rationalisation” in which capital concentrates on fewer assets with clear regulatory narratives, strong evidence packages and integration into EHDS‑style data flows rather than stand‑alone devices.​ Funding rounds and capital flows FineHeart in France has raised about €83m (private plus European public funds) to advance its implantable heart‑failure device, signalling continued appetite for high‑acuity cardiovascular hardware with rich data exhaust.​ ShanX Medtech in Eindhoven has secured €24m to scale ultra‑rapid AMR diagnostics, reinforcing antimicrobial resistance as a strategic EU priority and positioning the Netherlands as a key diagnostics hub.​ Innovation themes: robotics, neuro, data Coverage of Paris‑based Robeauté’s micro-robotics platform for diagnosis and treatment in neuro underscores growing interest in micro‑robotic and neuro‑interventional devices as 2026 MedTech frontiers.​ Investors are prioritising devices that combine novel hardware with longitudinal data capture and AI‑supported workflows in cardiovascular, neurovascular, advanced diagnostics and surgical robotics, often designed to plug into emerging EHDS infrastructures.​ Strategic and cross‑border moves Weekly deal wraps put FineHeart and ShanX among the top European startup transactions for 5–9 January, setting a strong tone for MedTech fundraising into Q1 2026.​ Strategic commentary highlights ongoing buy‑and‑build strategies in fragmented device niches and MedTech‑adjacent software, with platforms that can scale across borders and align with EU data infrastructure seen as prime consolidation candidates.​ Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Strategic Roadmap for European HealthTech and MedTech Shareholder Value in 2026 Strategic Roadmap for European HealthTech and MedTech Shareholder Value in 2026 The European healthcare technology and medical technology (MedTech) landscape entering 2026 stands at a profound inflection point, characterised by a transition from the speculative fragmentation of the early 2020s to a disciplined era of "Industrial Maturity". The macroeconomic environment has shifted decisively from the "growth at all costs" paradigm that defined the Zero Interest Rate Policy (ZIRP) era to a rigorous focus on "profitable efficiency," unit economics and regulatory fortitude. This is not merely a cyclical adjustment; it is a structural transformation of the asset class. For founders and boards operating in this space, 2026 is not simply another fiscal year; it is a "clearing event" driven by Regulatory Darwinism. The simultaneous full enforcement of the EU Medical Device Regulation (MDR), the mandatory utilisation of EUDAMED, the In Vitro Diagnostic Regulation (IVDR) and the implementation of the EU AI Act has created a high-barrier environment. These regulations are no longer administrative hurdles but the primary determinants of asset value. In this ecosystem, regulatory compliance has mutated into a financial asset, a "compliance moat" that protects incumbents and validated scale-ups while effectively barring undercapitalised entrants. Furthermore, the capital markets in 2026 are defined by the "Dry Powder Paradox." While private equity and venture capital funds hold nearly $2.5 Trillion in unallocated capital, deployment is highly selective, favouring platforms that demonstrate industrial logic over theoretical potential. The "Series B+ Gap" has widened, creating a bifurcation where companies either achieve "industrial scale" or face distressed acquisition. The investment logic has shifted from "venture subsidies" to "industrial logic," where value is created through operational leverage, vertical integration, and the arbitrage of fragmented markets. This report provides a strategic blueprint for European founders to maximise shareholder value in this transformed landscape. It synthesises regulatory deadlines, capital market trends, and operational shifts into ten critical imperatives. It is written for the sophisticated operator who understands that in 2026, the margin for error has vanished, and the opportunity for category dominance has never been higher for those who can execute with precision. 1. Fortify the "Compliance Moat": Leveraging Regulatory Darwinism as a Valuation Driver In the prevailing market conditions of 2026, regulatory status has ascended to become the single most critical metric for valuation, surpassing traditional SaaS metrics like Annual Recurring Revenue (ARR) growth in early-stage assessments. The market is undergoing a phenomenon best described as "Regulatory Darwinism," where the exponentially high cost and complexity of compliance act as a filter, ruthlessly eliminating "science projects" and rewarding "industrial assets" that have successfully navigated the labyrinth. Founders must pivot their strategic mindset from viewing regulation as a cost centre, a tax on innovation, to treating it as a defensive moat that justifies significant valuation premiums. The 2026 Regulatory Convergence: A Perfect Storm Three major regulatory timelines converge in 2026, creating a bottleneck that will strangle unprepared ventures while propelling compliant firms to leadership positions. This convergence creates a binary outcome for companies: those with certificates are investable assets; those without are distressed liabilities. Critical Regulatory Deadlines and Milestones in 2026 Regulation Key Deadline Strategic Implication & Founder Action EU MDR (Medical Device Regulation) May 26, 2026 Deadline for Class III custom-made devices; marks the effective end of the transition period for many legacy devices. This creates a supply crunch and an M&A opportunity for compliant firms. EUDAMED (European Databank on Medical Devices) May 28, 2026 Mandatory use of Actor, UDI/Device, Certificate, and Market Surveillance modules. Transparency becomes absolute; competitors' failures become visible. EU AI Act August 2, 2026 Enforcement begins for High-Risk AI systems (Annex III), including many medical AI tools. Non-compliance risks fines up to 7% of global turnover and market withdrawal. NIS2 Directive Throughout 2026 Full enforcement of cybersecurity requirements for "essential entities," extending liability to the C-suite. Navigating the Notified Body Bottleneck The "bottleneck" predicted for 2026–2027 regarding Notified Body (NB) capacity is now an operational reality. NBs are facing a massive surge in demand as thousands of legacy devices, previously marketed under the Medical Device Directive (MDD) or In Vitro Diagnostic Directive (IVDD), rush to transition to the new Regulations before the final cutoffs. The removal of the "sell-off" provision means that non-compliant inventory cannot even be liquidated, turning assets into write-offs overnight. For founders, the strategic imperative is twofold. First, they must have secured Notified Body capacity well in advance. For those currently in the review queue, the focus must be on the impeccable quality of technical documentation. The "stop-the-clock" mechanisms utilized by NBs during reviews, where the timeline pauses while the manufacturer addresses deficiencies—are becoming lethal for cash runways in a tight funding environment. Ensuring first-pass acceptance is not just a quality goal; it is a treasury survival strategy. Second, the valuation impact of this bottleneck is profound. Companies possessing a valid MDR/IVDR certificate in 2026 command a premium because they offer acquirers—particularly US strategics looking to enter Europe, immediate market access without the 18–24 month regulatory risk profile. The certificate itself is a transferable asset that enhances the enterprise value significantly above the sum of the technology and talent. EUDAMED as a Transparency Engine and Competitive Weapon From May 28, 2026, the European Databank on Medical Devices (EUDAMED) becomes mandatory for critical modules, including Actor Registration, UDI/Device Registration, and Notified Body Certificates. This shifts data transparency from a voluntary best practice to an obligatory standard. For the astute founder, EUDAMED is more than a reporting requirement; it is a source of competitive intelligence. The public accessibility of the database allows companies to verify the certification status of competitors. Founders should actively monitor EUDAMED to identify competitors who have failed to meet the deadline or whose certificates have lapsed. These distressed competitors represent prime acquisition targets for "buy-and-build" strategies, allowing stronger firms to acquire customer bases and IP from non-compliant entities at distressed multiples. Conversely, ensuring one's own data is pristine in EUDAMED is essential for maintaining trust with hospital procurement departments, which will increasingly use the database to vet suppliers. The AI Act Binary Filter The EU AI Act, with key obligations for high-risk systems effective August 2, 2026, introduces a binary filter for investment in HealthTech. Medical AI tools classified as high-risk (which encompasses most diagnostic and therapeutic AI) must demonstrate robust data governance, human oversight, and transparency. The investment consequence is immediate: Investors in 2026 are rigorously avoiding "Black Box" AI models. Founders must engineer "Glass Box" interpretability into their algorithms to satisfy Article 13 (Transparency) and Article 14 (Human Oversight) of the AI Act. Failure to do so renders the asset un-investable to institutional capital, regardless of the algorithm's performance metrics. The cost of retrofitting explainability into a black-box model is often prohibitive; thus, "privacy by design" and "compliance by design" must be evidenced in the technical due diligence process. 2. Operationalise "Profitable Efficiency": The Shift to EBITDA and Industrial Logic The financial thesis for 2026 has definitively moved away from revenue growth at the expense of margins. The "Industrialisation" of the sector means that the cost of capital remains elevated compared to the pre-2022 era, and investors are prioritizing "profitable efficiency" over speculative scale. The End of the "Growth at All Costs" Era In the ZIRP era (2019–2021), valuations were often detached from unit economics, driven by user acquisition metrics and top-line expansion. In 2026, the metric of choice is EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) or a credible, near-term path to it. The market has fatigued on "science projects", companies with promising technology but broken business models. The Evolution of the "Rule of 40" Investors are applying a stricter, more nuanced version of the "Rule of 40" (Growth Rate + Profit Margin). In previous cycles, a company could satisfy this rule with 50% growth and -10% margins. For 2026, the weight is shifting heavily toward the profit component. High-growth, high-burn companies are seeing their multiples compressed to 3x–4x revenue, whereas profitable, moderate-growth platforms command 10x–14x EBITDA. This shift necessitates a rigorous review of the P&L, cutting non-essential R&D and focusing on high-margin product lines. Arbitraging the Valuation Gap in Services A specific opportunity exists for founders in "analog" healthcare services (veterinary, dental, ophthalmology) to structure their companies to take advantage of the valuation arbitrage driving Private Equity (PE) activity. Buy-and-Build Strategy: PE firms are aggressively acquiring smaller, fragmented assets at lower entry multiples (6x–8x EBITDA) and integrating them into larger pan-European platforms. These consolidated platforms, once scaled, trade at significantly higher exit multiples (12x–15x EBITDA). Actionable Insight: If a founder cannot achieve platform scale independently, the optimal shareholder value play in 2026 may be to position the company as a premium "bolt-on" for a larger PE-backed platform. This requires standardising back-office operations and financial reporting to ensure seamless integration post-acquisition, thereby making the target more attractive and commanding a higher premium. Revenue Cycle Management (RCM) as a Cash Flow Engine There is a massive capital rotation toward Revenue Cycle Management (RCM) and administrative automation tools. In an environment of strained public health budgets and hospital deficits, technologies that offer immediate ROI to healthcare providers by improving billing efficiency and reducing denials are highly prized. Strategic Pivot: Founders of digital health platforms should pivot their value proposition to emphasize financial ROI for their customers (e.g., "Our tool saves the hospital €X per patient" or "Reduces administrative overhead by Y%") rather than purely clinical outcomes. Tools that directly improve the P&L of the customer are recession-resilient and command higher valuations because they are "must-haves" rather than "nice-to-haves". 3. Master the Data "Plumbing": Capitalizing on the European Health Data Space (EHDS) While consumer-facing digital health apps have lost favor due to high customer acquisition costs and low retention, "smart capital" in 2026 is flowing into the "unsexy" backend infrastructure of healthcare, the plumbing that enables interoperability and data fluidity. The operationalisation of the European Health Data Space (EHDS) is the structural driver of this shift, creating a unified market for health data. EHDS Implementation Timeline and Strategic alignment The EHDS Regulation, having entered into force, is in a critical transition phase. By 2026, the focus is on the preparatory infrastructure for mandatory data sharing. The regulation creates two distinct value streams: Primary Use (patient care) and Secondary Use (research, innovation, and policy). Founders must align their technology to support the HealthData@EU infrastructure, ensuring they are not locked out of the ecosystem. Table 2: EHDS Implementation Phase and Founder Actions Timeline Milestone Strategic Implication for Founders 2026 Preparation for General Application Invest heavily in FHIR and OMOP standards. Ensure data architecture is machine-readable and interoperable by design. March 2027 Deadline for Commission Implementing Acts Align product roadmap with emerging technical specifications for European Electronic Health Record Exchange Formats (EEHRxF). 2028-2030 Full Obligation for Secondary Use Access Position proprietary datasets as "curated assets" for pharmaceutical and research buyers, leveraging the mandated access pathways. Interoperability as a Product Requirement In 2026, interoperability is not a feature; it is a market-entry requirement. The era of the "walled garden" in health tech is over. The "Translation Layer": Startups that serve as middleware, translating legacy EMR data into modern standards like FHIR or openEHR, are high-value targets. These "plumbing" companies facilitate the connection between fragmented legacy systems and modern applications, a critical need for the realisation of the EHDS. Data Sovereignty and Opt-Outs: With the EHDS facilitating cross-border data exchange, founders must ensure their systems respect the complex "opt-out" mechanisms and privacy safeguards mandated by the regulation. Platforms that can automate the management of patient consent and data rights across different jurisdictions will be essential infrastructure. Monetization of Curated Data: The EHDS effectively creates a new asset class: Curated Clinical Data. Companies that hold proprietary, high-quality, longitudinal datasets (e.g., patient registries, real-world evidence banks) are becoming prime acquisition targets for pharmaceutical companies facing patent cliffs and needing real-world data to support R&D and market access. 4. Secure Reimbursement via National Fast-Tracks: Moving from Pilot to Permanent A critical failure mode for European healthtechs in the past decade has been the "pilot trap", an endless cycle of unpaid or low-paid pilots with hospitals that never convert to statutory reimbursement. In 2026, maximising shareholder value requires bypassing the pilot trap by securing permanent reimbursement through national fast-track programs like Germany's DiGA and France's PECAN. These pathways provide the recurring revenue streams that investors demand. Germany: The Mature DiGA Market Germany's Digital Health Application (DiGA) pathway remains the gold standard for digital therapeutics reimbursement in Europe, but it has matured significantly by 2026. 2026 Status: The DiGA Fast-Track (managed by BfArM) is fully operational for Class I and IIa devices.However, the bar for demonstrating "positive healthcare effects" (pVE) has risen. The initial "easy wins" are gone; regulators now scrutinise data rigorously. Strategy: Founders must move beyond the provisional listing (which allows 12 months of reimbursement) to permanent listing. This requires robust Randomized Controlled Trials (RCTs) or high-quality Real-World Evidence (RWE) that demonstrates a statistically significant benefit. Failure to convert to permanent listing results in de-listing, which can lead to a collapse in shareholder value and a loss of market credibility. France: The PECAN Opportunity France has introduced the PECAN (Prise en Charge Anticipated Numérique) scheme, offering a one-year "early reimbursement" bridge for digital therapeutics and telemonitoring, modeled to accelerate access compared to the traditional LPPR route. Advantage: Unlike the strict initial requirements of DiGA, PECAN allows reimbursement before the completion of final clinical studies, provided there is "initial clinical evidence" and a presumption of innovation. Execution: Founders should utilise the PECAN pathway to generate revenue while simultaneously gathering the conclusive data required for the permanent LPPR (List of Reimbursable Products and Services) listing. This dual-track approach reduces cash burn, provides non-dilutive funding, and validates commercial viability to investors early in the lifecycle. UK and Nordics: System-Level Procurement UK (NHS): The NHS in 2026 is focused on a massive "Analogue to Digital" transformation. The 2026 NHS Planning Framework incentivises technologies that release clinical capacity, such as AI scribes and primary care triage tools Founders should target "Framework Agreements" which simplify procurement for NHS Trusts. Nordics: Finland is piloting a national reimbursement model for digital therapies modelled on DiGA/PECAN, launching in late 2025/2026. Founders should view the Nordics not just as a market, but as a premier testbed for generating high-quality RWE due to the region's longitudinal patient registries and unique personal identification numbers, which allow for long-term outcome tracking. 5. Implement "Vertical AI" with Governance: Beyond the Hype The investment thesis for AI in 2026 has matured beyond the "hype cycle" of generalist Large Language Models (LLMs) to Vertical AO models trained on proprietary, domain-specific data sets that solve specific, high-value clinical or operational problems. The Shift to "Clinical Co-Pilots" and Ambient Intelligence Investors are no longer funding "AI for AI's sake" or generic chatbots. They are funding Ambient Clinical Intelligence (ACI) and workflow automation tools that reduce administrative burden without disrupting the clinician-patient relationship. Use Case: AI notetaking tools that listen to consultations and generate real-time clinical summaries are being backed by health systems like the NHS to free up clinician time, addressing the workforce crisis. Value Proposition: The value lies in the "unsexy" backend: coding automation, discharge planning, and patient flow optimization. These applications offer measurable efficiency gains (e.g., reducing appointment length by 8% or increasing patient throughput), which translates directly to the provider's bottom line. High-Risk AI Compliance as a Differentiator As noted in Section 1, the AI Act's enforcement in August 2026 acts as a binary filter. Governance as a Product: Founders must implement a Quality Management System (QMS) that specifically addresses AI risks, aligning with ISO 42001 (Artificial Intelligence Management System). This includes "post-market monitoring plans" specific to AI performance drift, ensuring the model remains accurate over time. Data Governance: High-quality, representative training data is essential not just for performance but for compliance with the AI Act's bias mitigation requirements. Founders must demonstrate the provenance and diversity of their training data to pass regulatory audits. 6. Engineer for Cyber-Resilience: NIS2 as a Clinical Priority In 2026, cybersecurity is no longer merely an IT concern; it is a board-level liability and a clinical safety imperative. The NIS2 Directive is fully enforceable, significantly expanding the scope of "essential entities" to include medical device manufacturers, digital health providers, and laboratories. The Liability Shift to the C-Suite NIS2 introduces a paradigm shift by assigning personal liability to management bodies. Executives can be held personally accountable, including fines and suspension from office, for failure to implement adequate cybersecurity risk management measures. Governance Implication: Founders must establish a dedicated cybersecurity governance committee with direct reporting to the Board of Directors. Cybersecurity is now a standing item on the board agenda. Incident Reporting: The strict reporting timelines (24-hour early warning, 72-hour full notification) require automated incident response systems. Manual processes will fail to meet these statutory deadlines, exposing the company to fines of up to €10 Million or 2% of global turnover. Supply Chain Security and the SBOM NIS2 mandates security assessments of the entire supply chain. This means that hospitals (Essential Entities) will demand rigorous security proof from their suppliers (MedTech startups). Vendor Management: Medtech founders must audit their software suppliers (e.g., cloud providers, third-party libraries). Providing a Software Bill of Materials (SBOM) is becoming a standard requirement for selling into hospital systems that are themselves NIS2-compliant entities. Failure to provide an SBOM can disqualify a vendor from procurement tenders. Optimise for the "Exit Window": Aligning with the Private Equity Liquidity Cycle The macro-financial context of 2026 is defined by a massive backlog of private equity assets that need to exit. Funds from the 2019–2021 vintage are reaching the end of their holding periods, creating a "use it or lose it" dynamic. This creates a unique window for exits, provided companies align with the buyers' needs. The "Private IPO" and Continuation Funds With the public IPO market remaining selective and volatile, PE firms are utilising Continuation Funds to hold high-performing assets longer while returning liquidity to Limited Partners (LPs). Strategy: Founders should position their companies as attractive assets for these continuation vehicles. This involves demonstrating consistent EBITDA growth, low churn, and a defensible market position. Being the "crown jewel" asset in a continuation fund can offer a partial exit for early investors while securing capital for the next growth phase. Secondary Buyouts: We expect a wave of secondary buyouts where larger PE funds acquire platforms from smaller mid-market funds to execute the next phase of growth (e.g., international expansion). Founders should maintain relationships with upstream PE funds to facilitate these transactions. Distressed M&A and Consolidation For companies that have failed to secure reimbursement or achieve MDR compliance, 2026 will be a year of distress. Acqui-hires and IP Sales: Large strategics will acquire struggling startups solely for their intellectual property or regulatory approvals ("compliance driven M&A"). Survival Strategy: Founders in a fragile cash position must explore strategic mergers early in 2026 before the "regulatory guillotine" of May/August 2026 forces a fire sale. Merging with a competitor to share the burden of regulatory compliance and commercial infrastructure can save shareholder value that would otherwise be wiped out in a bankruptcy. Execute a Dual-Market Strategy: Navigating the EU-US Divergence While Europe undergoes regulatory hardening, the US market remains a critical target for scale. However, the FDA is also evolving in 2026, particularly with the harmonisation of its Quality System Regulation (QSR) with ISO 13485 (the QMSR rule). The FDA QMSR Alignment In February 2026, the US FDA's Quality Management System Regulation (QMSR) goes live, aligning the US 21 CFR Part 820 with the international ISO 13485 standard. Opportunity: This harmonisation reduces the friction for European companies (who are already ISO 13485 compliant) to enter the US market. The duplicate burden of maintaining two separate quality systems is significantly reduced. Strategy: Founders should leverage their existing ISO 13485 certification to streamline US market entry. However, they must remain vigilant about specific FDA requirements that remain distinct (e.g., complaint handling, labelling and Medical Device Reporting) to avoid 483 observations during inspections. US Market Entry as a Valuation Multiplier European valuations are traditionally lower than US valuations. Establishing a commercial footprint in the US, even a modest one, can significantly expand the valuation multiple. Reimbursement Arbitrage: The US reimbursement landscape (CPT codes) is often more fragmented but can offer higher per-unit revenue than European centralised systems. Securing US reimbursement (e.g., Remote Patient Monitoring codes) validates the business model for global investors and opens up a larger Total Addressable Market (TAM). A dual-market strategy diversifies regulatory risk; if a product is delayed in the EU due to Notified Body bottlenecks, US revenue can sustain the company. Align with Corporate Venture (CVA) Needs: Solving the Pharma Patent Cliff Large pharmaceutical and medtech incumbents are facing a severe "patent cliff" between 2026 and 2030, with an estimated $180 Billion to $400 Billion in revenue losing exclusivity. They are desperate for external innovation to fill their revenue gaps and defend their market position. The "TechBio" Convergence Pharma companies are aggressively acquiring AI-driven drug discovery platforms ("TechBio") to compress development timelines and reduce costs. Generative Biology: Startups using Generative AI for molecule design, protein folding, and target identification are high-value targets. Action: Founders in the TechBio space should structure their business development to offer "platform deals" rather than single-asset licenses. This aligns with Pharma's need for scalable R&D engines that can produce multiple candidates over time. MedTech Incumbents as Strategic Buyers Medtronic, Johnson & Johnson, Philips, and Siemens Healthineers are using their corporate venture arms (CVA) as strategic reconnaissance tools. Strategic Fit: These incumbents are looking for assets that integrate into their existing hardware ecosystems (e.g., AI software that runs on Siemens MRI machines or robotic surgery add-ons). Partnership Strategy: Securing a strategic investment or commercial partnership with a major incumbent in 2026 is often a precursor to acquisition. It validates the technology and provides a distribution channel that startups cannot build organically. Founders should actively cultivate relationships with CVA teams, framing their startups as the "R&D department" that the incumbent cannot build internally. 10. Future-Proof via ESG & Supply Chain Transparency (CSRD) Sustainability has graduated from a "nice-to-have" marketing message to a license to operate. The Corporate Sustainability Reporting Directive (CSRD) requires large companies to report on their environmental and social impact. While many startups fall below the direct reporting thresholds, they are indirectly affected as part of the supply chain of larger entities. Emissions and the Supply Chain Large medtech and pharma companies (the customers and acquirers of startups) must report on their Scope 3 emissions (which includes their supply chain). Competitive Advantage: Founders who can provide granular, verifiable data on the carbon footprint of their products (e.g., sustainable packaging, energy-efficient software, localized manufacturing) become preferred suppliers. Green Procurement: Hospitals and health systems, particularly in the Nordics and the UK (NHS Net Zero targets), are introducing strict environmental criteria into procurement tenders. Non-compliant vendors risk being locked out of the market entirely. Social Governance and Diversity Investors are increasingly scrutinising "Social" and "Governance" factors as indicators of risk. Diversity & Inclusion: Diverse leadership teams are viewed as a proxy for good governance and innovation capacity. Ethical AI: As part of ESG, the ethical use of AI (bias mitigation, fairness) is a key governance metric that aligns with the AI Act requirements. Demonstrating a proactive stance on ethical AI reduces reputational risk and appeals to ESG-focused funds. Conclusion: The Great Rationalisation The year 2026 represents a "Great Rationalisation" for the European HealthTech and MedTech sector. The era of easy money, regulatory ambiguity, and "growth at all costs" is over. It has been replaced by a landscape defined by industrial rigour, regulatory enforcement, and financial discipline. For founders, the path to maximizing shareholder value lies not in chasing hype cycles, but in building robust, compliant, and efficient infrastructure. It requires a mastery of the "boring" elements of the business: Quality Management Systems, regulatory technical files, unit economics, interoperability standards, and cybersecurity protocols. The winners of 2026 will be those who successfully navigate the "Regulatory Darwinism," turning compliance into a competitive advantage, and who position themselves as essential infrastructure in the digitized healthcare systems of Europe and the United States. They will be the "industrial assets" that attract the trillions of dollars of dry powder waiting to be deployed. Summary Checklist for Founders in 2026 Regulatory: Secure MDR/IVDR certification immediately, prepare for AI Act enforcement (Aug 2026). Financial: Optimise for EBITDA and the evolved "Rule of 40"; prepare financial data for PE due diligence. Data: Align technology with EHDS technical standards; build native interoperability (FHIR). Reimbursement: Convert DiGA/PECAN pilots to permanent listings with robust clinical data. AI: Implement "Glass Box" Vertical AI with robust ISO 42001 governance. Cyber: Ensure NIS2 compliance; establish Board-level cybersecurity oversight. Exit: Position for the PE liquidity cycle (Continuation Funds/Secondary Buyouts). Global: Leverage ISO 13485 for FDA QMSR alignment to open the US market. Partnerships: Target Pharma/MedTech incumbents facing patent cliffs with platform solutions. ESG: Provide specific carbon/sustainability data for supply chain reporting to customers. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Future of Patient Portals as 'Engines and Infrastructure supporting the NHS App' Strategic Context: The Death of the Destination Portal The digital architecture of the United Kingdom's National Health Service (NHS) is currently executing a fundamental pivot, a transformation that marks the end of the "destination portal" era and the rise of the "aggregation engine." For the past decade, the prevailing model for digital patient engagement was characterised by fragmentation and sovereign operational silos. Individual NHS Trusts, operating as semi-autonomous fiefdoms, procured standalone Patient Engagement Platforms (PEPs), proprietary "front doors" that required patients to register, retain credentials and navigate distinct user interfaces for every provider they encountered. A patient with complex needs might manage a login for myhospital.com for their oncology care, a separate account for their General Practitioner (GP) and yet another for mental health services. This fragmented landscape, while functionally operative, created profound friction, limiting adoption and stifling the potential for a unified longitudinal health record. The current strategic trajectory, crystallised by the NHS England "Wayfinder" program and the statutory weight of the Data Saves Lives strategy, mandates a reversal of this fragmentation. The NHS App is no longer merely a utility for ordering repeat prescriptions or displaying COVID-19 vaccination status; it has been designated as the "single front door" for the health service. This designation is not simply a branding exercise but a rigid architectural mandate that redefines the commercial and technical reality for third-party suppliers. In this new ecosystem, patient portals are ceasing to be standalone destinations. Instead, they are evolving into "engines", sophisticated backend infrastructure layers that handle complex business logic (scheduling, triage, clinical correspondence, rule-based routing) but surface their functionality through the national infrastructure of the NHS App. The Policy Imperative and the "Wayfinder" Mandate The catalyst for this shift lies in the aggressive policy frameworks established post-pandemic. The unprecedented adoption of the NHS App, driven by the necessity of the NHS COVID Pass, saw registered users swell to over 28 Million by July 2022, representing approximately 63% of the adult population in England. By late 2024, this figure had surpassed 32 Million users. This critical mass fundamentally altered the strategic calculus for NHS England. The cost of customer acquisition for a standalone hospital app marketing to patients, guiding them through registration, verifying identity, became unjustifiable when compared to the existing, verified user base of the NHS App. Consequently, the "Wayfinder" program (technically the Secondary Care Integration Programme) was launched with a clear objective: to integrate secondary care appointment data directly into the NHS App. The mandate, reinforced by the Wayfinder Services Directions 2023, compelled acute trusts to expose their appointment data to the national aggregator. The directive was unambiguous: by March 2024, all non-specialist acute trusts were required to be integrated. This effectively closed the market for standalone portals that could not, or would not, integrate. The value proposition for Trusts shifted overnight. Procurement decisions were no longer based solely on the quality of a vendor's user interface, but on their ability to act as a compliant "engine" that could feed the national "front door". This policy is rooted in three strategic pillars: Friction Reduction: Eliminating the cognitive load on patients who previously had to navigate multiple digital identities. The "single sign-on" (SSO) capability via NHS Login is the cornerstone of this friction reduction, allowing seamless passage from the national app to the provider's specific domain. Standardisation of Experience: Ensuring that a referral letter looks and behaves consistently whether it originates from a Cerner Millennium system in London or a System C instance in Manchester. The "Wayfinder" architecture imposes a baseline of standardized metadata on these interactions. Market Shaping: By controlling the primary access point, NHS England forces interoperability on a supplier market that has historically profited from vendor lock-in. To participate in the national app ecosystem, vendors must adopt open standards (FHIR), breaking the "walled garden" business models of legacy EPR providers. The "Engine" Defined: From SaaS to BaaS In this emerging paradigm, successful digital health vendors are transitioning from providing Software-as-a-Service (SaaS) destination sites to providing Backend-as-a-Service (BaaS) or "headless" engines. An "engine" in this context is a specialised software platform that manages the complexity of healthcare workflows, writing back to the Patient Administration System (PAS), managing clinical safety rules for appointment cancellation, generating accessible letter formats, without necessarily owning the primary pixel-level interaction with the patient. This mirrors the broader trend in enterprise technology toward "headless" Content Management Systems (CMS), where the repository of content is decoupled from its presentation. In healthcare, the "content" is the patient's care pathway. Vendors like DrDoctor, Patients Know Best (PKB), and Induction Zesty are positioning themselves as these invisible engines. Their value is no longer judged by the beauty of their proprietary app icon on a patient's home screen, but by the reliability of their API endpoints and their ability to handle high-volume transactions through the NHS App "shell". The Strategic Shift – Destination Portal vs. Aggregation Engine Operational Dimension The Legacy Model (Standalone Portal) The Future Model (NHS App Engine) Primary Access Point Proprietary URL (e.g., mytrust.nhs.uk) or Vendor App NHS App (National Infrastructure) Identity & Auth Local credentials or Vendor-specific account NHS Login (National Biometric SSO) User Acquisition Trust-led marketing (Posters, leaflets) Organic (32M+ pre-verified users) Notification Channel SMS / Letter (High operational cost) App Push Notifications (Near-zero cost) Data Architecture Siloed Data Lake per Trust Federated Aggregation via FHIR APIs Vendor Value Prop "We own the patient relationship." "We power the national infrastructure." Clinical Governance Local Trust Governance Distributed Chain of Custody (DCB0129) The operational and commercial implications of this shift are profound. For vendors, the "engine" model offers immediate scale but threatens commoditisation. If the user experience is standardised by the NHS App, vendors must compete on backend performance, integration depth, and ancillary features (like AI triage) rather than UI design. For the NHS, the model promises a unified patient experience but introduces significant systemic risks regarding single points of failure and data governance, which will be explored in depth in subsequent sections. 2. Technical Architecture: The Mechanism of Aggregation The realisation of the "single front door" vision relies on a complex technical architecture known as the Patient Care Aggregator (PCA). Understanding the mechanics of the PCA is essential to grasping how "engines" interact with the national infrastructure and where the limitations of this model lie. The Patient Care Aggregator (PCA) and Wayfinder The PCA acts as a national routing layer, a federated broker that sits between the NHS App (the front end) and the myriad local systems (the back ends). Crucially, the PCA is designed to be stateless regarding clinical data; it does not create a massive central database of all patient appointments. Instead, it operates on a query-response model. When a patient opens the "Appointments" tab in the NHS App, the following sequence occurs: Identity Assertion: The user is authenticated via NHS Login, leveraging OpenID Connect (OIDC) standards to assert identity (LOA P2 - high level of assurance). Endpoint Resolution: The PCA queries a central registry to identify which Trusts or PEPs hold a relationship with the patient's NHS Number. Broadcasting: The PCA broadcasts a request to the registered "engines" (e.g., DrDoctor, Zesty, Netcall). The request effectively asks: "Do you have any active bookings for NHS Number X?" Aggregation: The engines query their local databases (or the Trust's PAS) and return a standardised JSON bundle containing metadata: Appointment Date, Time, Specialty, Location, and Status. Rendering: The NHS App aggregates these responses and renders a unified list. To the patient, appointments from three different hospitals appear in a single, consistent view. Deep Linking vs. Native Experience A critical architectural distinction exists between native rendering and deep linking, which defines the user experience and the technical burden on the engine. Native Experience (Read-Only): The listing of appointments is "native." The NHS App reads the standardized data returned by the engine and displays it using its own UI components. This ensures accessibility compliance and visual consistency. The patient stays strictly within the NHS App environment. Deep Linking (Transactional Handoff): When a patient wishes to act on an appointment, for example, to cancel, reschedule, or complete a pre-operative questionnaire, the PCA cannot handle the complex business logic required. (e.g., "This appointment cannot be cancelled within 24 hours," or "This MRI requires a safety checklist first"). Instead, the PCA generates a Deep Link. The user clicks "Manage Appointment." The NHS App uses a secure token handoff (OAuth 2.0) to seamlessly log the user into the PEP's specific web portal. A "WebView" (an in-app browser window) opens, loading the vendor's interface (e.g., DrDoctor or PKB) inside the NHS App frame. The user performs the action on the vendor's infrastructure. Upon completion, the user is returned to the native app view. Critique of the Deep Linking Model: While theoretically seamless, research indicates significant friction in this handoff. Users report disorientation when the design language shifts from the NHS standard to a third-party interface. Furthermore, technical failures in the token exchange can lead to "login loops," where a patient is asked to re-enter credentials for a system they do not recognise, undermining the "single sign-on" promise. The reliance on Deep Linking means the "engine" must still maintain a robust, user-facing web front end; it cannot be purely an API service. The engine must effectively run a high-performance web app that can load instantly within the constraints of a mobile WebView. The "Headless" Healthcare CMS The move to an engine model aligns with the broader "Headless" trend in software architecture. Just as a Headless CMS decouples content from display, a Headless PEP decouples the clinical pathway from the patient interface. Research suggests that forward-thinking vendors are re-architecting their platforms to treat the NHS App as just one of many "heads." A single appointment slot in the database might be surfaced via: The NHS App (via PCA API). A bedside tablet in the hospital (via a local web app). A kiosk in the waiting room. A text message chatbot. This "Omnichannel" capability is the defining characteristic of the next generation of patient portals. It allows data consistency across all touchpoints. If a patient updates their demographics in the NHS App, the Headless architecture ensures this change propagates instantly to the kiosk and the PAS, without manual reconciliation. Vendors adopting this architecture (e.g., using technologies like GraphQL or rigorous RESTful APIs) gain a significant competitive advantage over legacy monolithic portals that are difficult to integrate. Integration Standards: FHIR and BaRS The lingua franca of this ecosystem is FHIR (Fast Healthcare Interoperability Resources). To function as an engine, a vendor must expose APIs that strictly conform to NHS England’s FHIR profiles.The Booking and Referral Standard (BaRS) is the specific implementation guide that dictates how booking data must be structured. This standardisation drives commoditisation. In a world where every vendor must output the exact same FHIR resource for an "Appointment," proprietary data structures lose their value. The value shifts to the reliability of the integration. Vendors are now competing on their ability to handle the "messy" reality of legacy hospital systems (HL7 v2 messages, CSV files, on-premise servers) and translate them into pristine FHIR resources for the PCA. The "engine" is effectively a translation layer that sanitises the chaotic data of the NHS back-office for consumption by the modern NHS App front end. Commercial Landscape: The Battle of the Engines The transition to the engine model has triggered a restructuring of the UK digital health market. The need for scale, compliance, and deep integration capabilities is driving consolidation, separating the market into "Infrastructure Titans" and "Niche Innovators." DrDoctor: The Transactional Engine DrDoctor has emerged as the premier "transactional engine" for secondary care. Their strategy is explicitly aligned with the "Wayfinder" vision, positioning their platform, HybridOS, as the operating system for the hybrid NHS. Integration Agnosticism: DrDoctor’s core value proposition is its ability to connect with over 20 different PAS/EPR systems, including major players like Oracle Cerner, Epic, System C, and Lorenzo.They market themselves to Trusts as the "universal adaptor" that bridges the gap between legacy on-premise infrastructure and the cloud-native NHS App. Strategic Milestone: DrDoctor facilitated the first-ever integration of an Epic EPR Trust (Birmingham Women's and Children's) into the NHS App. Epic’s native "MyChart" portal is notoriously self-contained, often functioning as a walled garden. DrDoctor’s ability to extract data from Epic and feed the PCA proved that the engine model can permeate even the most closed ecosystems. This success cemented DrDoctor’s status as a critical infrastructure partner rather than just an app developer. Operational Focus: Their "engine" focuses on high-volume, high-value transactions: appointment rescheduling, digital letters, and DNA reduction. By embedding these flows into the NHS App, they deliver the efficiency savings (paperless switching) that Trusts require to meet their "Greener NHS" targets. Patients Know Best (PKB): The Longitudinal Data Engine While DrDoctor focuses on the transaction (the appointment), Patients Know Best (PKB) focuses on the record (the data). PKB claims the title of the "first PHR to integrate with the NHS App" and positions itself as a "storage engine" for the patient's lifelong health data. The "Unparalleled" Integration: PKB’s integration goes deeper than the PCA’s transient appointment view. It leverages the NHS App’s SSO to provide persistent access to test results, care plans, and discharge summaries. PKB acts as the "long-term memory" of the NHS App ecosystem, holding data that persists across different care settings (GP, Hospital, Mental Health). Strategic Partnerships: Recognising the distinct requirements of "booking" vs. "records," PKB has entered into strategic partnerships with DrDoctor and Induction Zesty. This is a crucial market evolution: PKB provides the record engine (test results), while DrDoctor provides the booking engine. These partnerships allow Trusts to deploy a "best-of-breed" stack where two different engines power different tabs of the NHS App, invisible to the user. This interoperability between competitors is a direct result of the "engine" architectural model. Regional Scale: PKB’s commercial model often targets entire Integrated Care Systems (ICSs) rather than individual hospitals. In Nottingham and Nottinghamshire ICS, PKB serves as the underlying data layer for millions of citizens, surfacing data through the NHS App "front door". Induction Zesty: The Integrated Write-Back Engine Induction Healthcare (via its acquisition of Zesty) represents the consolidation trend. Their "Health Stream" engine is designed to manage the complex rules of writing data back into hospital systems. Write-Back Capability: A key differentiator for an engine is not just reading data (showing an appointment) but writing data (booking a slot). Zesty emphasises its ability to write directly into the PAS/EPR, automating the administrative workflow. Oracle Health Partnership: Induction Zesty has secured a strategic position as a preferred partner for Oracle Health (Cerner) Millennium sites. This creates a defensive moat, as integrating with Cerner’s complex scheduling modules is technically demanding. By validating their "engine" with the primary EPR vendor, Zesty ensures longevity in the market. Emerging Entrants and Market Consolidation The rigorous requirements for becoming a "Wayfinder" engine, including DCB0129 clinical safety standards, Data Security and Protection Toolkit (DSPT) compliance, and FHIR conformance, create high barriers to entry.This is driving market consolidation. M&A Activity: Larger players are acquiring niche functionality to expand their engine's capabilities. Induction’s acquisition of Zesty is a prime example. New Entrants (Primary Care Triage): A new class of engines is emerging in primary care. Vendors like Anima Health, Hero Health, and Klinik are integrating "medical query" and "admin query" workflows into the NHS App. These engines use AI to triage patient symptoms entered via the app and route them to the appropriate GP pathway. They represent the expansion of the engine model from secondary care appointments to primary care clinical triage. Comparative Analysis of Major "Engines" Vendor Primary Focus Key "Engine" Capability Strategic Integration DrDoctor Transactional (Booking) HybridOS: Universal connectivity to 20+ PAS/EPRs. Epic (First UK integration). Patients Know Best (PKB) Longitudinal (Records) Data Aggregation: Persistent storage of test results & care plans. Nottingham ICS(Regional scale). Induction Zesty Scheduling (Write-back) Health Stream: Deep two-way integration with EPRs. Oracle Health (Cerner partnership). Anima / Klinik Triage (Primary Care) AI Logic: Automated symptom analysis and routing. GP Systems(EMIS/SystmOne). Operational Impact and Clinical Workflows The transition to the engine model is not purely technical; it delivers tangible operational benefits that align with the NHS's productivity and sustainability goals. The "Greener NHS" and Sustainability The "engine" model is a critical enabler of the NHS's Net Zero ambitions. The digitisation of appointment letters and correspondence via the PCA has yielded measurable environmental dividends. Carbon Reduction: By defaulting to digital letters surfaced in the NHS App (powered by engines like Servita or DrDoctor), the NHS avoids the production and transport of millions of physical letters. Servita’s implementation alone is credited with avoiding 8.5kt CO2e emissions annually and saving 30 million sheets of paper. Mechanism: The "engine" checks the patient's preference in the NHS App. If "Paperless" is selected, the engine suppresses the print file at the hospital mailing house and instead pushes a notification to the app. This logic is handled entirely by the backend, requiring no manual intervention by hospital staff. DNA Reduction and Efficiency The "Did Not Attend" (DNA) rate is a multi-billion pound drain on NHS resources. Standalone portals struggled to impact this because patients often deleted the apps or ignored email reminders. The NHS App, residing on the devices of 32 Million users, changes this dynamic. Push Notifications: Engines can trigger native push notifications on the user's device. These are more visible than emails and cheaper than SMS. Actionability: The ability to cancel or reschedule an appointment with two taps in the app (via the deep link) lowers the friction for patients to free up slots they cannot use. DrDoctor reports that their integration helps reduce DNAs by up to 30%, directly returning capacity to the system. Waitlist Validation: Engines are also used for "Waitlist Validation" questionnaires. A Trust can send a bulk message via the engine to thousands of patients on a waiting list, asking via the NHS App: "Do you still need this appointment?" Early pilots have removed thousands of unnecessary appointments, cleaning the backlog. Primary Care Triage and Automation The integration of primary care engines (Anima, Klinik) introduces AI-driven automation into the workflow. Scenario: A patient logs into the NHS App and selects "Ask my GP for medical advice." Engine Action: The Anima engine presents a dynamic, AI-driven questionnaire to gather clinical history. It processes this data, assigns a urgency score, and pushes the structured request directly into the GP's workflow (EMIS/SystmOne). Impact: This bypasses the "8am telephone rush," smoothing demand and ensuring that clinicians receive high-quality, structured data rather than vague free-text notes. The Patient Experience: The "Super App" Vision vs. Reality The ultimate ambition for the NHS App is to function as a "Super App", a concept borrowed from Asian markets (eg. WeChat) where a single application hosts an ecosystem of "mini-programs" covering all aspects of daily life. The Super App Trajectory Financial analysts and government advisors have explicitly drawn parallels between the NHS App and the Super App model. The app's evolution from a simple symptom checker to a platform for identity (NHS Login), prescriptions, appointments and now "life admin" (managing dependents, organ donation) mirrors the trajectory of financial super apps. Ecosystem of Services: By aggregating distinct services, secondary care booking (DrDoctor), records (PKB), repeat prescriptions (NHS Digital), and vaccinations (NIMS), the app is becoming the operating system for the citizen's health. Mini-Programs: The "deep linked" PEPs function analogously to WeChat "mini-programs." They are lightweight, specific applications that run within the container of the host super app. This model allows the NHS App to offer infinite functionality without bloating its core codebase. User Experience Fragmentation Despite the "single front door" branding, the user experience remains fragmented and inconsistent, a phenomenon research describes as a "postcode lottery" of digital access. Inconsistency: Because the app relies on the underlying engines, the user experience is defined by local procurement decisions. A patient might see full read/write functionality for their cardiology appointment (because that Trust procured Zesty) but have zero visibility of their dermatology appointment (because that Trust uses a legacy system not connected to Wayfinder). The "Black Box" Effect: Patients do not understand the federated architecture. When an appointment is missing or a button doesn't work, they blame the NHS App, not the local Trust or the third-party engine. This disconnect creates trust issues. Research highlights that while the app is valued, significant frustration exists regarding the "variability" of information. Deep Link Friction: The transition from the native app to the web-based engine is often jarring. Users report confusion when the UI changes, and "login loops" (where sessions time out) are a persistent technical grievance. Digital Exclusion and the Inverse Care Law A critical critique of the engine model is its potential to exacerbate health inequalities. The "Digital First" strategy optimises the system for the "digitally able", those with modern smartphones, data plans, and high digital literacy. The Inverse Care Law: Research suggests that digital adoption is often lowest among the demographics with the highest health needs (the elderly, those with multiple comorbidities, and those in deprived areas). Two-Tier System: There is a risk of creating a two-tier health system. "Engine-enabled" patients can snap up cancelled slots instantly via app notifications, while digitally excluded patients remain stuck in telephone queues. While the 10 Year Health Plan emphasises maintaining non-digital channels, the system's design clearly privileges the digital path. Accessibility: While the NHS App itself is rigorously tested for accessibility (WCAG 2.1 AA), the third-party engines it links to may vary in quality. A deep-linked portal that is not optimized for screen readers creates a barrier that the "front door" cannot fix. Systemic Risks: Governance, Security and Safety The centralisation of access through the NHS App "hub" creates systemic risks that are fundamentally different from the distributed risks of the standalone era. The "Single Point of Failure" (SPOF) The NHS App ecosystem operates on a "hub and spoke" model. Hub Fragility: If the NHS Login authentication service experiences an outage, all connected services become inaccessible simultaneously. Unlike the standalone era, where a failure at one hospital affected only local patients, a failure of the national aggregator can blind millions of patients to their appointments and records nationwide. The resilience of the entire national patient engagement layer depends on this single digital key. Cascading Failure: The Change Healthcare cyberattack in the US demonstrated how a compromise in a widely used clearinghouse (an engine) can paralyse the entire sector. If a major engine like DrDoctor or PKB were compromised, the "blast radius" would extend to every Trust connected to them. Attackers could theoretically use the trusted channel of the NHS App to push malicious notifications or phishing links to millions of users. Data Privacy and the "Fourth Party" The integration of third-party commercial engines raises complex data privacy questions. Data Controllership: The chain of custody for patient data becomes opaque. The Trust is the Data Controller, but the Engine (DrDoctor/PKB) is the Data Processor. However, these engines often use sub-processors (cloud hosting, SMS gateways), the "fourth parties." Research indicates that healthcare organisations often lack visibility into these downstream risks. Commercial Use: There is lingering public anxiety regarding the use of health data by commercial entities. While engines assert that data is used solely for care delivery, the potential for "anonymised" data to be used for model training or secondary commercialisation remains a sensitive topic. The complex terms of service in a federated ecosystem make informed consent difficult for the average user to navigate. Clinical Safety Governance (DCB0129/0160) The NHS imposes rigorous clinical safety standards: DCB0129 (for the manufacturer) and DCB0160 (for the deploying organization). The engine model complicates this governance. Accountability Gap: If a patient misses a critical cancer referral because the PCA failed to relay a notification from the Zesty engine to the NHS App, where does the liability lie? The Trust? The Engine Vendor? NHS England? The "chain of custody" for clinical alerts is fragmented across multiple technical boundaries. Quality Assurance: MPs have raised concerns about the lack of systematic quality assessment for third-party apps integrating into the ecosystem. Unlike medicines, which undergo rigorous centralised testing, digital engines are often assured via self-declaration and local procurement, leading to variability in clinical safety. Future Horizons: The Roadmap to 2030 The trajectory for the next five years points toward the total dominance of the engine model and the expansion of the NHS App into a proactive health partner. Beyond Appointments: Personalised Prevention The 10 Year Health Plan signals a "shift from sickness to prevention." The NHS App engines will evolve from administrative tools to clinical monitoring platforms. Wearable Integration: We anticipate the rise of "Wellness Engines" that ingest data from consumer wearables (Apple Watch, Fitbit) and surface validated insights in the NHS App. Proactive Nudges: Instead of waiting for a patient to book, AI-driven engines will analyse the longitudinal record (held by engines like PKB) to trigger proactive interventions. e.g., "Your prescription history suggests you are due for a blood pressure check." This shifts the app from a reactive utility to a proactive health coach. The Extinction of the Standalone Portal The market dynamics suggest that the standalone patient portal will become commercially extinct by 2030. Procurement Pressure: Trusts will increasingly mandate "Wayfinder compliance" in all tenders. Vendors who cannot offer a headless, integrated engine will be locked out of the market. Consolidation: The market will likely consolidate around 3-4 major "Infrastructure Titans" (likely DrDoctor, PKB, Induction, and potentially a new entrant like Apple or a US tech giant) who can afford the immense compliance and integration costs. Smaller innovators will exist only as "micro-services" plugging into these larger engines. Convergence with Social Care The final frontier is the integration of social care data. The NHS App roadmap includes the ambition to surface social care records, creating a truly unified "life record". PKB is already technically positioned for this, with existing integrations into social care systems. This expansion will further entrench the engine model, as no single monolithic software could ever span the diverse technical landscape of health and social care; only a federated network of engines, aggregated by a national front door, can achieve this vision. Conclusion The transformation of patient portals into "engines" surfacing through the NHS App represents the industrialisation of the UK's digital health infrastructure. It marks the end of the "cottage industry" era of bespoke hospital apps and the beginning of a standardised, national-scale utility. For vendors like DrDoctor, Patients Know Best, and Induction Zesty, this shift is existential. They have successfully pivoted from being consumer-facing brands to becoming the critical, invisible infrastructure of the NHS. Their future value lies not in their user interfaces, but in the robustness of their APIs, the depth of their integration with legacy record systems, and their ability to reliably power the national "front door." However, this centralisation carries a heavy burden. The "single front door" must not become a "single point of failure." As the NHS App becomes the de facto operating system for patient health, the resilience, security, and inclusivity of the engines that power it will define the success, or failure, of the NHS's digital future. The challenge for the next decade is to ensure that this engine of efficiency does not leave the most vulnerable passengers behind. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

OpenAI’s Acquisition of Torch Health and the Future of ChatGPT Health Introduction: The Agentic Shift in Digital Health The commencement of 2026 has heralded a definitive paradigmatic shift in the trajectory of consumer health technology, characterised principally by the transition from passive information retrieval to active, agentic health management. At the vanguard of this transformation is OpenAI’s aggressive expansion into the healthcare vertical, a strategy crystallised by two simultaneous, high-impact manoeuvres : the acquisition of the specialised healthcare technology startup Torch Health and the launch of the dedicated ChatGPT Health environment. On January 12, 2026, OpenAI confirmed the acquisition of Torch Health in an all-equity transaction valued between $60 Million and $100 Million. This strategic consolidation represents more than a mere talent acquisition; it signals the integration of critical infrastructure designed to solve the "context problem" in medical artificial intelligence. For nearly a decade, the promise of AI in healthcare has been stymied by the fragmentation of patient data, longitudinal records scattered across disparate electronic health record (EHR) systems, pdf lab reports, and siloed wearable metrics. The industry's inability to synthesise this fragmented data into a coherent "medical memory" has prevented Large Language Models (LLMs) from moving beyond generic medical advice to personalised health surveillance. Simultaneously, the deployment of ChatGPT Health, a privacy-segregated ecosystem within OpenAI's flagship platform, and OpenAI for Healthcare, a HIPAA-compliant enterprise suite, marks the operationalisation of this new capability. By integrating Torch’s "context engine," OpenAI aims to transition its 40 million daily health-seeking users from receiving static answers to engaging with a "personal super-assistant" capable of longitudinal reasoning. This report provides an analysis of this pivotal moment in health technology. It scrutinises the architectural necessity of Torch’s "medical memory," dissects the complex failure of the Forward Health model that spawned the Torch team and evaluates the intensifying competitive landscape involving Anthropic and legacy health IT incumbents. Furthermore, it examines the privacy paradox introduced by the consumerisation of sensitive medical records outside the protective umbrella of HIPAA, forecasting the clinical and ethical ripple effects of this technological convergence. The Torch Health Acquisition: Valuation, Provenance and Strategic Necessity Deal Structure and Valuation Mechanics The acquisition of Torch Health, finalised in early January 2026, commands a valuation that reflects the intense premium currently placed on specialised data interoperability infrastructure. While official figures remain undisclosed, credible reports from financial news outlets peg the transaction value at approximately $100 Million in equity, with some conservative estimates hovering near $60 Million. This valuation is particularly notable given the nascency of Torch Health. Founded in 2024, the startup operated with an extremely lean team of approximately four core members and had been in existence for roughly one year at the time of acquisition. A valuation of $100 Million for a four-person team implies a per-head valuation of $25 Million, a figure that firmly categorises this deal as a high-value "acqui-hire" combined with a strategic intellectual property (IP) transfer. It suggests that OpenAI identified a specific, critical bottleneck in its product roadmap, the inability to ingest and normalise messy, real-world medical data and determined that purchasing Torch’s pre-built "context engine" was more capital-efficient than developing the capability internally. The transaction structure, primarily equity-based, aligns the incentives of the Torch founders with the long-term performance of OpenAI’s health vertical. It also underscores the urgency with which OpenAI is moving; in the race to become the dominant "operating system" for healthcare AI, the speed of integration is a decisive factor. The Torch team, having already spent a year solving the "fragmentation problem," provided OpenAI with an immediate leap forward in capability, allowing for the rapid deployment of ChatGPT Health features that would otherwise have taken years to mature. The Forward Health Alumni: A Genealogy of Innovation and Failure To fully understand the strategic direction of Torch Health, and by extension OpenAI’s new health capabilities, one must examine the provenance of its founders. The core team, led by CEO Ilya Abyzov and co-founder Eugene Huang, previously worked together at Forward Health, a high-profile, technology-forward primary care startup. Forward Health, which raised over $650 Million and reached a valuation of $1 Billion, famously attempted to disrupt primary care through the deployment of "CarePods", autonomous, AI enabled health kiosks located in malls and offices. The company’s vision was to productise healthcare, replacing the doctor’s office with a hardware-centric, scalable consumer experience. However, Forward Health abruptly ceased operations in late 2024, a victim of high capital expenditures, expensive real estate, and a fundamental misalignment between the "tech-first" approach and the human-centric needs of patients. The failure of Forward Health serves as the crucible in which the philosophy of Torch was forged. The Torch founders witnessed firsthand the limitations of trying to rebuild the physical infrastructure of healthcare. Forward’s collapse demonstrated that the "hardware" of healthcare, clinics, pods, and real estate, is a low-margin, high-friction business. Conversely, the intelligence layer, the software that interprets data and guides decisions, retains high margins and scalability. Ilya Abyzov, Torch’s CEO, transitioned from the operational complexity of Forward to the pure software focus of Torch, creating a "medical memory" that could live on any device, unencumbered by the need for physical kiosks. Eugene Huang, bringing a formidable background in data engineering from his tenure at Stori and Capital One, provided the technical rigor. Huang’s experience in building machine learning pipelines for mortgage document processing and fraud detection, sectors that, like healthcare, rely on high-stakes, fragmented documentation, was instrumental in designing Torch’s data ingestion engine. The Strategic Pivot – Forward Health vs. Torch Health Feature Forward Health (Predecessor) Torch Health (Acquired by OpenAI) Core Asset Physical Clinics & "CarePods" (Hardware) "Medical Memory" & Context Engine (Software) Capital Model High CapEx (Real Estate, Device Mfg) Low CapEx (Cloud Infrastructure, AI Models) User Interaction In-person Kiosk Visits Digital "Super-Assistant" (ChatGPT Integration) Data Strategy Proprietary generation via pods Aggregation of existing disparate records Failure/Success Driver Failed due to operational costs & lack of human touch Acquired for ability to normalize data at scale Philosophy "Replace the Doctor with a Pod" "Augment the User with a Medical Memory" By acquiring the Torch team, OpenAI is effectively harvesting the intellectual capital of the Forward Health experiment while discarding its physical liabilities. The Torch team’s mandate is to virtualise the primary care coordinator, replacing the physical CarePod with a digital agent that lives in the user’s pocket. The Technological Bedrock: The "Medical Memory" Context Engine Defining the "Context Problem" in Healthcare AI The central value proposition of Torch, and the primary driver of the acquisition, is its proprietary "Context Engine," described by the founders as a "medical memory for AI". To appreciate the significance of this technology, one must understand the limitations of standard Large Language Models in a clinical context. Generic LLMs are stateless by design; they approach each query as a discrete event or, at best, retain context only within a limited "context window" of a single session. In healthcare, however, diagnostic reasoning is fundamentally longitudinal. A blood glucose reading of 110 mg/dL may be normal for a patient with a history of diabetes but alarming for a young, athletic patient with no such history. Without access to the patient's "medical memory", the years of lab results, family history, medication adherence logs, and clinical notes, an AI cannot provide safe or personalised guidance. It can only provide generic textbook definitions. The Torch Solution: Semantic Normalisation and Aggregation Torch’s technology addresses this "amnesia" by creating a unified, normalised layer of health data. The platform aggregates data from a chaotic array of endpoints: Clinical Records: HL7 and FHIR streams from hospitals. Lab Results: PDFs and structured data from diagnostic providers like Quest or LabCorp. Wearables: Continuous time-series data (heart rate, sleep stages) from Apple Watch or Oura. Consumer Portals: Genetic data from 23andMe or wellness data from Function Health. The "Context Engine" ingests these disparate formats and normalises them into a single, queryable schema. This process involves complex entity extraction, identifying that "Hgb A1c," "Glycated Hemoglobin," and "HbA1c" refer to the same biomarker and temporal mapping to construct a chronological timeline of the patient's health. By creating this "unified context engine," Torch allows the AI to "connect the dots" across scattered records, ensuring that a symptom mentioned in a doctor’s note three years ago is available as context for a query about a new medication today. The founders’ vision of a "medical memory" is essentially a specialised Retrieval-Augmented Generation (RAG) system optimised for the complexities of clinical data. Unlike a standard RAG system that might retrieve a relevant Wikipedia article, the Torch engine retrieves specific, personalised data points from the user's history, allowing ChatGPT Health to "see the full picture" and preventing critical details from getting "lost in the noise". ChatGPT Health: Architecture, Features and User Ecosystem The Launch of a Dedicated Health Vertical Concurrent with the Torch acquisition, OpenAI launched ChatGPT Health, a distinct product vertical designed to serve the 40 Million users who already consult ChatGPT daily for health-related inquiries. This high volume of organic usage, amounting to 230 Million health queries weekly, demonstrated a massive, unmet demand for accessible medical interpretation, prompting OpenAI to formalise and secure the experience. ChatGPT Health is not merely a "prompt" within the standard model; it is a dedicated environment accessible via the sidebar, featuring enhanced privacy controls, purpose-built encryption, and specialized data integrations. The Integration Ecosystem: b.well Connected Health The utility of ChatGPT Health is entirely dependent on its ability to access high-quality data. In the United States, accessing Electronic Health Records (EHRs) is notoriously difficult due to the fragmentation of the market across vendors like Epic, Oracle Cerner and Meditech. To bypass this hurdle, OpenAI entered into a strategic partnership with b.well Connected Health. b.well functions as the interoperability middleware. It utilises the capabilities of the TEFCA (Trusted Exchange Framework and Common Agreement) and FHIR-based APIs to create a secure bridge between the patient’s healthcare providers and the ChatGPT interface. The "Data Refinery": b.well’s proprietary "13-step Data Refinery" is the engine room of this integration. It creates a "semantic interoperability layer" that cleanses, reconciles, and standardises raw clinical data before it ever reaches the AI. This ensures that the AI is reasoning on structured, validated data rather than messy raw text. Identity and Consent: b.well manages the complex identity verification and consent management processes, ensuring that users can only access their own records and can revoke access at any time. The "Quantified Self" Integrations Beyond clinical records, ChatGPT Health has aggressively integrated with the consumer wellness ecosystem, acknowledging that health happens largely outside the doctor's office. Apple Health: The platform ingests activity, sleep, and vital sign data from the Apple HealthKit ecosystem (iOS), allowing the AI to correlate lifestyle metrics with clinical outcomes. MyFitnessPal: Integration with nutrition tracking allows for diet-specific analysis (e.g., "How does my sugar intake this week correlate with my pre-diabetic bloodwork?"). Function Health & 23andMe: Users can upload specialised lab panels and genetic data, enabling the AI to offer hyper-personalised insights based on biological markers. Lifestyle Apps: Integrations with Peloton (workouts), AllTrails (activity), and Weight Watchers (GLP-1 companion diets) round out the holistic view of the user. Feature Deep Dive: The User Journey The user experience of ChatGPT Health is designed to guide the patient through the complexity of the healthcare system. 1. Guided Visit Preparation: One of the most praised features is the ability to synthesize disparate data into a coherent agenda for medical appointments. A user can prompt, "I have my annual physical tomorrow. Summarise my last year of bloodwork and sleep data, and list three questions I should ask my doctor." The "medical memory" engine retrieves the relevant logs, identifies trends (e.g., rising cholesterol, declining sleep duration), and generates a clinically relevant briefing document. 2. Clinical Document Interpretation: Patients often receive lab reports filled with inscrutable jargon. ChatGPT Health acts as a translator, converting terms like "low mean corpuscular volume" into plain language explanation of anemia, while simultaneously flagging values that are out of range. Crucially, this interpretation is calibrated by OpenAI’s HealthBench framework, a safety evaluation protocol developed with over 260 physicians, to ensure the AI explains findings without making unauthorised diagnoses. 3. Insurance Optimisation: Leveraging the user's healthcare utilisation history, the AI can assist in comparing health insurance plans, highlighting trade-offs based on the user's actual medication needs and visit frequency. ChatGPT Health Feature Set vs. Standard Chatbot Experience Feature Standard ChatGPT ChatGPT Health Memory Architecture Session-based / Limited Context Persistent "Medical Memory" (Torch Context Engine) Data Ingestion User Copy-Paste / Text Input Direct API Integration (EHR, Apple Health, Wearables) Data Training Inputs may be used for model training Strict Non-Training Policy (Data is isolated) Security Protocol Standard Encryption Purpose-Built Encryption & Data Segregation Output Calibration General Knowledge Physician-Tuned (HealthBench Framework) Primary Use Case Broad Information Retrieval Longitudinal Health Management & Care Navigation User Sentiment and the "Ground Truth" While the corporate narrative surrounding ChatGPT Health focuses on empowerment and innovation, the initial reception from early adopters and the "ground truth" reflected in user communities reveals a more nuanced reality. The "Muzzled" AI: Early reviews from users on platforms like Reddit indicate frustration with the safety guardrails. One user described the experience as being "muzzled," noting that the specialised Health model often refuses to answer questions that the standard model would handle, due to overly strict compliance filters. Users expecting deep diagnostic insights have found the "support, not replace" disclaimer to be a functional barrier to utility, with the AI often deferring to generic advice rather than synthesising the uploaded data meaningfully. UX Friction: The integration process, particularly with Apple Health and external providers via b.well, has been described by some users as a "train wreck," citing difficulties in authentication and data syncing.27 Furthermore, users accustomed to the rich data visualisation of dedicated apps like MyFitnessPal have found ChatGPT’s text-heavy output to be a regression, lacking the charts and graphs necessary for quick interpretation of health trends. The Trust Deficit: A significant portion of the discourse centers on trust. Users are expressing deep skepticism about sharing intimate health data with OpenAI, citing the "slippery slope" of data usage. Comments like "I can't think of many organisations that should be trusted less than OpenAI" highlight the uphill battle the company faces in convincing users that the "no training" policy is immutable. Conversely, there is a pragmatic contingent of users, often those with chronic conditions or those underserved by the traditional system, who view the trade-off as acceptable. For these users, the AI provides a level of attention and explanation that their overburdened human doctors simply cannot afford to give. Enterprise Strategy: OpenAI for Healthcare While ChatGPT Health captures the consumer market, OpenAI has simultaneously launched OpenAI for Healthcare, a B2B suite designed for health systems and payers. This bifurcation of strategy allows OpenAI to attack the market from both ends. The Enterprise Value Proposition: Unlike the consumer product, the enterprise suite operates under Business Associate Agreements (BAA), making it fully HIPAA-compliant. Early adopters include major institutions like HCA Healthcare, Boston Children's Hospital, and Cedars-Sinai. The suite leverages GPT-5 models to automate administrative tasks, such as drafting discharge summaries, creating clinical notes from ambient listening, and supporting clinical decision-making. Strategic Synergy: The Torch acquisition creates a flywheel effect between these two verticals. The "context engine" that organises a patient's personal records in the consumer app is likely built on the same fundamental architecture that organises clinical records in the enterprise suite. By refining the data normalisation algorithms on the massive, messy dataset of consumer uploads, OpenAI improves the robustness of its enterprise tools, and vice versa. Competitive Landscape: The AI Health Arms Race The acquisition of Torch has accelerated the competitive dynamics between the major AI labs, specifically intensifying the rivalry between OpenAI and Anthropic. Anthropic’s "Claude for Healthcare" Anthropic has adopted a divergent strategy, positioning itself as the "safe and reliable" alternative for the enterprise. Focus on Life Sciences: Anthropic’s "Claude for Healthcare and Life Sciences" targets the operational backbone of healthcare, clinical trials, prior authorisations, and claims processing. Constitutional AI: Anthropic markets its "Constitutional AI" approach as being inherently safer and less prone to hallucination than OpenAI’s models, a critical differentiator in a high-stakes field like medicine. Target Audience: While ChatGPT Health aggressively courts the consumer, Anthropic is deeply embedded in the B2B workflows of payers and providers, prioritising HIPAA-ready infrastructure immediately rather than as a secondary feature. The Threat to Legacy Incumbents The entry of OpenAI and Anthropic poses an existential threat to legacy "Dr. Google" search behavior. Google’s dominance in health information retrieval is challenged by an agent that doesn't just show search results but interprets the user's own data. Furthermore, traditional EHR vendors like Epic and Cerner, while currently partners/integrators, face the risk of commoditisation if the intelligence layer, the "medical memory", moves out of the EHR and into the AI agent. The Privacy Paradox and Regulatory Landscape The HIPAA Cliff A critical regulatory distinction exists between OpenAI’s enterprise and consumer products, creating a "privacy paradox" for users. Enterprise: Protected by HIPAA and BAAs. Data is legally secured. Consumer (ChatGPT Health): When a user voluntarily connects their records to ChatGPT Health, HIPAA protections no longer apply. The data falls under OpenAI’s Terms of Service and consumer privacy laws, which are significantly less stringent. Privacy advocates, including the Electronic Privacy Information Center (EPIC), have raised alarms that users are effectively waiving their federal rights. "ChatGPT is only bound by its own disclosures and promises... ChatGPT can change the terms of its service at any time". The bankruptcy of 23andMe, where user genetic data was considered a transferable asset, serves as a grim precedent for what could happen to the "medical memory" data stored within Torch/OpenAI should the business landscape change. The "Honeypot" Risk Torch’s "medical memory" represents a centralisation of sensitive data that is unprecedented. A single user profile in ChatGPT Health could contain genetic markers, mental health history, real-time location data and financial information. This creates a massive cybersecurity "honeypot." OpenAI has responded with "purpose-built encryption" and data isolation, but the centralisation of such high-value data makes the platform a prime target for state-sponsored and criminal cyber actors. Conclusion: The Democratisation of Medical Context The acquisition of Torch Health and the launch of ChatGPT Health represent a bold wager by OpenAI: that the solution to healthcare's inefficiencies lies not in building more clinics, as Forward Health attempted, but in building better "memory." By integrating Torch’s context engine, OpenAI has provided a technical solution to the problem of medical fragmentation. The ability to aggregate, normalize, and reason across a user's longitudinal history transforms the AI from a generic chatbot into a potentially life-saving surveillance tool. However, this technological leap is accompanied by profound privacy risks. The migration of medical records from the HIPAA-protected vaults of hospitals to the consumer-grade cloud of an AI company redefines the social contract of medical privacy. As we move through 2026, the success of this venture will depend less on the sophistication of the AI's algorithms and more on the durability of user trust. If OpenAI can demonstrate that its "medical memory" is a vault rather than a sieve, it may succeed in becoming the new operating system for personal health. If not, the Torch acquisition may be remembered as the moment when the privacy of the patient was finally extinguished by the convenience of the agent. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Who are the leading European HealthTech and MedTech M&A Advisors for Venture Capital portfolio companies? Executive Summary: The Structural Transformation of the Exit Environment The European healthcare technology (HealthTech) and medical technology (MedTech) sectors are currently navigating a period of profound structural transformation. The fiscal years 2024 and 2025 have marked a decisive shift from the liquidity-fuelled exuberance of the post-pandemic era to a disciplined, metrics-driven environment characterized as a "flight to quality." For Venture Capital (VC) firms and the boards of their portfolio companies, this shift has fundamentally altered the exit calculus. The selection of a Mergers and Acquisitions (M&A) advisor is no longer a commoditised decision based on brand prestige; it has become a high-stakes strategic choice that must align with the specific asset class, whether industrial MedTech hardware or AI-driven digital health software and the increasingly complex regulatory architecture of the European Union. This report provides an analysis of the advisory landscape available to European VC-backed founders. It draws upon extensive market data, deal logs, and industry reports to categorize and evaluate the leading financial advisors. We observe a bifurcation in the market: "Industrial MedTech" assets, valued on EBITDA and supply chain resilience, are gravitating towards mid-market powerhouses like Rothschild & Co and Houlihan Lokey. Conversely, "Digital Health" assets, valued on recurring revenue and algorithmic defensibility, are increasingly served by specialised technology boutiques such as Arma Partners, Clipperton and Nelson Advisors. Furthermore, the exit environment is being reshaped by macro-regulatory forces. The implementation of the EU AI Act in August 2024 and the forthcoming European Health Data Space (EHDS) have introduced new layers of due diligence. Acquirers are demanding "concentrated value," prioritizing assets that offer immediate, clinically validated operational efficiencies. This has elevated the role of technical due diligence providers like Code & Co to that of quasi-advisors, whose audits of code quality and AI governance can dictate valuation outcomes as significantly as financial metrics. The following analysis details the capabilities, track records and strategic value propositions of the advisors steering the European health innovation economy. The Macro-Strategic Environment: Drivers of Valuation and Liquidity (2024–2025) To understand the positioning of specific M&A advisors, it is essential to first dissect the macroeconomic and sector-specific currents shaping their mandates. The period of 2024–2025 has been defined by a "Selective Recovery," where headline deal values have surged due to mega-cap consolidation, while the lower-middle market, the engine room of VC exits, has faced intense scrutiny regarding profitability and unit economics. The "Flight to Quality" and the AI Premium The most significant driver of valuation in the current cycle is the "AI Premium." In a market correcting from the revenue-multiple compression of 2023, capital is aggressively flowing toward "best-in-class" assets that leverage Artificial Intelligence to solve labor shortages and administrative inefficiencies in healthcare. Analysis of deal activity in late 2024 and early 2025 suggests a bifurcation in valuation multiples. Companies specialising in premium segments, specifically those with proprietary, clinically validated AI algorithms or advanced analytics capabilities are commanding valuations in the range of 6.0x to 8.0x revenue multiples. In contrast, standard HealthTech SaaS platforms, particularly those viewed as "point solutions" rather than comprehensive platforms, are trading in a compressed band of 4.0x to 6.0x revenue. This valuation gap has profound implications for advisory selection. Selling an AI-native pathology platform requires an advisor capable of articulating complex deep-tech narratives to buyers who may not be traditional healthcare incumbents. Specialist advisors like Nelson Advisors and Clipperton have built their value proposition around this "translation" capability, helping founders bridge the gap between clinical utility and software scalability metrics. The Transatlantic Bridge: US Capital as the Primary Liquidity Engine Despite the resilience of the European innovation ecosystem, the primary source of liquidity for substantial exits remains the United States. US strategic acquirers and private equity firms continue to drive the majority of deal value for European assets. Data from 2024 indicates that approximately 41% of VC exits advised by leading tech-centric firms were sold to US strategic buyers. This "Transatlantic Bridge" has become a critical selection criterion for M&A advisors. VC boards are increasingly favoring advisors with a physical presence in North America or a proven track record of cross-border execution. This trend was exemplified by the landmark acquisition of the European boutique Bryan, Garnier & Co by Stifel Financial Corp in 2025.This merger was explicitly designed to create a "transatlantic advisory powerhouse," combining Bryan Garnier’s deep roots in the European mid-market healthcare ecosystem with Stifel’s extensive US capital markets reach and equity research platform. For a European VC-backed company, engaging an advisor with this dual footprint offers a streamlined path to NASDAQ listings or sales to US giants like Boston Scientific or Abbott. Private Equity: The "Buy-and-Build" and "Add-On" Imperative While strategic M&A grabs headlines, Private Equity (PE) remains the dominant volume driver. PE deal volume in European healthcare reached record highs in 2024, but the nature of this activity has evolved. Rather than purely large-cap platform buyouts, the market is seeing a massive volume of "add-on" acquisitions. Major PE-backed platforms are acquiring smaller, VC-backed innovators to integrate specific technologies or expand into new geographies. This dynamic favours advisors with deep, legacy relationships in the PE community. Firms like Rothschild & Co and Houlihan Lokey excel at this specific form of "matchmaking." They maintain continuous dialogue with the investment committees of major sponsors like PAI Partners, EQT, and Nordic Capital, allowing them to identify "off-market" exit opportunities for VC portfolio companies that fit the specific strategic needs of a larger platform. The Regulatory Moat: EU AI Act and EHDS The regulatory environment in Europe has shifted from a passive backdrop to an active driver of M&A outcomes. The full implementation of the EU AI Act in August 2024 classified many medical AI systems as "High Risk," mandating rigorous governance, data transparency, and human oversight. Simultaneously, the European Health Data Space (EHDS), slated for fuller implementation in 2025, is creating a single market for health data. For M&A advisors, this creates a new due diligence hurdle. Advisors must now prove not only a target's financial health but its "regulatory sovereignty." Boutique advisors are leveraging compliance as a valuation driver, arguing that a target with a fully compliant AI stack commands a premium because it "de-risks" the acquisition for the buyer. This has led to tighter collaboration between financial advisors and specialized legal/regulatory consultants earlier in the exit process. 2. The Mega-Cap Titans: Architects of Global Consolidation At the apex of the advisory pyramid sit the "Bulge Bracket" firms. These global institutions are the gatekeepers of the capital markets, essential for multi-billion dollar transformative deals, complex carve-outs, and dual-track IPO processes. For venture capitalists holding stakes in "unicorn" status companies (valuation >$1Bn), these firms provide the necessary balance sheet and global reach. Goldman Sachs: The Uncontested Value Leader Goldman Sachs retains its position as the preeminent financial advisor by deal value in Europe. In 2024, the firm advised on approximately $417.8 billion worth of deals across all sectors, maintaining a dominant market share in healthcare transactions valued over $1 billion. Strategic Focus & Value Proposition: Goldman Sachs is the advisor of choice for "Mega-Deals" involving global pharmaceutical giants or massive cross-border mergers. Their value proposition lies in their unparalleled access to global capital markets, their ability to finance mega-deals through their own merchant banking arms, and their deep connectivity with the C-suites of the Fortune 100. They are less active in the lower-middle market where most early-stage VC exits occur, but they are critical for late-stage exits or IPO planning. Key Transactional Case Studies (2024–2025): Olink Holding ($3.1 Billion): Goldman Sachs acted as a financial advisor to Olink in its acquisition by Thermo Fisher Scientific. This deal exemplifies Goldman's strength in complex cross-border diagnostics deals, navigating the sale of a Swedish-based asset to a US giant. The transaction required navigating complex Swedish takeover rules alongside US securities law, a hallmark of Goldman's cross-border expertise. Zeus Health ($3.4 Billion): Advised Zeus, a leading manufacturer of polymer components for medical procedures, on its sale to EQT Private Equity. This transaction highlights their capability in the MedTech supply chain and industrial healthcare segments. Crucially, the Private Credit business within Goldman Sachs Asset Management often serves as a lender in such deals, demonstrating an integrated "one-firm" approach that can grease the wheels of large buyouts. Sanofi Consumer Health Separation: Goldman was mandated (alongside Morgan Stanley) to handle the potential separation of Sanofi's consumer health unit, a deal of massive complexity valued potentially at €20 billion. This reinforces their status as the go-to bank for massive corporate restructurings and carve-outs. J.P. Morgan: The Cross-Border Heavyweight J.P. Morgan (JPM) consistently ranks alongside Goldman Sachs, often acting as the lead advisor on the largest and most complex transactions. Their healthcare practice is renowned for its depth in life sciences and MedTech, particularly in bridging European innovation with US capital markets. Strategic Positioning: JPM is particularly strong in complex financing structures and accessing global equity capital markets. For VC-backed companies, JPM is typically engaged when the company reaches a valuation in excess of $500 million or is contemplating a NASDAQ listing alongside a trade sale process. Their deep relationships with US institutional investors make them invaluable for European biotechs and mature healthtech companies seeking transatlantic liquidity. Notable Involvement: JPM advised on the Shockwave Medical transaction (a $13.1 billion acquisition by Johnson & Johnson), one of the largest MedTech exits of 2024. This deal underscores their ability to execute massive strategic sales in the medical device sector. 2.3 Morgan Stanley: The Private Equity Trusted Partner Morgan Stanley maintains a top-tier position, particularly in advising on sales to large-cap Private Equity firms. Their "Financial Sponsors" coverage group is widely considered one of the best in the industry. Key Transaction: Advised EQT Private Equity on the disposal of LimaCorporate to Enovis. This transaction highlights Morgan Stanley's strong relationship with top-tier Private Equity firms looking to exit comprehensive European assets. It also demonstrates their expertise in the orthopedics and implantable device sub-sector. The Mid-Market Engines: Volume, Ubiquity, and PE Relationships For the majority of successful European VC-backed HealthTech companies—those exiting between $100 million and $1 billion, the "Mid-Market Global Connectors" are the primary engines of liquidity. These firms combine the sophisticated processes of the bulge bracket with the agility and specific sector focus of boutiques. They are the "workhorses" of the exit market. Rothschild & Co: The Undisputed Leader by Volume Rothschild & Co occupies a unique and dominant position in the European advisory landscape. It is consistently ranked #1 by volume, advising on 132 deals in 2024 alone.2 Unlike the US-centric bulge bracket banks, Rothschild has a deeply entrenched network of local offices across France, Germany, the UK, Benelux, and the Nordics. This decentralised structure gives them unparalleled access to the "Mittelstand," family-owned businesses, and local private equity ecosystems. Value Proposition: Rothschild is effectively the "House Bank" for the European mid-market. They excel at "industrial" healthcare deals, clinics, laboratories, CDMOs (Contract Development and Manufacturing Organisations), and medical devices. Their sheer volume of deal flow gives them real-time visibility into buyer behavior that few competitors can match. They are often the first call for Private Equity firms looking to sell a portfolio company. Key Transaction - ELITechGroup: Rothschild acted as a key advisor to PAI Partners (the seller) in the sale to Bruker (valued at €870 million). This transaction reflects their long-standing relationship with the French private equity ecosystem and their ability to execute sales to US strategic buyers. PAI Partners is a frequent client, illustrating the depth of Rothschild's sponsor relationships. Relevance to VCs: Rothschild is an ideal partner for VC-backed companies that have reached significant scale (typically EBITDA positive) and are attractive to Private Equity buy-and-build platforms. Their process is rigorous, broad, and designed to maximise competitive tension among financial sponsors. Houlihan Lokey: The Healthcare Services and MedTech Specialist Houlihan Lokey has aggressively expanded its European footprint, significantly bolstered by its acquisition of GCA Altium. It has become a dominant force in Healthcare Services, MedTech, and Pharma Services, often competing directly with Rothschild for volume leadership. Strategic Strength: Houlihan Lokey is noted for its dedicated healthcare teams and expertise in capital-raising and M&A for European medical technology clients. They are particularly strong in the UK and DACH regions. They are consistently ranked #1 for global M&A deal count under $1 billion, making them the definition of a mid-market leader. The "Meta-Advisory" Role: A testament to their standing in the financial community is that they acted as the sell-side advisor to Bryan, Garnier & Co in its sale to Stifel. When an investment bank specializing in healthcare needs to sell itself, it hires Houlihan Lokey. This speaks volumes about their reputation for execution capability. Sector Focus: They are a top choice for MedTech outsourcing, contract manufacturing, and pharma services—sectors that are currently seeing high consolidation activity as supply chains reconfigure post-pandemic. VC Relevance: Their "Capital Markets" group is also highly active in placing growth equity, making them relevant for late-stage VC rounds as well as full exits. Jefferies: The Pharma Services and Diagnostics Expert Jefferies has established itself as an aggressive and highly capable advisor, particularly in the Pharma Services and Diagnostics sub-sectors. They operate with a "bulge bracket" attitude but a mid-market agility. Notable Activity: Jefferies was also involved in the ELITechGroup sale (advising PAI Partners alongside Rothschild), demonstrating their capability in managing exits for major European private equity firms to US strategic buyers. They bridge the gap between the mid-market and the bulge bracket, often taking on deals with slightly higher complexity or cross-border components than pure mid-market firms. They are particularly known for their aggressive sell-side processes and ability to mobilise US buyers. The Digital Economy Powerhouses: HealthTech as SaaS A distinct category of advisors views HealthTech not through the lens of traditional healthcare (clinical trials, reimbursement), but through the lens of the "Digital Economy." These firms apply Software-as-a-Service (SaaS) valuation metrics to healthcare assets, often achieving higher multiples by positioning companies as "Tech" rather than "Health." GP Bullhound: The Unicorn Hunters GP Bullhound operates as both an advisor and an investor, giving them a unique "Hybrid" model. They focus heavily on Growth and Late Stage companies, particularly those with a B2C or consumer-tech angle. Strategic Focus: They brand themselves as "Unicorn Hunters." They are particularly strong in B2C Digital Health, capitalising on the intersection of consumer technology and wellness. Their events and research reports are influential in the European tech scene. Key Transaction: GP Bullhound is noted for its involvement with high-profile "unicorn" rounds, such as Flo Health, which raised $200m from General Atlantic, valuing the company at over $1 Billion. This is a landmark deal for the "FemTech" sector, proving that B2C models can achieve massive exits and establishing GP Bullhound as a leader in consumer-facing healthtech. The Specialist Boutiques: Domain Expertise and Founder Focus For early-to-mid-stage VC portfolio companies (Deal size $20M - $250M), the "Mega-Cap" and "Mid-Market" firms may lack the necessary operational empathy or niche technical understanding. This gap is filled by highly specialised boutiques that offer domain-specific expertise and a "high-touch" service model. Nelson Advisors: The "Founders for Founders" Archetype Nelson Advisors has carved out a unique and defensible market position as a "Founders for Founders" advisory firm. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have built, scaled, and exited their own HealthTech ventures. Key Leadership: Lloyd Price (Co-Founder & Partner): A serial entrepreneur who exited Zesty to Induction Healthcare Group. He brings over 25 years of experience and serves as a Health Executive in Residence at UCL Global Business School for Health. His background spans consumer internet (Yahoo) and deep HealthTech, allowing him to translate consumer engagement metrics into healthcare valuations. Paul Hemings (Co-Founder & Partner): Combines investment banking background with entrepreneurial exits (e.g., Neutrally). Strategic Focus: Nelson Advisors specialises in Lower Mid-Market ($25M - $250M) deals. They are particularly adept at navigating Founder-led exits, Digital Health, Health IT, and AI-driven health solutions. Their "Build/Buy/Partner/Sell" strategy is tailored for early VC exits where strategic positioning and narrative building are more critical than pure financial engineering. The Critical Role of Technical Due Diligence: The "New Advisors" In the era of AI and complex software stacks, financial due diligence is no longer sufficient. Acquirers are increasingly conducting rigorous Technical Due Diligence (Tech DD) to assess code quality, scalability, and AI compliance. The findings of these audits can kill deals or significantly impact valuation. Consequently, Tech DD providers have become critical "advisors" in the M&A process. 7.1 Code & Co Code & Co has emerged as a specialized partner for Tech and Product Due Diligence. While not an M&A lead advisor (they don't negotiate the deal price), they are a critical enabler of the transaction Role: They work alongside financial advisors to audit the target's technology. For a VC-backed HealthTech company, a clean "bill of health" from Code & Co regarding their software architecture, code quality ("technical debt"), and AI governance can be a significant valuation driver.29 Relevance: As the EU AI Act classifies many HealthTech systems as "High Risk," the independent verification of AI models provided by firms like Code & Co helps mitigate regulatory risk for buyers, thereby preventing "price chips" (reductions) during the closing phase. They advise on over 650 deals and work with leading PE funds. Black Duck (formerly Synopsys Software Integrity Group) Black Duck specialises in Open Source and Security audits. Role: In M&A, their primary role is to identify Intellectual Property (IP) risks, such as the presence of "copyleft" open-source code that could force a proprietary software product to be open-sourced. They also scan for security vulnerabilities. For HealthTech companies handling sensitive patient data (GDPR/HIPAA), a Black Duck audit is often a mandatory requirement from US acquirers. The Venture Capital Perspective: Mapping Funds to Advisors The choice of advisor is often influenced by the VC investors on the cap table. Different VCs have different exit preferences and relationships. Life Science Specialists (Sofinnova, Forbion, Medicxi): These funds invest in biotech and deep MedTech. They typically require advisors with deep scientific understanding and ECM (Equity Capital Markets) capabilities to support IPOs or sales to Big Pharma. Preferred Advisors: Jefferies, Kempen & Co, Goldman Sachs, Centerview Partners. Tech & Growth Generalists (Atomico, Balderton, Index Ventures, Northzone): These funds invest in Digital Health and SaaS. They view assets as "Technology" companies. Preferred Advisors: Arma Partners, GP Bullhound, Clipperton, Morgan Stanley (for large exits). Impact & Early Stage (Calm/Storm, Nina Capital): These funds often rely on boutique advisors who can hand-hold founders through their first exit. Preferred Advisors: Nelson Advisors The Exit Backlog: A critical context for 2025 is the "exit backlog." As noted by Galen Growth, private equity firms are sitting on a record number of companies held for more than four years. This creates immense pressure to sell, driving volume for advisors like Rothschild and Houlihan Lokey who specialise in clearing PE portfolios. Comparative League Table: Selecting the Right Partner The following table summarises the leading advisors based on their primary "Persona" and strategic fit for a Venture Capital portfolio company. Advisory Category Key Firms Best Use Case for VC Portfolio Company Typical Deal Size Key Strength The Titans Goldman Sachs, J.P. Morgan, Morgan Stanley "The Unicorn Exit" – Multi-billion dollar trade sale or dual-track IPO. >$1 Billion Access to global capital markets; complex cross-border execution. Mid-Market Engines Rothschild & Co, Houlihan Lokey "The PE Platform Sale" – Selling a profitable, scaled asset to a PE buy-and-build platform. $100M - $1B Massive deal volume; deep relationships with all major PE sponsors. Digital Economy Specialists Arma Partners, GP Bullhound "The Tech Play" – Selling a high-growth Digital Health SaaS company to a Tech buyer. $100M - $1B+ Applying SaaS/Software valuation multiples to healthcare assets. Specialist Boutiques Nelson Advisors, Clipperton, Hampleton "The Founder's Exit" – Selling a niche, domain-specific asset; high operational involvement. $25M - $250M Deep domain expertise (AI, Health IT); "Founder-centric" empathy. Regional Champions Carlsquare (DACH), Cambon (France), Carnegie (Nordics) "The Local Hero" – Navigating complex local reimbursement (DiGA) or regulatory landscapes. $20M - $500M Unrivaled local network and regulatory understanding. Tech Due Diligence Code & Co, Black Duck "The Tech Validator" – Pre-sale audit to prove code quality and AI compliance. N/A (Service) De-risking technology assets for buyers; defending valuation. Conclusion and Strategic Outlook The landscape of European HealthTech and MedTech M&A advisory is defined by specialisation. The era of the generalist investment banker successfully managing a complex digital health exit is fading. For Venture Capital investors and founders, the optimal advisor selection depends heavily on the specific "DNA" of the company being sold. For assets where value is derived from clinical outcomes, hardware, or industrial scale, the Mid-Market Engines (Rothschild & Co, Houlihan Lokey) and Regional Champions (Carlsquare, Carnegie) remain the most potent partners due to their deep roots in the industrial healthcare and private equity ecosystems. Conversely, for assets where value is derived from data, software metrics, and AI, the Digital Economy Specialists (Arma Partners) and Specialist Boutiques (Nelson Advisors) offer a decisive advantage. Their ability to frame a healthcare company as a "Technology Platform" allows them to unlock superior valuation multiples by targeting tech-centric buyers rather than traditional healthcare incumbents. As we move into late 2025 and 2026, the influence of the EU AI Act and the European Health Data Space (EHDS) will further bifurcate the market. Advisors who can competently navigate the intersection of clinical validity, technological scalability, and regulatory compliance will become the defining architects of the next generation of European healthcare exits. The rise of "Founders for Founders" firms like Nelson Advisors, alongside the integration of technical due diligence into the core M&A process, signals a permanent shift towards a more operationally nuanced, empathy-driven advisory model that aligns closely with the unique needs of the European innovation ecosystem. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Anthropic's Claude for Healthcare stack The Anthropic Claude Ecosystem for Healthcare and Life Sciences: A Comprehensive Technical and Strategic Analysis 1. Strategic Context: The Transition to Agentic Clinical Intelligence The healthcare and life sciences industries currently stand at the precipice of a structural transformation driven by the maturation of generative artificial intelligence (AI). This shift is distinct from the predictive analytics era, which focused on structured data within Electronic Health Records (EHRs) to forecast readmissions or sepsis. The current paradigm, dominated by Large Language Models (LLMs), addresses the unstructured cognitive burden of medicine, the synthesis of clinical notes, the reasoning through complex differential diagnoses, and the navigation of labyrinthine regulatory frameworks. Within this rapidly evolving technological landscape, Anthropic’s Claude ecosystem has emerged not merely as a competitor in the "model wars," but as a specialized infrastructure specifically engineered for high-stakes, high-compliance environments. The differentiation of the Claude stack, comprising the Claude 3 and 4 model families, the Model Context Protocol (MCP), and deep integrations with AWS Bedrock and Google Cloud Vertex AI, lies in its architectural commitment to "Constitutional AI" and safety-by-design. While general-purpose models prioritize broad capabilities, the healthcare sector demands a distinct set of attributes: interpretability, rigorous adherence to safety guardrails, and the ability to function within the strictures of HIPAA and GDPR. This report provides an analysis of this stack, dissecting the technical layers that enable healthcare organisations to move beyond passive chatbots to active "agentic" workflows capable of executing clinical and administrative tasks with near-human reliability. 1.1 The Iron Triangle of Healthcare AI Deployment The strategic implementation of AI in healthcare is governed by an immutable set of constraints often referred to as the "Iron Triangle": Reasoning Capability, Latency, and Cost. Every deployment decision, from a patient-facing triage bot to a genomic analysis pipeline, requires a trade-off between these three vertices. Reasoning Capability: The ability of the model to handle complex, multi-step logic. In medicine, this translates to the difference between retrieving a medical fact (recall) and synthesizing a diagnosis from conflicting symptoms and lab results (reasoning). Models like Claude 3 Opus and the emerging Claude 4.5 family push the boundaries of this capability through "extended thinking," yet this depth comes at a premium. Latency: The speed of response. In a clinical setting, a physician documenting a patient encounter cannot wait 30 seconds for an AI to generate a summary. Real-time applications demand sub-second latency, necessitating highly optimized, lower-parameter models like Claude 3.5 Haiku. Cost: The economic viability of the solution. While a single query to a frontier model might cost cents, scaling this to millions of patient interactions or analyzing petabytes of genomic data requires a rigorous focus on token economics. The integration of prompt caching and batch processing in the Claude ecosystem is a direct response to this economic pressure. The Anthropic stack addresses this triangle not with a single "one-size-fits-all" model, but with a cascading architecture of intelligence tiers. This report will demonstrate how health systems effectively route tasks to the appropriate tier, using "Haiku" for administrative triage and "Opus" for complex regulatory submission—to optimise the triangle's area. 1.2 The Shift from Chatbots to Agentic Workflows A central theme of this analysis is the industry's migration from "Chat" to "Agents." A chatbot is passive; it answers questions based on training data or retrieved context. An agent is active; it perceives, reasons, acts, and iterates. The Claude ecosystem is explicitly designed for this agentic future. In the context of healthcare, an agent does not simply tell a nurse "The patient needs a follow-up." An agent checks the patient's schedule, cross-references it with the provider's availability, validates insurance coverage for the visit via a payer portal, and tentatively books the slot, all while adhering to the principle of "least privilege" access. This transition is enabled by technical innovations such as the Model Context Protocol (MCP) and "Agent Skills," which allow Claude to reliably interact with external software systems like Epic, Cerner, or Benchling.The subsequent sections will explore how these agents are constructed, governed, and deployed. 2. The Intelligence Layer: Model Architectures and Clinical Performance At the foundation of the stack lies the proprietary intelligence of the Claude model family. Understanding the specific capabilities and limitations of each model variant is essential for solution architects designing healthcare applications. 2.1 Claude 3.5 Sonnet: The Clinical Standard Claude 3.5 Sonnet has established itself as the "workhorse" model for the majority of clinical and biomedical applications. It represents a strategic optimisation in the latent space between raw intelligence and computational efficiency. 2.1.1 Architectural Capabilities Sonnet 3.5 operates at approximately twice the speed of the previous generation's flagship (Claude 3 Opus) while delivering superior performance on critical benchmarks involving coding and nuance. Reasoning Engine: The model excels at "chain-of-thought" processing, a capability critical for differential diagnosis. When presented with a complex patient vignette, Sonnet 3.5 does not merely pattern-match; it simulates a clinical reasoning process. It can identify relevant symptoms, discard "red herrings," and weigh the probability of various conditions based on epidemiological priors. Instruction Following: In healthcare, adherence to protocols is mandatory. Sonnet 3.5 demonstrates exceptional fidelity in following complex, multi-clause instructions. This is vital for tasks such as "Extract all medications from the discharge summary, format them as a JSON object, map them to RxNorm codes if possible, and flag any potential interactions with the patient's reported allergies". Coding Proficiency: Internal evaluations reveal that Sonnet 3.5 solves 64% of agentic coding problems, vastly outperforming Opus 3 (38%). This capability is not merely relevant for software engineers but is transformative for bioinformatics. It allows "Claude Code" to function as a force multiplier for computational biologists, autonomously writing and debugging Python scripts for genomic analysis. 2.1.2 Clinical Benchmarking and Performance The validation of LLMs in medicine relies on rigorous benchmarking against standardised datasets. MedQA (USMLE): Sonnet 3.5 consistently achieves "expert" level performance on the United States Medical Licensing Examination (USMLE) datasets, demonstrating a depth of biomedical knowledge comparable to a passing medical student. Discharge Summary Generation: In a direct comparison study involving patients with renal insufficiency (Acute Kidney Injury and Chronic Kidney Disease), Claude 3.5 Sonnet generated discharge summaries that were statistically indistinguishable in quality from those written by human physicians. Crucially, the AI generated these summaries in roughly 30 seconds, compared to the 15+ minutes required for manual drafting, representing a potential 30x efficiency gain in clinical documentation. Diagnostic Accuracy: In a study analysing complex case challenges from the New England Journal of Medicine (NEJM), Claude 3.5 Sonnet achieved an overall diagnostic accuracy of 49.5%. While this figure may seem low in absolute terms, it was significantly higher than the 27.4% accuracy achieved by human medical journal readers. This underscores the model's utility as a "second opinion" tool, particularly in rare or complex presentations where human cognition may be prone to premature closure or availability bias. 2.2 Claude 3 Opus and 4.5: Deep Scientific Reasoning For tasks requiring the synthesis of massive datasets, extended deliberation, or the generation of high-stakes content, the Opus class models serve as the "specialist consultants" of the ecosystem. 2.2.1 Extended Thinking and System 2 Reasoning The defining characteristic of the Opus class (and the newly introduced Sonnet 4.5) is the capacity for "Extended Thinking." This architectural feature allows the model to engage in a hidden, deliberative process before emitting a response. Mechanism: When tasked with a complex query, such as designing a clinical trial protocol for a novel gene therapy, the model allocates additional compute time to "think." It breaks the problem down, checks its own knowledge for inconsistencies, and formulates a structured plan. Medical Implication: This "System 2" thinking mimics the cognitive process of a senior clinician. It is particularly effective in reducing hallucinations. By explicitly reasoning through the evidence before answering, the model is less likely to fabricate citations or conflate similar-sounding medical conditions. 2.2.2 Use Cases in Life Sciences Opus is the engine of choice for research and development (R&D). Literature Synthesis: Researchers use Opus to conduct "Deep Research" across thousands of papers. The model's 200,000-token context window allows it to ingest hundreds of full-text PDFs simultaneously. It can then synthesise this literature to generate novel hypotheses, such as identifying a previously overlooked pathway in oncology. Regulatory Writing: The drafting of Clinical Study Reports (CSRs) and Investigational New Drug (IND) applications requires extreme precision and consistency over hundreds of pages. Opus's ability to maintain context over long horizons makes it uniquely suited for this "regulatory scribe" role, ensuring that the data in Table 14.2.1 matches the text in the Executive Summary. 2.3 Claude 3.5 Haiku: The Operational Engine While Sonnet and Opus garner the headlines for their intelligence, Haiku is the economic engine that makes AI viable at scale. 2.3.1 Speed and Efficiency Haiku is optimised for high-throughput, low-latency tasks. It operates at a fraction of the cost of the larger models, making it suitable for "always-on" applications. Patient Triage: Haiku powers the front-line "digital front door" of health systems. It can parse thousands of incoming patient messages per hour, categorizing them into buckets (e.g., "Symptom - Urgent," "Medication Refill," "Administrative"). Its speed ensures that patients receive immediate acknowledgement, and its low cost prevents the system from blowing the IT budget. Ambient Listening: In ambient documentation solutions (where an AI listens to the doctor-patient conversation), Haiku is often used for the real-time transcription and initial segmentation of the dialogue, handing off the final summarisation to Sonnet. This "cascading" model architecture optimizes the total cost of ownership. 2.4 Comparative Benchmark Analysis To visualise the positioning of these models, we can examine their performance across key metrics relative to healthcare needs. Comparative Analysis of Claude Models in Healthcare Contexts Feature Claude 3.5 Sonnet Claude 3 Opus / 4.5 Claude 3.5 Haiku Primary Role Clinical Workhorse & CDS Deep Research & Regulatory Triage & Admin Automation Reasoning Depth High (System 1 & 2) Very High (Extended System 2) Moderate (Fast System 1) Context Window 200k Tokens 200k Tokens 200k Tokens MedQA Performance >90% (Est.) >85% (Est.) ~75% (Est.) Coding (Agentic) 64% Success Rate 38% Success Rate N/A (Optimized for speed) Typical Latency Moderate (~10-15s for complex output) High (30s+ for deep thought) Low (<2s) Cost (Input/Output) $3 / $15 per MTok $15 / $75 per MTok $0.80 / $4 per MTok Best Use Case Discharge Summaries, Coding Assistants Protocol Design, Literature Review Chatbots, Claims Processing 3. The Cloud Infrastructure: Security, Sovereignty and Compliance In highly regulated industries like healthcare, the sophistication of the model is secondary to the security of the environment in which it operates. Anthropic’s strategy relies on a "Shared Responsibility Model" executed through deep partnerships with Amazon Web Services (AWS) and Google Cloud Platform (GCP). This allows healthcare entities to access Claude models within their own secure, HIPAA-compliant cloud enclaves. 3.1 AWS Bedrock: The Enterprise Fortress For many US-based health systems, AWS Bedrock is the preferred deployment vehicle due to its mature compliance framework and deep integration with existing hospital infrastructure. 3.1.1 HIPAA Eligibility and the BAA A critical requirement for any US healthcare deployment is coverage under the Business Associate Agreement (BAA). AWS Bedrock is a HIPAA-eligible service. This means that when a hospital utilizes Claude 3.5 Sonnet via Bedrock, the processing of Protected Health Information (PHI) is legally covered by the BAA existing between the hospital and AWS. This legal structure shifts significant liability and ensures that the physical and logical security controls meet the rigorous standards of the HIPAA Security Rule. 3.1.2 Zero Data Retention and Privacy Trust in AI is predicated on data sovereignty. A primary concern for health systems is that their sensitive patient data might be used to train future versions of the model, potentially leaking PHI. The Guarantee: AWS Bedrock provides a contractual guarantee of "Zero Data Retention" for base models. Prompts sent to Claude and the completions generated are processed in ephemeral memory. They are not logged by AWS, nor are they accessible to Anthropic for model training. This isolation is absolute and is a prerequisite for processing sensitive data like genomic sequences or psychiatric notes. 3.1.3 AgentCore and Secure Orchestration The "AgentCore" feature within Bedrock allows developers to build stateful, autonomous agents that persist across interactions. Architecture: An "Appointment Scheduling Agent" built on Bedrock AgentCore does not just generate text. It maintains a state machine (e.g., "Waiting for patient to confirm date"). It executes logic using AWS Lambda functions, which can query the hospital's SQL databases. Security: These agents run within the hospital's Virtual Private Cloud (VPC). Data in transit is encrypted via TLS 1.2+, and data at rest (e.g., the conversation history) is encrypted using AWS Key Management Service (KMS) with customer-managed keys (CMK). This ensures that even AWS administrators cannot access the patient interaction data. 3.2 Google Cloud Vertex AI: The Data Integrator Google Cloud’s implementation of the Claude stack appeals strongly to organisations leveraging the broader Google Health ecosystem, particularly those utilising FHIR-native stores. 3.2.1 Deep Integration with Google Healthcare API Vertex AI facilitates direct connectivity between Claude and Google’s Healthcare API, which hosts enterprise-grade FHIR stores. Latency Advantage: Because the model endpoint and the data store reside within the same high-speed Google fiber network, the latency for Retrieval-Augmented Generation (RAG) is minimised. This is critical for real-time clinical decision support where every millisecond counts. MedLM and Grounding: Google provides specialized services for "grounding"—the process of anchoring AI responses in truth. Healthcare organizations can use Vertex AI Search to index their internal clinical guidelines. When Claude answers a query, it can be forced to "cite" these internal documents, significantly reducing the risk of hallucination. 3.3 Reference Architecture: HIPAA-Compliant De-Identification While the cloud platforms provide robust security, defense-in-depth principles dictate that PHI should be minimized wherever possible. A "Gold Standard" reference architecture for healthcare RAG involves a dedicated de-identification layer. 3.3.1 The Tokenisation Gateway This architecture introduces a middleware layer between the clinical application and the LLM. Ingestion & Detection: The system receives a prompt: "Patient John Doe (MRN 12345) reports severe chest pain." An NLP-based Named Entity Recognition (NER) system (e.g., Amazon Comprehend Medical or Google Healthcare NLP) scans the text for the 18 HIPAA identifiers. Tokenisation: The identifiers are replaced with irreversible or reversible tokens. "Patient reports severe chest pain" Inference: The de-identified prompt is sent to Claude. Since the clinical context ("severe chest pain") remains, the model can still perform its reasoning task. Re-Identification: The model's response is intercepted by the gateway. If the response includes placeholders, they are mapped back to the original identifiers before being presented to the authorised clinician. Cloud Infrastructure Comparison for Healthcare AI Feature AWS Bedrock Google Cloud Vertex AI HIPAA Coverage BAA Covered (Eligible Service) BAA Covered (Eligible Service) Data Retention Zero Retention (Base Models) Zero Retention (Base Models) Network Security AWS PrivateLink (VPC Isolation) VPC Service Controls Key Management AWS KMS (Customer Managed Keys) Cloud KMS (Customer Managed Keys) Healthcare APIs AWS HealthLake (FHIR) Google Healthcare API (FHIR) Orchestration Bedrock Agents (Lambda-based) Vertex AI Agents (Cloud Run/Functions) Differentiator Mature Enterprise Security Controls Deep Integration with Google Search/MedLM 4. Interoperability and Data Fabric: The Model Context Protocol The greatest barrier to AI utility in healthcare is data fragmentation. Clinical truth is scattered across the EHR, the LIMS, the PACS, and payer portals. To function as an "agent," Claude must be able to read and write across these silos. Anthropic addresses this via the Model Context Protocol (MCP), an open standard designed to solve the "last mile" problem of connecting LLMs to data. 4.1 The Model Context Protocol (MCP) Explained MCP acts as a universal interface, a USB-C port for AI models. Instead of building bespoke integrations for every specific database or API, developers build standardised MCP Servers. Mechanism: An MCP server sits on top of a data source (e.g., a SQL database of patient labs). It exposes "resources" (data) and "tools" (functions) to the MCP client (Claude). Discovery: When Claude connects to the server, it performs a handshake to discover capabilities. The server might say, "I have a tool called get_hemoglobin_a1c (patient_id)." Security Context: Crucially, the MCP server runs within the healthcare organization's infrastructure. When Claude "calls" a tool, the execution happens locally. Claude never gets direct access to the database credentials. It merely requests an action, and the secure server executes it. 4.2 Specialised Healthcare Connectors Anthropic and its partners have developed a suite of MCP-compliant connectors that serve as the bridge between the model and the biomedical world. 4.2.1 The Benchling Connector: A Scientific Copilot In life sciences, the Electronic Lab Notebook (ELN) is the source of truth. The Benchling connector allows Claude to interface directly with this structured data. Use Case: A scientist can ask, "Summarise the results of the toxicity assay for Candidate X from last week." Workflow: Claude identifies the intent and calls the Benchling MCP tool search_entries(query="toxicity assay Candidate X"). The Benchling server retrieves the specific experiment data, including tables and images. Claude synthesises this raw data into a narrative summary, providing direct hyperlinks back to the source entry in Benchling. Impact: This maintains data lineage. The scientist doesn't just get an answer; they get a traceable path back to the raw evidence, a requirement for GxP compliance. 4.2.2 Clinical and Regulatory Connectors To support the broader ecosystem, connectors have been built for: CMS & Payer Policies: Allowing agents to query the latest National Coverage Determinations (NCDs) for Medicare. ICD-10 & CPT: Enabling automated coding agents to verify procedure codes against standard ontologies. Medidata & ClinicalTrials.gov: Facilitating the oversight of clinical trials by pulling real-time enrollment metrics and cross-referencing them with public registries. 4.3 Agent Skills: Automating Domain Expertise Beyond simple data retrieval, "Agent Skills" encapsulate domain-specific logic. These are essentially packages of prompts, code, and tool definitions that teach Claude how to perform a specialised task. 4.3.1 The Single-Cell RNA QC Skill Bioinformatics is a field characterised by complex, multi-step data processing pipelines. The single-cell-rna-qcskill automates the quality control of single-cell RNA sequencing (scRNA-seq) data. Functionality: The skill utilises "Claude Code" (an agentic coding environment) to write and execute Python scripts using the scanpy and scverse libraries. Process: The user uploads an .h5ad file (raw genomic data). The skill instructs Claude to calculate quality metrics (e.g., mitochondrial count, total counts per cell). Claude generates and executes the code to filter out low-quality cells (e.g., dead cells with high mitochondrial content). The skill produces visualisation plots (violin plots) to confirm the data quality. Value: This democratizes bioinformatics. A wet-lab biologist without deep Python expertise can now perform rigorous QC on their own data, accelerating the experimental cycle. 4.3.2 The FHIR Interoperability Skill Fast Healthcare Interoperability Resources (FHIR) is the global standard for healthcare data exchange, but its nested JSON structure is complex and often difficult for standard LLMs to parse accurately. Skill Capability: The FHIR skill trains Claude on the specific schemas and profiles of FHIR Resources (Patient, Observation, Encounter). Application: A developer can ask Claude to "Create a FHIR Bundle for a patient with hypertension and a prescription for Lisinopril." The skill ensures that the generated JSON adheres strictly to the HL7 FHIR R4 standard, validating the cardinality and data types. This significantly accelerates the development of interoperable health applications. 5. Agentic Workflows: Case Studies in Transformation The combination of the Intelligence Layer (Claude), the Infrastructure Layer (Bedrock/Vertex), and the Data Layer (MCP) enables the creation of transformative "Agentic" applications. These are not theoretical; they are currently being deployed by industry leaders. 5.1 Case Study: Hippocratic AI’s "Nurse Agents" The nursing shortage is a critical global crisis. Hippocratic AI utilises the Claude ecosystem to build "Nurse Agents" capable of autonomous patient interaction. Architecture: The system utilises a "constellation" architecture. A primary conversational model handles the dialogue, while specialised "safety support models" monitor the conversation in real-time for compliance and medical accuracy. Application: These agents perform tasks such as: Chronic Care Management: Calling heart failure patients to check their daily weight and ask about shortness of breath. Pre-Operative Instructions: Walking patients through their "NPO" (nothing by mouth) guidelines before surgery. Social Determinants of Health (SDOH) Screening: Assessing patients for food insecurity or transportation issues. Validation (RWE): The defining feature of this deployment is its rigorous testing. Hippocratic AI established a "Real World Evaluation" framework where thousands of licensed US nurses and physicians acted as "red teamers." They role-played as patients, testing the agents on empathy, medical accuracy, and safety protocols. The agents were only deployed after demonstrating safety metrics superior to human benchmarks in specific tasks. 5.2 Case Study: Genmab and Agentic R&D Genmab, a leading biotech company, partnered with Anthropic to transform its drug development process using "Agentic AI." Strategic Goal: To move from a labor-intensive, document-centric R&D process to a data-centric, automated one. Implementation: Genmab deploys Claude-powered agents to automate the "drudgery" of science. Clinical Data Cleaning: Agents review incoming data from clinical trial sites, identifying discrepancies (e.g., "Patient weight recorded as 150kg in Visit 1 and 60kg in Visit 2") and automatically generating queries for the site coordinators. Scientific Insight Generation: By connecting Claude to Open Targets and internal databases, scientists can execute high-level queries: "Identify all solid tumour targets with a safety profile compatible with our bi specific antibody platform." The agent plans the research, queries multiple databases, synthesises the findings, and presents a ranked list of targets. 5.3 Administrative Automation: The Revenue Cycle Agent The administrative burden of the US healthcare system is immense. Claude agents are deployed to automate the Revenue Cycle Management (RCM) process. Prior Authorisation Appeals: When a payer denies a claim for "medical necessity," an agent is triggered. Ingest: The agent reads the denial letter and the payer's specific policy document (via MCP). Analyse: It scans the patient's chart for the specific clinical criteria required by the policy (e.g., "Tried and failed two previous therapies"). Draft: It drafts a formal appeal letter, explicitly citing the medical records that prove necessity. Review: A human specialist reviews the draft and submits it. ROI: This workflow turns a 45-minute task into a 5-minute review, drastically reducing the cost of collections and ensuring patients receive the care they are entitled to. 6. Evaluation, Governance and Safety Frameworks The deployment of non-deterministic probabilistic models in a life-critical domain like healthcare requires a new class of evaluation and governance. "Accuracy" is insufficient; "Safety" is paramount. 6.1 Constitutional AI: The Safety Foundation Anthropic’s unique contribution to AI safety is "Constitutional AI." Mechanism: Rather than relying solely on Reinforcement Learning from Human Feedback (RLHF)—which can be brittle—Claude is trained to follow a "Constitution" of principles. These principles include "Do not give harmful advice," "Respect privacy," and "Avoid stereotyping." Healthcare Impact: This intrinsic alignment makes the model fundamentally more resistant to "jailbreaks." Even if a user tries to trick the model into prescribing a controlled substance, the model's internal constitution overrides the instruction. This safety is verified through extensive "Red Teaming," where domain experts attempt to break the model before release.2 6.2 Advanced Evaluation Frameworks Standard benchmarks like MedQA (multiple choice questions) do not capture the complexity of real-world clinical practice. The industry is adopting more dynamic frameworks. CRAFT-MD (Conversational Reasoning Assessment Framework): This framework acknowledges that diagnosis is a dialogue, not a test question. It evaluates the model's ability to ask the right questions. Does the model ask about travel history when a patient presents with fever? CRAFT-MD simulates these multi-turn interactions, revealing that models with high MedQA scores often struggle with the active process of history-taking. This insight drives the need for agentic frameworks that can prompt the model to "think" about what information is missing. Real World Evaluation (RWE): As pioneered by Hippocratic AI, this framework focuses on output testing. It doesn't just check if the answer is "correct"; it checks if it is safe, empathetic, and appropriate for the patient's literacy level. This involves large-scale human evaluation by licensed clinicians, creating a feedback loop that continuously refines the model's behaviour. 6.3 Governance and the Human-in-the-Loop The "Claude for Healthcare" stack is designed around the principle of Human-in-the-Loop (HITL). Autonomy Levels: Applications are architected with distinct autonomy tiers. Level 1 (Read-Only): The agent can analyze data and answer questions. (e.g., "Summarize this chart"). Level 2 (Drafting): The agent can create drafts but cannot send them. (e.g., "Draft a discharge summary"). Level 3 (Action with Approval): The agent can propose an action, which requires human click-through. (e.g., "I recommend ordering a CBC. Approve?"). Auditability: Every step of the agent's reasoning, its "Thought" process, is logged. This creates a transparent audit trail. If an error occurs, forensic analysis can determine why the agent made that decision, a capability essential for medical liability and malpractice defense. 7. Economic Analysis and Strategic Roadmap 7.1 The Economics of Agentic AI The move to "token-based" pricing requires a reassessment of IT economics. Cost-Benefit Analysis: While high-end models like Claude 3 Opus are expensive ($15/$75 per million tokens), their cost must be weighed against the labor they replace. A "Regulatory Agent" running on Opus might cost $50 to process a submission. However, if it saves 20 hours of time for a Regulatory Affairs professional (billing at $200/hour), the ROI is 8,000%. Optimization Strategy: Smart organizations utilize a "Cascading Model Architecture." A "Router" model (often Haiku or a small classifier) analyzes the incoming query. Simple: "Schedule an appointment" -> Routed to Haiku ($0.80/MTok). Complex: "Analyze this genomic variant" -> Routed to Opus ($15.00/MTok). This tiered approach ensures that the organization pays only for the intelligence required for the specific task. 7.2 Implementation Roadmap for Health Systems For a health system or life sciences company embarking on this journey, the roadmap is clear: Phase 1: Foundation & Compliance (Months 1-3): Establish the secure AWS Bedrock or Vertex AI environment. Sign the BAA. Implement the Tokenisation Gateway. Phase 2: Internal RAG & Copilots (Months 3-6): Deploy internal-facing tools. "Chat with your Policy Documents" or "Coding Assistant." These have low clinical risk but high operational value. Phase 3: Agentic Pilots (Months 6-12): Roll out "Nurse Agents" or "Scientific Copilots" in controlled pilots. Use frameworks like RWE to validate safety. Phase 4: Scaled Autonomy (Year 1+): Expand the autonomy of agents, allowing them to execute tasks (like booking or ordering) under supervision. 8. Conclusion The "Anthropic Claude for Healthcare stack" is not merely a collection of large language models; it is a comprehensive, enterprise-grade operating system for the cognitive age of medicine. By harmonising the raw intelligence of the Claude 3/4 families with the rigorous security of AWS and Google Cloud, and bridging the data gap with the Model Context Protocol, Anthropic has created a viable path for the deployment of Agentic AI. The transition from passive tools to active agents offers the potential to resolve the fundamental paradox of modern healthcare: the explosion of data coupled with the scarcity of human attention. By offloading the cognitive drudgery of documentation, coding, and synthesis to safe, constitutional AI agents, the healthcare system can allow its most valuable resource, its clinicians, to return to the high-value, uniquely human task of caring for patients. The organisations that successfully master this stack will not just be more efficient; they will define the standard of care for the coming decade. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Distressed M&A predicted to play a major role in European HealthTech and MedTech 2026 Executive Summary The European healthcare technology (HealthTech) and medical technology (MedTech) landscape enters 2026 at a profound inflection point, characterised by a transition from the speculative fragmentation of the early 2020s to a disciplined era of "industrial maturity." Following a period of post-pandemic recalibration in 2024 and a tentative recovery in 2025, the market is poised for a robust, albeit structurally transformed, resurgence in mergers and acquisitions (M&A). The defining theme for the 2026 vintage is "Industrialisation." This concept signifies a departure from the fragmented, venture-subsidised experimentation that characterised the 2019–2022 era, moving instead toward scalable, profit-generating platforms that leverage operational leverage, regulatory fortitude, and vertical integration to dominate their respective sub-sectors. While headline deal values are projected to rise, the underlying mechanics of the market have shifted fundamentally toward distress-driven consolidation. The convergence of macroeconomic pressure, the maturity of the private equity liquidity cycle, and most critically the "Regulatory Darwinism" imposed by the full implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has created a sharp bifurcation in asset quality. For 2026, the outlook is not a rising tide that lifts all boats. Instead, it is a "clearing event." On one side, high-quality, AI-enabled assets and profitable platforms will command premium multiples (12x–15x EBITDA).On the other, a vast swath of small and medium-sized enterprises (SMEs), particularly in legacy hardware and In Vitro Diagnostics (IVD), face an existential crisis due to compliance costs and capital scarcity, making them prime targets for distressed acquisition, carve-outs, and insolvency-led restructuring. The financial architecture of 2026 is defined by a massive overhang of unallocated capital ("dry powder") alongside a pressing need for liquidity events. Global private equity funds are sitting on nearly $2.5 trillion in dry powder. However, the deployment of this capital is highly selective. The "growth-at-all-costs" thesis has been replaced by a focus on unit economics, EBITDA expansion, and cash flow predictability. This report provides an analysis of these dynamics, dissecting the market into key verticals of consolidation, financial mechanisms and regional hotspots. It explores how specialized funds like GHO Capital, ArchiMed, and turnaround experts like Mutares and Aurelius are positioned to capitalize on this dislocation, and why corporate divestitures from giants like Siemens Healthineers and Philips are reshaping the competitive landscape. The Macro Financial Architecture of 2026 To understand the specific drivers of distressed M&A in healthcare, one must first situate the sector within the broader European financial architecture of 2026. The market is defined by a paradox: record levels of capital availability for top-tier assets exist alongside a severe liquidity crunch for growth-stage and lower-middle-market assets, creating a bifurcated environment ripe for consolidation. The Liquidity Wall and the Vintage Overhang Entering 2026, the private equity (PE) industry faces a critical maturity wall. The industry is grappling with a significant backlog of assets acquired during the high-valuation vintage years of 2019–2021. These assets, often bought at peak multiples, have struggled to grow into their valuations amidst the higher interest rate environment that persisted through 2024 and 2025. Limited Partners (LPs) are exerting immense pressure on General Partners (GPs) to return capital, forcing a clearing of portfolios. With the IPO market remaining selective and focused only on assets with proven profitability and scale such as the rare "unicorns" that have managed to maintain high growth with positive unit economics, sponsors are increasingly forced to utilise continuation funds and secondary buyouts to drive consolidation. This allows them to hold high-performing assets for longer, financing further add-on acquisitions to build pan-European champions before an eventual exit. However, for assets that have underperformed or failed to achieve "platform" status, the exit route is increasingly a distressed sale or a complex restructuring process. The "Series B+ Gap" has exacerbated this dynamic. Historically, European biotechs and HealthTech scaleups have struggled to raise funding rounds larger than $50 million. In 2026, this gap has widened into a chasm. Companies that raised seed and Series A capital in 2023/2024 are now hitting the market for growth capital just as investors have pivoted to a "flight to quality." Those unable to demonstrate clear unit economics and regulatory compliance are finding themselves un-investable, driving a wave of insolvency-led M&A. This is not merely a pause in funding; it is a structural reset where companies with high burn rates and undefined paths to profitability are being allowed to fail or are being acquired for their intellectual property alone. Interest Rates, Inflation and the Cost of Capital While interest rates have stabilised and begun to ease by 2026 compared to the peaks of 2024, the era of "free money" is definitively over. The cost of debt servicing remains a significant burden for highly leveraged healthcare services assets. This is particularly acute for "buy-and-build" platforms in dental, veterinary and ophthalmology sectors that relied on cheap debt to finance aggressive acquisition sprees during the previous cycle. As debt tranches mature in 2026, many of these platforms face refinancing risks, potentially triggering debt-for-equity swaps or distressed sales to turnaround funds. The European Central Bank's monetary policy, while loosening slightly, has left a legacy of higher borrowing costs that continues to filter through the corporate sector. Corporate interest expenses are trailing behind rate hikes, meaning the full impact of the 2023-2024 tightening cycle is only being fully felt on balance sheets in 2026 as fixed-rate terms expire and refinancing becomes necessary at significantly higher spreads. This divergence in financing conditions has created a bifurcated market: investment-grade corporates and large-cap PE funds have access to capital, while SMEs and unprofitable growth companies face punitive costs of capital. This disparity fuels the consolidation engine: cash-rich strategics and large PE funds are positioned to acquire distressed smaller competitors at attractive multiples, effectively arbitraging the cost of capital. Corporate Divestitures and Portfolio Rationalisation A major source of deal flow in 2026 is the proactive "pruning" of portfolios by large multinational corporations. The pervasive emphasis on "strategic carve-outs," "portfolio optimisation," and "reducing complexity" signals a fundamental shift in corporate strategy. This contrasts with distressed M&A driven by insolvency, representing instead a strategic retreat to core competencies. Notable examples setting the tone for 2026 include Siemens Healthineers' strategic deconsolidation to unlock value and focus on high-growth digital and AI segments. By spinning off or reducing stakes in lower-margin or non-core divisions, these giants aim to improve their valuation multiples and focus capital allocation on high-growth areas like "Precision Therapy" and AI-driven diagnostics. Similarly, Philips continues to refine its portfolio, focusing on "bolt-on" acquisitions that support its informatics and patient monitoring capabilities while divesting legacy hardware businesses that no longer fit its "mid-single-digit growth" trajectory. These moves create opportunities for private equity to acquire stable, cash-generative divisions that no longer fit the growth narrative of their parent companies. The "carve-out" has become the preferred mechanism for value creation, with firms like Aurelius and Mutares specifically targeting these complex separation cases. For instance, Mutares' acquisition of SABIC's Engineering Thermoplastics business and Aurelius' acquisition of Louwman Group's Care Division illustrate the scale and complexity of carve-outs characterising the 2026 market. Regulatory Darwinism: The Primary Catalyst for Distress The most potent force driving distressed M&A in European MedTech and HealthTech in 2026 is not economic, but regulatory. The convergence of the Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), and the new AI Act has created a "compliance moat" that is insurmountable for many smaller players, fundamentally altering the competitive landscape. The MDR and IVDR Clearing Event By 2026, the extended transition periods for legacy devices under the MDR and IVDR are nearing their critical deadlines. The "grace periods" granted in previous years served only to delay the inevitable for companies lacking the capital or data to re-certify their portfolios. The implementation of these regulations has created a capital-intensive barrier to entry. The costs associated with Notified Body certification, clinical data generation, and post-market surveillance act as a guillotine for undercapitalized firms. Estimates suggest that compliance costs can consume 8-15% of revenue for SMEs, a burden that erases profit margins for low-margin device manufacturers and renders many product lines economically unviable. The Legacy Device Cliff A specific driver of distress is the "legacy device cliff." Thousands of older, yet clinically necessary, medical devices are being withdrawn from the market because the cost of bringing them into MDR compliance exceeds their future revenue potential. This has forced companies to make hard decisions about portfolio rationalization. Many SMEs, particularly in the In Vitro Diagnostics (IVD) space, are facing an existential crisis as they simply cannot afford the transition for their entire product suites. Under the previous directive (IVDD), only about 20% of IVDs required Notified Body involvement; under IVDR, this figure has skyrocketed to approximately 80%, creating a massive bottleneck and cost explosion. This dynamic creates a specific type of M&A opportunity: "Compliance-Driven Consolidation." Large strategic acquirers, possessing the regulatory infrastructure and balance sheet strength to handle certification, are acquiring the intellectual property (IP) and customer bases of distressed SMEs. The value in these deals lies not in the target's standalone viability, but in the acquirer's ability to migrate the target's products onto their own compliant quality management systems (QMS), thereby preserving market access for critical technologies. The Revisions of December 2025: Too Little, Too Late? In December 2025, the European Commission proposed targeted revisions to the MDR and IVDR to address the structural deficiencies causing these bottlenecks. These proposals acknowledged the "structural deficiencies" of the regulations and aimed to prevent a public health crisis caused by device shortages. Key proposals included: Removal of Certificate Validity Limits: Replacing the five-year cap on certificates with periodic risk-based surveillance, theoretically reducing the administrative burden of recertification. Simplification for "Well-Established Technologies": Reducing clinical evidence burdens for standard, low-risk devices that have a long history of safe use, exempting them from some of the most onerous reporting requirements. SME Relief: Easing requirements for the Person Responsible for Regulatory Compliance (PRRC), allowing micro and small enterprises to rely on external experts rather than requiring a permanent employee, which had been a significant hiring bottleneck. Targeted IVD Reforms: Removing the requirement for "no equivalent device" for in-house IVDs, easing the pressure on hospital laboratories. However, for many SMEs, these changes come too late to prevent distress in 2026. The legislative timeline for these proposals involves negotiation with the European Parliament and Council, meaning full implementation and the translation of these rules into Notified Body practice will likely not take effect until 2027 or 2028.Consequently, 2026 remains a "danger zone" where the pressure of the current rules forces insolvencies before the relief of the new rules arrives. The uncertainty itself acts as a catalyst for M&A, as investors refuse to fund companies whose regulatory status is in limbo, forcing them into the arms of acquirers. The AI Act and the "Digital Omnibus" Simultaneously, 2026 marks a pivotal year for digital health regulation with the full implementation of the EU AI Act and the proposed Digital Omnibus. The AI Act categorises many medical AI tools as "high-risk," imposing rigorous requirements for data governance, transparency, human oversight, and post-market monitoring. This creates a "bifurcation of investability" in HealthTech. Early-stage AI companies that followed the "move fast and break things" mantra without building robust regulatory foundations are finding themselves uninvestable. They are becoming distressed targets for "acquil-hiring" or asset sales. Conversely, companies that have built "compliance moats", proprietary, compliant data sets and validated algorithms that meet the AI Act's stringent standards, are commanding significant valuation premiums. The Digital Omnibus further complicates this by harmonizing GDPR, data governance, and cybersecurity rules (NIS2), favoring large platforms that can amortize the cost of compliance across a broader revenue base. The complexity of adhering to the AI Act, GDPR, MDR, and the European Health Data Space (EHDS) simultaneously creates a barrier to entry that protects incumbents and "industrialised" scale-ups while crushing new entrants. Sector Deep Dives: Winners, Losers and Consolidation Logic The "Industrialisation" of the sector implies that consolidation will follow distinct industrial logic across different verticals. The market is moving away from hype toward unit economics, scale, and operational efficiency. We observe a stark divergence in the fate of "Analog" versus "Digital" healthcare assets. MedTech: The Hardware Rationalisation The traditional MedTech sector (orthopedics, surgical instruments, capital equipment) is the epicenter of distress-driven M&A. This sector is characterised by high fixed costs, complex supply chains, and extreme sensitivity to the MDR compliance burden. Distress Drivers: Supply chain inflation, high inventory costs, and the MDR compliance burden have eroded margins. The "legacy device cliff" is particularly acute here, with many low-volume but clinically essential tools being discontinued. Consolidation Logic: Scale is the only defense. Mid-sized players are merging to create entities large enough to absorb regulatory overheads and negotiate with centralised hospital procurement bodies. Hotspots: Surgical Robotics: While high-growth, this segment is capital intensive. We see consolidation where larger platforms acquire niche robotic solutions (e.g., for specific microsurgeries) to integrate them into broader surgical ecosystems. Companies like CMR Surgical are bellwethers for the European market's ability to scale against US incumbents. Orthopedics & Implants: A classic "buy-and-build" sector. Specialized manufacturers (e.g., spinal, trauma) are being rolled up into pan-European groups. The sale of Citieffe by ArchiMed to Poly Medicure illustrates this trend of cross-border consolidation to achieve global scale. In Vitro Diagnostics (IVD): The Existential Crisis The IVD sector faces the steepest regulatory cliff of any healthcare vertical. As noted, the shift from 20% to 80% Notified Body oversight under IVDR has created a bottleneck that threatens the viability of hundreds of European diagnostic SMEs. Distress Drivers: The massive backlog at Notified Bodies means many companies cannot sell their products legally in the EU. Without certification, revenue stops, leading to immediate insolvency risk. Consolidation Logic: "Rescue mergers." Large diagnostic giants (Roche, Siemens Healthineers, Abbott) and specialized PE funds are acquiring IVD SMEs solely for their assays and IP, effectively discarding the corporate shell. The focus is on acquiring "menu expansion" for existing platforms. Valuation Impact: Valuation multiples for non-compliant IVD firms have collapsed, often trading at or below liquidation value. In contrast, compliant platforms with approved assays trade at significant premiums due to their scarcity value. Distressed M&A predicted to play a major role in European HealthTech and MedTech 2026 Digital Health and HealthTech: From Point Solutions to Platforms The era of the "single-solution app" is over. 2026 is defined by the aggregation of digital health tools into integrated platforms. Investors have soured on fragmented point solutions that require separate sales cycles and integration efforts for hospitals. Distress Drivers: High cash burn, lack of reimbursement (outside of Germany's DiGA and France's PECAN/PECAP), and "pilotitis" (getting stuck in pilot phases without scaling). The "Series B+ gap" is particularly lethal here. Consolidation Logic: Vertical integration. Telehealth providers are acquiring remote monitoring startups; Electronic Health Record (EHR) vendors are acquiring AI workflow tools. The goal is to offer a "full stack" solution to healthcare providers that integrates diagnostics, monitoring, and therapy. Winners: Companies with "infrastructure" status—those embedded in hospital workflows or with established reimbursement codes. AI-enabled platforms in radiology and pathology are seeing strategic consolidation as hardware incumbents seek to secure "data sovereignty". Losers: Direct-to-consumer (D2C) wellness apps with high churn and no clinical validation. These are seeing valuation compression to 3x-4x revenue or lower. Healthcare Services: The Outpatient Shift Capital is rotating aggressively out of acute care hospitals and into outpatient and home care settings. This structural shift is driving M&A activity in service provision. Drivers: Aging populations, workforce shortages (a shortfall of 1.2 million clinicians in the EU), and public budget constraints are forcing care into lower-cost settings. Consolidation Logic: Geographic and specialty arbitrage. Private equity is executing "buy-and-build" strategies in fragmented specialties like ophthalmology, fertility, and dentistry, particularly in Southern and Eastern Europe where multiples remain lower (6x-8x EBITDA) compared to the saturated UK and Nordic markets. Distress Angle: Many small clinic chains that over-leveraged during the cheap debt era of 2020-2022 are now struggling with debt service. These are being snapped up by larger, better-capitalized platforms. For example, Aurelius' acquisition of Louwman's care division highlights the interest in specialised care and mobility services that can be scaled operationally. Insolvency Trends and Deal Structures As financial distress mounts, the mechanisms of M&A are evolving. 2026 is seeing a rise in complex deal structures designed to navigate insolvency regimes, preserving value for senior creditors while often wiping out equity holders. Rising Insolvency Rates across Europe Data indicates a continued rise in insolvencies across Europe in 2025/2026, driven by the "delayed effect" of interest rate hikes and the withdrawal of pandemic-era support measures. Germany: Business insolvencies are projected to rise significantly (+10% in 2025), driven by the industrial slowdown, energy costs, and the high cost of capital. The MedTech "Mittelstand" is heavily exposed here. France: Insolvencies are reaching historical highs (projected 67,500 cases in 2025), impacting smaller healthcare service providers and biotech startups. UK: Insolvencies remain elevated, with the "restructuring plan" mechanism becoming a key tool for mid-market distress. The UK is expected to see stabilisation but at a high level. Global Context: Globally, business insolvencies are set to rise by +6% in 2025 and +5% in 2026, marking five consecutive years of increases. The Rise of the Restructuring Plan and Pre-Pack To preserve value, stakeholders are increasingly using pre-packaged insolvency sales ("pre-packs") and court-sanctioned restructuring plans. These tools allow for the separation of viable assets from toxic balance sheets. Germany: The StaRUG Mechanism The German StaRUG (Stabilisation and Restructuring Framework for Enterprises) has become a pivotal tool in the 2026 distressed landscape. Unlike traditional insolvency, StaRUG allows a debtor to negotiate a restructuring plan with a majority of creditors (75%) and "cram down" the dissenting minority, all while avoiding the stigma and operational disruption of formal insolvency proceedings. Implication for M&A: StaRUG enables "Loan-to-Own" strategies. Distressed debt funds can buy into a MedTech company's debt stack, vote for a restructuring plan that converts their debt to equity, and wipe out the existing shareholders. This mechanism is increasingly used to take control of German device manufacturers that are operationally sound but over-leveraged or burdened by MDR transition costs. However, recent court rulings regarding "arbitrary creditor selection" have added complexity, requiring robust justification for excluding certain creditor classes. UK Restructuring Plans The UK's Restructuring Plan (Part 26A of the Companies Act 2006) continues to be a favored tool for complex, cross-class restructurings. The ability to bind dissenting classes of creditors ("cross-class cram-down") makes it a powerful weapon for imposing haircuts on junior debt or landlords. This is becoming prevalent in healthcare services (e.g., care home chains) where lease liabilities need to be restructured alongside financial debt. Poland and Other Jurisdictions The Polish market is seeing an uptake in pre-pack transactions, allowing investors to acquire assets free of encumbrances. This makes Poland an attractive jurisdiction for acquiring distressed manufacturing assets to near-shore supply chains. Similarly, the EU's push for harmonisation of insolvency laws (Insolvency III directive) is slowly standardising the pre-pack mechanism across member states, though national differences remain significant. Deal Structures: Carve-Outs and Earn-Outs Complex Carve-Outs: As conglomerates divest non-core assets, the "complex carve-out" is a dominant deal type. These transactions require specialized operational capabilities to separate IT, HR, and supply chains from the parent company. Funds like Aurelius and Mutares thrive here, as evidenced by Mutares' acquisition of SABIC's thermoplastics business and Aurelius' deal for McKesson UK. Earn-Outs: To bridge the "valuation gap" between sellers (anchored to 2021 prices) and buyers (focused on 2026 risks), earn-outs have become ubiquitous. Up to 20-30% of deal value is often contingent on post-closing performance, particularly in digital health deals where revenue trajectories are unproven. This aligns incentives and de-risks the transaction for the buyer. Regional Hotspots and Arbitrage The distress and consolidation wave is not uniform across Europe. Regional nuances dictate the flow of capital and the specific nature of opportunities. DACH (Germany, Austria, Switzerland) Germany remains the engine of European MedTech but also the center of distress. The high concentration of "Mittelstand" device manufacturers makes it uniquely vulnerable to the MDR/IVDR shock. Trend: "Succession crisis" meets "Regulatory crisis." Family-owned device firms are selling to PE as the next generation refuses to take on the regulatory burden. Mechanism: StaRUG proceedings and distressed asset sales are the primary mechanisms for transfer. Valuation: Restructuring pressure remains highest in Germany, with significant opportunities for turnaround investors to acquire high-quality engineering assets at distressed prices. UK and Ireland The UK market is distinct due to the post-Brexit regulatory divergence. Trend: While the UK seeks to establish its own sovereign regulatory framework, UK MedTechs must still comply with MDR to export to the EU. This "double burden" of maintaining two regulatory files is crushing smaller UK firms. Opportunity: Inbound M&A from US and Asian buyers taking advantage of depressed valuations and the UK's strong R&D base (e.g., in genomics and AI drug discovery). The UK remains a leader in deal volume, particularly in BioPharma and digital health. Southern Europe (Italy, Spain) Southern Europe is the primary target for "buy-and-build" services consolidation. Trend: Healthcare provision (dental, vet, imaging) remains highly fragmented compared to the Nordics or UK. Arbitrage: Entry multiples in Spain or Italy are significantly lower (e.g., 6x-8x EBITDA) than in Northern Europe, offering PE sponsors a clear multiple arbitrage opportunity upon exit. "Analog" services are the main play here. Central and Eastern Europe (CEE) CEE is emerging as a manufacturing and R&D hub, but also a source of distressed manufacturing assets. Trend: Near-shoring of supply chains. Western European firms are acquiring Polish or Czech manufacturers to shorten supply lines and reduce geopolitical risk. Distressed M&A is active as local firms struggle with energy costs and inflation. The Buyer Universe: Who is Buying the Distress? The buyer landscape in 2026 has shifted from growth equity tourists to hardened specialists and industrial strategics. The "Tourists" have left the building; the "Industrialists" have taken over. The Turnaround Specialists: "The Fixers" Funds specialising in special situations, carve-outs, and distress are the most active players in the lower-middle market. Their model relies on operational restructuring rather than financial leverage. Mutares: A key player in acquiring distressed industrial and chemical/material assets. Their acquisition of SABIC's Engineering Thermoplastics business (Enterprise Value $450m) marks a new strategic segment. They actively hunt for "unloved" subsidiaries of large corporates, fixing operations (supply chain, SG&A) to drive value. Aurelius: Demonstrated capability in complex healthcare carve-outs. Their acquisition of McKesson UK (LloydsPharmacy) and the recent deal for Louwman Group's Care Division in the Netherlands showcase their focus on operational transformation in healthcare services and mobility. Healthcare Specialist PE: "The Growers" Sector-specialist funds are leveraging their domain expertise to pick winners from the wreckage. They focus on "picks and shovels" businesses that support the broader industry. GHO Capital: Europe's largest healthcare-specialist PE firm (Fund IV closed at €2.5bn). They focus on "Better, Faster, More Accessible" healthcare, targeting sub-sectors like CDMOs, BioPharma services, and MedTech. Their recent investments (e.g., Avid Bioservices, Scientist.com) reflect a trans-Atlantic "buy-and-build" strategy. ArchiMed: A leading player in the mid-market, focusing on trans-Atlantic expansion for European assets. Their strategy involves aggressive buy-and-build in fragmented verticals like IVD and pharma services. The spin-off of SuanNutra and the sale of Citieffe demonstrate their ability to generate returns through operational scaling. Apposite Capital: Focuses on the lower-middle market and SMEs, emphasising impact and operational improvement in healthcare provision and social care. They act as the first institutional capital for growing SMEs. Corporate Strategics: "The Scalers" Large corporates are using their strong balance sheets to acquire technology and IP at discounted valuations. Siemens Healthineers: Following its planned deconsolidation, Siemens Healthineers is actively streamlining its portfolio. It is focusing on high-growth "Precision Therapy" and AI, raising its mid-term revenue growth targets to 6-9%. It is positioned to acquire AI-enabled assets that fit this high-growth narrative while potentially divesting lower-margin diagnostics assets. Philips: After navigating its own recall challenges, Philips is returning to the M&A market with a focus on "bolt-on" acquisitions in informatics and patient monitoring. The company is adhering to a disciplined "mid-single-digit growth" trajectory, looking for assets that can be immediately accretive to its connected care ecosystem. Roche: Shifting from large consolidation to "optimization," prioritizing partnerships and targeted acquisitions in oncology and digital pathology over mega-mergers. Roche has allocated capital to acquire late-stage assets that can bolster its pipeline without the integration risk of massive mergers. Valuation Landscape: The Bifurcation and Startup Runway Valuations in 2026 are characterized by extreme variance based on sub-sector and regulatory status. The market has moved away from "revenue multiples for everyone" to a strict dichotomy. Valuation Multiples Analysis The following table summarises the valuation landscape in late 2025/early 2026: Asset Class EV/Revenue EV/EBITDA Key Drivers Premium AI / Digital Platforms 6.0x – 8.0x+ 14.0x+ Scarcity value, "compliance moat," recurring revenue, reimbursement status. Standard MedTech (Profitable) 4.0x – 6.0x 10.0x – 14.0x Stability, cash flow, market share. Targets for PE buyouts. Value-Based Care Solutions 5.5x – 7.0x 12.0x – 15.0x Alignment with payer priorities, proven cost savings. Distressed / Non-Compliant SMEs < 3.0x Negative / N/A Regulatory risk. Valued on IP/Customer list only. Premium Assets: AI-driven diagnostics with reimbursement are the "crown jewels," commanding the highest multiples due to their potential to disrupt clinical workflows. Distressed Assets: Non-compliant SMEs trade at deep discounts. In many cases, these are asset sales rather than share deals, allowing the buyer to leave the liabilities (and non-compliant legacy products) in the insolvent shell. Startup Runway and Burn Rates For the startup ecosystem, 2026 brings a harsh reality check regarding cash runways. The Crunch: Startups are under immense scrutiny regarding burn rates. Investors now expect a cash runway of 24–30 months for seed-stage companies, a significant increase from previous norms. Burn Multiples: The "Burn Multiple" (cash burned per dollar of new ARR) is the key metric. Top-performing startups are achieving burn multiples below 1.0x. Those with burn multiples >2.0x are finding it nearly impossible to raise capital without massive down-rounds. Survey Data: Surveys indicate that securing financing and liquidity remains the biggest challenge for startups in 2025/2026. A significant portion of startups have less than 12 months of runway remaining, forcing them into M&A processes or insolvency. The median pre-money valuation for pre-seed/seed rounds has stagnated, meaning founders suffer greater dilution for the same capital. The Role of "Dry Powder" in Valuation Support A key question for 2026 is: Why haven't valuations collapsed completely across the board? The answer lies in the $2.5 Trillion of dry powder. While buyers are disciplined, the sheer volume of capital that must be deployed puts a "floor" under valuations for decent assets. PE firms cannot charge management fees on uninvested capital indefinitely. As the 2026 investment period deadlines approach for funds raised in 2021/2022, there is pressure to deploy. This creates a competitive dynamic for "A-minus" assets, companies that are not perfect, but "good enough" to serve as platforms, preventing a total market capitulation. Conclusion: The Industrialisation of Care The year 2026 will be remembered as the year European HealthTech grew up. The romantic phase of digital health—characterised by pilot projects, press releases, and unproven revenue models is dead. It has been replaced by a ruthless focus on Industrialisation: scale, compliance, margins, and integration. Distressed M&A is the crucible in which this transformation is taking place, stripping away the inefficiencies of the past to forge the healthcare giants of the future. The "Great Rationalisation" is purging the market of unviable business models and regulatory laggards. In their place, a new generation of "Industrialised" healthcare platforms is emerging, entities that combine the agility of tech with the rigour of regulated manufacturing. For investors, the opportunity lies not in passive allocation, but in active operational transformation. The winners of 2026 will be those who can navigate the "Regulatory Darwinism," acquire distressed assets at efficient prices, and integrate them into compliant, scalable platforms. Key Takeaways for Market Participants For SMEs: The window for "wait and see" regarding MDR/IVDR has closed. If you are not compliant, seek a strategic partnership or sale immediately before liquidity runs out. The costs of compliance are a barrier to entry that you likely cannot climb alone. For PE Investors: The arbitrage opportunity in 2026 lies in "Regulatory Turnarounds", buying fundamentally sound technologies that are trapped in non-compliant corporate structures and applying the capital/expertise to fix them. Look for carve-outs from frustrated corporates. For Strategics: Use the 2026 dislocation to acquire IP and talent at a discount. The "buy vs. build" calculus heavily favours buying distressed innovators over internal R&D in the current environment, especially for AI and digital capabilities. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 9th January 2026 European HealthTech this week is dominated by EU‑level AI and data policy moving into implementation, new EU and national funding windows for digital health, and early‑year signals of tighter but more predictable MedTech regulation in 2026. Dealmaking and startup activity continue to tilt towards AI‑enabled automation, data‑rich diagnostics and devices, and cross‑border virtual care infrastructure.​ Policy and regulatory moves The European Commission has released a new report on emerging health technologies, feeding into implementation of the AI Act, MDR/IVDR and broader digital health strategy as the reference framework for “robust and trustworthy” AI in care.​ EU commentary now explicitly links the AI Act, MDR and the Digital Omnibus as the core stack for health AI, aiming to harmonise rules and cut compliance friction for innovators from 2026 onward.​ NHS England is preparing for 2026 workforce and digital policy changes, with an overhaul of workforce models tied to expanded use of digital tools and automation across the system. Funding windows and capital flows The UNITE Open Call for European digital health innovators is live with a €4 million budget, offering up to €1 million per cross‑border project and a submission deadline of 15 January 2026.​ The 2026 cycle of the Future of Health Grant in Switzerland is opening this month, targeting early‑stage digital health startups in telemedicine, patient analytics, preventive care and digital therapeutics.​ Horizon Europe’s 2026–2027 work programme allocates part of a €14 billion R&I envelope to health and digital technologies, while Global Health EDCTP3 plans up to €147 million across six research topics relevant to infectious‑disease‑linked digital and clinical innovation.​ MedTech regulation and market structure New guidance and draft implementing regulations around MDR/IVDR and Notified Body conformity assessments are progressing, with consultation timelines running into mid‑January and pointing to tighter but more predictable oversight for EU devices and IVDs.​ EUDAMED’s staged roll‑out, with four modules now functional, starts a six‑month transition that will increase transparency on device registrations, vigilance and market actors from mid‑2026, directly affecting payer scrutiny and MedTech due diligence.​ Market outlook pieces frame 2026 as a “Great Rationalisation” year in European HealthTech/MedTech, with PE‑backed roll‑ups in services and strategic consolidation in AI radiology, digital pathology and tech‑enabled home care, alongside portfolio pruning under MDR/IVDR.​ Startups, AI automation and CES health tech A feature on European startups highlights strong investor interest in AI tools that automate healthcare administration and back‑office workflows, especially those integrating with hospital information systems rather than purely consumer apps.​ Health tech launches at CES 2026 include novel consumer‑adjacent devices such as smart menstrual pads, allergy devices and LED‑based masks, underscoring ongoing convergence between consumer wellness and regulated HealthTech.​ Eindhoven‑based ShanX Medtech secured a €24 million round to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing the region’s position as a MedTech innovation hub.​ Key implications for deals EU‑backed grants and Horizon Europe calls are providing non‑dilutive capital for cross‑border platforms built around EHDS‑style data flows, which may emerge as future roll‑up nuclei in digital health infrastructure.​ The combination of AI‑focused regulation, EUDAMED transparency and MDR/IVDR simplification is expected to concentrate M&A on fewer, higher‑value assets with clear regulatory narratives and data advantages, particularly in robotics, neuro, advanced diagnostics and AI‑enhanced workflows. >>> European MedTech this week is being shaped by tightening but clearer EU regulation (MDR/IVDR plus EUDAMED timing), notable funding rounds in cardiology and anti‑microbial resistance, and continued investor focus on robotics, neuro and data‑rich devices.​ Regulation and guidance The European Commission’s late‑2025 proposal to simplify MDR/IVDR is setting the 2026 agenda, focusing on digitalised procedures, harmonised Notified Body practice and clearer rules for software, AI and nano‑materials.​ EUDAMED has been confirmed as fully mandatory from 28 May 2026, with four modules (actor registration, UDI/device registration, notified bodies & certificates, market surveillance) triggering fixed deadlines and making transparency, traceability and post‑market oversight central to EU MedTech.​ MDCG‑endorsed documents from December 2025 are adding detailed guidance on MDR/IVDR application to software and AI‑driven products, which many MedTech software and SaMD vendors are now using to plan 2026 submissions.​ Market structure and MDR pressure 2026 is framed as a defining MDR year, with looming transition deadlines (2027–2028) and Notified Body bottlenecks forcing portfolio rationalisation and prioritisation of higher‑value devices.​ EUDAMED’s go‑live in May 2026 means all devices must be registered in the database before being placed on the EU market, adding operational burden but also standardising data for payers and regulators.​ Strategy and law‑firm notes expect M&A to concentrate on fewer, higher‑quality assets that combine clean MDR roadmaps, strong clinical and economic evidence, and clear health‑technology‑assessment narratives.​ Funding rounds and capital flows French MedTech FineHeart has secured about €83 million in a mix of private capital and non‑dilutive European public funding to advance its implantable device for advanced heart failure, underlining investor appetite for high‑acuity cardiovascular hardware‑plus‑data plays.​ Dutch, female‑led ShanX Medtech has raised €24 million to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing AMR diagnostics as a key EU strategic priority.​Weekly funding wraps list ShanX and FineHeart among the top European startup deals for 5–9 January 2026, signalling a strong start to the year for MedTech fundraising.​ Innovation focus: robotics, neuro and data Coverage of Paris‑based Robeauté’s microrobotics platform for diagnosing, treating and monitoring brain disease highlights the tilt toward complex neuro and micro‑robotic interventions as a 2026 MedTech theme.​ Outlook pieces emphasise devices that pair novel hardware with rich data exhaust and AI‑enhanced workflows, especially in cardiovascular, neurovascular, advanced diagnostics and surgical robotics.​ Analysts expect European investors to favour platforms that can integrate with EHDS‑style data infrastructures, creating defensible positions around longitudinal data and decision‑support rather than “device‑only” propositions.​ Key implications for strategy and deals Regulatory clarity around MDR/IVDR and EUDAMED is raising the bar on quality systems and data, increasing the relative value of assets with scalable compliance infrastructure and experienced regulatory teams.​ Portfolio pruning under MDR/IVDR, combined with capital flowing into high‑complexity segments like heart failure, AMR diagnostics and neuro‑robotics, is likely to create a two‑speed market: consolidation among premium, evidence‑rich platforms and potential distress among sub scale, non‑differentiated device players. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk